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CHAPTER 1
General introduction
Sections of this chapter have been published as:  
VanDerNagel, J. E. L., Kemna, L. E. M., & Didden, R. (2013). Substance use among 
persons with Mild Intellectual Disability: approaches to screening and interviewing. 
NADD Bulletin, 16, 87-92. 
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1
INTRODUCTION
The aim of this thesis is to assess rates and risks of substance use and substance use disorder 
in individuals with mild to borderline intellectual disability (IQ 50-85), an area of research 
that had not been explored systematically in the Netherlands before. This chapter starts with 
the clinical observations that led to the Substance use and Misuse in Intellectual Disability (SumID) 
project in 2008, followed by definitions and background information about intellectual disability, 
substance use and substance use disorder. Thereafter, we provide a brief description of the body 
of knowledge prior to the SumID project, and an overview of the aims and structure of this thesis. 
The start of the SumID project
In June 2007, the Dutch secretary of Health, Welfare and Sport, and the Dutch secretary of 
Youth and Family, stated that there would be several hundred addicted juveniles in Dutch 
services for individuals with intellectual disability (Parliament proceedings, 2007). In the 
same year, professionals at Tactus addiction medicine and Aveleijn intellectual disability 
services treated clients such as A, B and C (see VanDerNagel, Kemna, & Didden, 2013).
Client A, 19-year-old male with a borderline ID (IQ = 74) was admitted at a community 
based facility for persons with mild to borderline ID, and was interviewed in the presence 
of his parents. During this interview, he conceded to being addicted to tobacco, and to 
occasionally drink a beer or two. He denied the use of illicit drugs, and his parents 
explained they would not tolerate such behaviour. After placement he now and then 
appeared passive and lethargic, at other times he was irritable and uncooperative. His 
personal hygiene was poor, and he looked increasingly tired and unhealthy. At first, it 
was hypothesized that living semi-independently and working at irregular shifts was too 
much of a burden for him. Only when a staff member smelled cannabis in his apartment, 
substance use was suspected. When cannabis use was discussed in a non-confrontational 
style, he admitted to using this substance regularly, and plans were made to taper. Several 
months later, an acquaintance mentioned that he also used cocaine. Again, when asked 
by a staff member, he conceded to be using this substance as well. Shortly afterwards, he 
moved in with his girlfriend and refused further help.
Client B, a 35-year-old woman with borderline ID (IQ = 76), ADHD, borderline personality 
traits and an history of cocaine dependency, who lived independently with support from a 
local ID service, was referred for psychological evaluation. In the course of time her emotional, 
social, and financial problems had gotten worse. Her mood had become increasingly instable, 
and interaction with caregivers/social workers was hindered by her irritability. She also 
seemed to spend a lot of money. These symptoms were first attributed to the borderline 
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personality traits and/or ADHD. Months later, a concerned neighbour called the police 
because she heard the client crying incessantly. She was found collapsed in the hallway of her 
apartment. The last couple of days she has used several grams of cocaine, and had slept nor 
eaten. Later she admitted to have been using drugs on and off for more than a year. 
 
Client C, a 38-year-old woman with Down syndrome (estimated IQ: 50) was referred for 
a psychiatric consultation after several alcohol intoxications that required a visit to the 
Emergency Department (ER) of the local hospital. Apparently, several of her friends had 
encouraged her into drinking. After the ER staff explained that drinking more than two 
units of alcohol is unhealthy, the drinking incidents stopped. She stated now to accepted only 
cigarettes from her friends. When questioned further, she explained that these were ‘special 
cigarettes, which make you feel drowsy’. Allegedly, the client has been allured to perform 
sexual acts with these “friends” while under the influence of alcohol or cannabis. 
These cases illustrate that substance use (SU) in individuals with mild to borderline intellectual 
disability (MBID) often remain unnoticed or unrecognized by third parties for a long period of 
time, even when signs and symptoms of SU are present. Some individuals – like client A – are not 
inclined to discuss their SU, either because they fear consequences of admitting to it, or because 
they do not relate SU to their problems in daily life. Family, friends or staff members working 
with persons with an ID often do not identify SU or even substance use disorder (SUD). In some 
cases, they hold the preconception that persons with MBID refrain from experimenting with 
substances. Often, signs and symptoms of SU are misattributed to other factors such as physical 
or psychiatric conditions (clients A & B). In other cases, SU is detected, but its scope, magnitude 
or adverse consequences are not (yet) seen. Client C, for instance, seems unaware about the fact 
that she is drugged with ‘cigarettes’. Systematic and comprehensive screening for signs of SU may 
contribute to early identification and adequate referral for treatment. In addition, it can provide 
data needed for treatment capacity planning. Unfortunately, in 2008 no systematic screening was 
in place, and reliable data on the scope of SU(D) in MBID were not available. 
Clinical involvement with clients such as A, B, C, combined with the lack of adequate tools for 
screening and assessment, as well as the need for data on risks and rates, eventually led to the 
start of the Substance use and misuse in Intellectual Disability (SumID) project. The SumID project 
is a collaboration project between Tactus addiction medicine, Aveleijn intellectual disability 
services, and the Nijmegen Institute for Scientist-Practitioners in Addiction (NISPA). The study 
of epidemiology of SumID was supported by a research grant from the Netherlands organisation 
for Health Research and Development (ZonMW; VanDerNagel et al., 2008). In this thesis we 
describe the findings of the SumID epidemiology studies. 
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1
DEFINITIONS
Epidemiology
‘Epidemiology is the study of the distribution and determinants of health-related states…,… and the 
application of this study to the control of diseases and other health problems’ (World Health Organization, 
2016a). It provides essential data for policy makers and the development of evidence-based practice 
by informing about determinants for disease and targets for preventive interventions. The lack 
of epidemiological data may lead to inadequate use of health resources, lack of recognition of the 
relevance of the disease or its risk factors, and subsequently lack of clinical and political attention 
to the topic. In the case of SU in individuals with MBID, our clinical experiences conflicted with 
politicians’, lay-men’s, and also other clinicians’ perception of the problem. In order to resolve 
this conflict, in this thesis the epidemiology SU(D) in MBID is studied with a variety of methods 
presented at the end of this chapter. 
Intellectual disability
The American Association of Intellectual and Developmental Disabilities (AAIDD) defines 
intellectual disability (ID) as: ‘… a disability characterized by significant limitations both in intellectual 
functioning (reasoning, learning, problem solving) and in adaptive behavior, which covers a range of everyday 
social and practical skills. This disability originates before the age of 18’ (AAIDD, 2012). 
Diagnostic criteria for a diagnosis of ID in the DSM5 (American Psychiatric Association, 2013) 
are  1) impairments of general mental abilities;
 2) that impact adaptive functioning in the conceptual, social and practical domain; and
 3) that occur during the developmental period. 
Though in the DSM5 text description the former DSM-IV criterion of an IQ test score of 70 or 
below is still used (i.e. two standard deviations below average), in the DSM5 the severity of the 
disability is based on impairments in adaptive functioning rather than on IQ tests alone (American 
Psychiatric Association, 2000, 2013). Adaptive functioning includes (American Association of 
Intellectual and Developmental Disabilities, 2012; American Psychiatric Association, 2013): 
	 •	 conceptual skills: literacy; self-direction; and concepts of number, money, and time;
	 •	 social skills: interpersonal skills, social responsibility, self-esteem, gullibility, naïveté (i.e., 
wariness), social problem solving, following rules, obeying laws, and avoiding being victimized;
	 •	 practical skills: activities of daily living (personal care), occupational skills, use of money, 
safety, health care, travel/transportation, schedules/routines, and use of the telephone. 
Although the limitations in adaptive functioning are centrepiece to the ID definition, the 
development of a comprehensive standardized assessment of adaptive behaviour is still underway 
(AAIDD, 2012). Therefore, in daily practice as well as scientific publications the IQ criteria to 
define ID are still in use. 
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The majority of the persons with ID falls into the ‘mild’ category (IQ 50-70, American Psychiatric 
Association, 2000). According to the normal IQ distribution (mean = 100, SD = 15), about 
2.1% of the population falls in this group. Borderline intellectual functioning (i.e. an IQ in the 
71-84 range, also called borderline ID) is not a disorder according to the DSM-5, but a V-code 
that can be used when an individual’s borderline intellectual functioning is the focus of clinical 
attention or has an impact on their treatment or prognosis (American Psychiatric Association, 
2013). About 13.6% of the population falls into this category (Wieland, & Zitman, 2015).
On terminology related to intellectual disability
The term ‘intellectual disability’ covers the same population of individuals who were diagnosed 
previously with ‘mental retardation’ (AAIDD, 2012). Other historic terms for ID have been 
‘feebleminded’ or ‘mental deficiency’. In the United Kingdom, ‘learning disability’ is also used 
for this population, while this term in other countries may refer to persons with for instance 
dyslexia, ADHD, and other learning or developmental disorders. In other languages, there are 
similar issues with divergent and at times rather confusing terminology. For instance, the Dutch 
term ‘zwakzinnigheid’ (mental retardation), is - like ‘mental retardation’ - considered archaic and 
pejorative, and thus the term ‘lichte verstandelijke beperking’ is preferred. However, the Dutch 
term ‘zwakbegaafdheid’ (borderline intellectual functioning) is often interpreted as referring to a 
lower level of functioning than the term ‘lichte verstandelijke beperking’. To add to the confusion: 
in the Netherlands, individuals with borderline intellectual functioning are eligible for state 
funded support from ID services, and often are referred to as having ´een lichte verstandelijke 
beperking´ (mild ID), while this is not the case according to the formal classifications. 
Unfortunately, the terminology associated with MBID is deceptive in another way too. Though 
the level of disability may be described as ‘borderline’ or ‘mild’, these individuals comprise a 
group with an accumulation of problems, including social disadvantages, limited social support, 
poorer access to specialized services and overrepresentation in the forensic system (Wieland, & 
Zitman, 2015). Individuals with MBID are also a risk group for mental health problems, such 
as anxiety, PTSD, ADHD, conduct disorder, psychotic disorders, and behavioral problems (e.g. 
Dekker, & Koot, 2003; Kerker, Owens, Zigler, & Horwitz, 2004; Hassiotis et al., 2008; Wieland, 
Haan, & Zitman, 2014). Though these individuals have cognitive limitations, they are often 
‘streetwise’, and well experienced in hiding their impairments. Therefore, MBID remains often 
unrecognized (Wieland, & Zitman, 2015; Fernell, & Ek, 2010). This in turn contributes to their 
problems. 
This dissertation focuses on individuals with mild ID and borderline intellectual functioning, 
and uses the term mild to borderline intellectual disability (MBID) to denote this group.
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1
Substance use and substance use disorder 
With the term ‘substances’, we refer to psychoactive substances, that are ‘… substances that, when 
taken in or administered into one’s system, affect mental processes, e.g. cognition or affect’ (World Health 
Organization, 2016b). Use of such substances is widely spread. For instance, according to the 
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), in individuals between 
15 and 64 years in European countries, past month use of tobacco varies between 24 % (Italy) 
and 46%, past month use of alcohol between 50% (Portugal) and 76% (the Netherlands), and 
past month use of cannabis between 0.1% (Romania) and 7% (France). Obviously, lifetime use is 
even higher, up to 81% for smoking in France, 96% for alcohol in Germany, and 41% for lifetime 
cannabis use in France (EMCDDA, 2016). Though SU may not be a problem in and of itself, it 
may progress to hazardous use or SUD.
The American Society of Addiction Medicine (ASAM) and the International Society of Addiction 
Medicine (ISAM) provide the following definition of addiction: 
‘Addiction is a primary, chronic disease of brain reward, motivation, memory and related circuitry. 
Dysfunction in these circuits leads to characteristic biological, psychological, social and spiritual 
manifestations. This is reflected in an individual pathologically pursuing reward and/or relief by 
substance use and other behaviors. Addiction is characterized by inability to consistently abstain, 
impairment in behavioral control, craving, diminished recognition of significant problems with 
one’s behaviors and interpersonal relationships, and a dysfunctional emotional response. Like other 
chronic diseases, addiction often involves cycles of relapse and remission. Without treatment or 
engagement in recovery activities, addiction is progressive and can result in disability or premature 
death’ (ASAM, 2011; ISAM, 2012).
A SUD can be diagnosed according to the DSM5 when at least 2 of 11 criteria are met, relating 
to:  1) impaired control over quantity and duration of substance use (criteria 1-4); 
 2) social impairment due to substance use (criteria 5-7); 
 3) risky use (criteria 8-9); and 
 4) tolerance and withdrawal (10-11). 
SUD severity is rated to be mild (two to three symptoms), moderate (four to five symptoms), or 
severe (six or more symptoms). 
On terminology related to substance use (disorder)
The DSM5 category SUD combines the DSM-IV categories of substance abuse (a maladaptive 
pattern of SU leading to clinically significant impairment or distress), and substance dependence 
(addiction) (APA, 2000, 2013). Other terms are also in use. For instance, the World Health 
Organization Lexicon uses ‘substance misuse’ to refer to ´use for a purpose not consistent with legal or 
medical guidelines’ (WHO, 2016b). It notes that the term ‘misuse’ may be regarded less pejorative 
than the term ‘abuse’. The ASAM (2013) distinguishes between 1) low or lower risk SU, and 2) 
unhealthy use, including a. hazardous use, b. harmful use, and c. addiction. 
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In this dissertation we use the term substance use (SU) to denote the use of psychoactive 
substances including tobacco, and substance use disorder (SUD) to denote disorders in using such 
substances, according to the classification of DSM5.
SUBSTANCE USE IN INDIVIDUALS WITH INTELLECTUAL 
DISABILITY
International literature at the start of this research project
According to the scarce literature available in 2008 on SU(D) in ID, large proportions of those 
with ID did not use substances. Those who did, were seen to be at increased risk for developing 
problems, including SUD (McGillicuddy, 2006; Taggart, McLaughlin, Quinn, & Milligan, 
2006). It was also postulated that individuals with ID could lead to more negative psychosocial 
consequences, such as work related problems, interaction problems, and lower accessibility of 
care (Cocco, & Harper, 2002; Taggart et al., 2006). However, most authors concluded that the 
prevalence of SUD in ID was still (much) lower than in the general population (Barrett & Paschos, 
2006; McGillicuddy, 2006; Sturmey, Reyer, Lee, & Robek, 2003).
Psychological, family, and social problems (Westermeyer, Phaobtong, & Neider, 1988); forensic 
issues (McGillivray, 2001), psychological trauma and social distance from the community 
(Taggart et al., 2007), and the shift from institutional to community based care (Degenhardt, 
2000; Taggart et al., 2006) were seen as potential risk factors for SUD in individuals with MBID, 
although there was little data to support these assumptions. 
Knowledge gaps
At the start of this project, the body of knowledge on SU and SUD in individuals with MBID 
was limited and fragmented. It had also several methodological issues. For instance (1) most 
studies focused on a relative small number of participants within a limited number of – often 
specialized – services, thus limiting their generalizability to the wider ID population, (2) most 
studies did not include the high risk group of individuals with borderline ID, (3) most studies 
relied on proxy-report or self-report with instruments that were not validated, or not adapted 
to the needs of individuals with MBID. Regrettably, widely used screening instruments have 
several shortcomings when using them in clients with ID. First, they require basic substance 
knowledge and a conceptual understanding that persons with intellectual disabilities may lack 
(Finlay & Lyons, 2001; Heal, & Sigelman 1995; McGillicuddy, 2006; Wallace, Keenum, & 
Roskos, 2007). Second, they do not take into account the tendency of many individuals with ID 
to give socially desirable answers and acquiescence (i.e. to agree with whatever statement), or to 
‘Say Nay’ regarding to questions relating to social taboos such as SU (Finlay & Lyons, 2001; Heal, 
1995; McGillicuddy, 2006; Sturmey et al., 2003). In addition to these methodological issues in 
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1
international studies, (4) it remained unclear whether the international studies would also reflect 
the situation in the Netherlands, given differences between countries, cultures and regions in 
socio-economic factors, ID services and addiction treatment facilities, as well as alcohol and drugs 
related policies and legislation. Therefore, in 2007 the Trimbos Institute stated that there was a 
need for national research on the prevalence of SU, substance abuse, and related problems among 
this group, and that such research should take into account methodological issues regarding the 
screening of SU, including whether self-reports are reliable (Mutsaers, Blekman, & Schipper, 
2007, p. 25).
To summarize, in 2008 there were several unresolved issues as to epidemiology of SU in MBID 
in the Netherlands, including: 
 1. Lack of data of epidemiology (risks and rates) of SU(D) in MBID
2. Lack of knowledge how to assess SU(D) in individuals with MBID
A variety of strategies can be used to fill these gaps, depending on the level of measurement 
(individual, group, population), respondents (individuals within the ID population or within the 
SUD population; proxies such as family or staff members; other stakeholders such as organizations, 
health insurance companies or politicians), type of data (questionnaires, biomarkers for SU, 
surveys, metadata such as case-registers) et cetera. 
This dissertation
In this PhD project several methods are used to address the lack of knowledge about rates and risk 
factors, as well as assessment strategies of SU(D) in individuals with MBID in the Netherlands: 
1. A review of the literature (chapter 2). 
 In this selective and critical review of international literature, we will describe the current 
knowledge and challenges regarding the epidemiology and treatment of SU(D) in ID.
2. Survey of ID services in the Netherlands (chapter 3). 
 In this study we explore staff member perspectives on SU and SUD in individuals with ID 
in the Netherlands, its consequences and solutions. 
3. Capture recapture study (chapter 4). 
 In this study we combine care registers of an intellectual disability service and an addiction 
treatment facility in the region of Twente in a capture recapture analysis to estimate the 
hidden and total population of individuals with MBID and SUD. 
4. A comparison of three assessment strategies of SU (chapter 5).
 In this study we compare rates of self-reported SU, collateral-reported SU and biomarker 
analysis (hair-, sweat patch-, and urine analysis), as well as agreement between these 
strategies. 
5. An exploration of SU risks and rates in individuals with ID (chapter 6).
 In this study in a large sample of individuals with MBID we assess SU patterns, rates of SU 
as well as risk factors for SU.
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For our studies 4 and 5 (chapter 5 and 6), we developed the SumID-Q, an instrument to assess 
SU in individuals with MBID (VanDerNagel, Kiewik, van Dijk, de Jong, & Didden, 2011; 
VanDerNagel, Kemna, & Didden, 2013). The SumID-Q incorporates several strategies to decrease 
self-report bias (for a more detailed explanation, see the appendix on screening and assessing SU 
in ID). In chapter 7, a summary of our findings will be provided, as well as a general discussion, 
conclusions and clinical recommendations and suggestions for further research.
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future directions
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ABSTRACT
Knowledge regarding substance use (SU) and substance use disorder (SUD) in individuals with 
mild to borderline intellectual disabilities (ID) has increased over the last decade, but is still 
limited. Data on prevalence and risk factors are fragmented and instruments for screening and 
assessment and effective treatment interventions are scarce. Also, scientific developments in other 
fields are insufficiently incorporated in the care for individuals with ID and SUD. In this selective 
and critical review, we provide an overview of the current status of SU(D) in ID and explore 
insights on the conceptualisation of SUD from other fields such as addiction medicine and general 
psychiatry. SU(D) turns out to be a chronic, multifaceted brain disease that is intertwined with 
other physical, psychiatric and social problems. These insights have implications for practices, 
policies and future research with regard to the prevalence, screening, assessment and treatment 
of SUD. We will therefore conclude with recommendations for future research and policy and 
practice, which may provide a step forward in the care for individuals with ID and SUD.
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INTRODUCTION
Although substance use (SU) and substance use disorders (SUD) among individuals with mild 
to borderline intellectual disability (ID; IQ 50–85, American Psychiatric Association [APA], 
2013) have gained attention over the past decade, there are still many gaps in our knowledge 
on prevalence and risk factors (Carroll Chapman & Wu, 2012) and there is a dearth of tools 
for assessment and effective treatment interventions (Kerr, Lawrence, Darbyshire, Middleton, & 
Fitzsimmons, 2013). In addition, practitioners and researchers working with this target group 
insufficiently incorporate scientific developments in other fields, including addiction medicine 
and general psychiatry, into the care of and research on SU(D) in ID. For example, while in ID 
services SUD is commonly viewed as a relatively simple behavioural problem (Simpson, 2012), 
in addiction medicine SUD is generally seen as a chronic brain disease (Hyman, 2005), which 
is characterised by the persistent desire to use and the inability to cut down or control SU, even 
in the face of negative consequences (APA, 2013)1. These insights should have consequences 
for the care and treatment of individuals with ID with SUD and the field of research on SU(D) 
in ID (Van Duijvenbode, Didden, Voogd, Korzilius, & Engels, 2012b). In this selective and 
critical review, we will first describe the current status and challenges regarding SU(D) in ID. 
We will then explore insights on the conceptualisation of SUD from general psychiatry and 
addiction medicine. Last, we will describe implications these conceptualisations have for the care 
and treatment of individuals with ID and SUD as well as future research in this area.
CURRENT STATUS
There is a growing body of research on SU(D) among individuals with ID, who have been identified 
as a risk group for more severe negative consequences of SU (Slayter, 2008) and for developing 
SUD (Burgard, Donohue, Azrin, & Teichner, 2000; McGillicuddy, 2006). In this section, we will 
describe the literature on the prevalence and risk factors, screening and assessment and treatment 
of SUD in ID and the gaps in our current knowledge on these topics.
Prevalence and risk factors of substance use disorders
Although large population-based studies into SU(D) among individuals with ID are lacking, 
data suggest that all types of substances are used in this group (To, Neirynck, Vanderplasschen, 
Vanheule, & Vandevelde, 2014; VanDerNagel, Kiewik, Buitelaar, & De Jong, 2011a). While 
1 According to the APA (2013), SUD encompasses a wide range of disorders from a mild to a severe state of 
chronically, relapsing and compulsive substance use. Substances are used in larger amounts or over a longer 
period of time than was intended, despite having knowledge of the adverse physical, psychological, social and 
interpersonal problems related to SU or even in the face of these consequences. As opposed to SUD, SU does not 
lead to these adverse consequences or risks. 
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alcohol is the main substance used and misused in both individuals with and without ID, 
percentages of alcohol use and misuse seem to be lower among those with ID and a large 
proportion of individuals with ID are teetotallers (i.e., they do not use any substances; Simpson, 
2012; VanDerNagel et al., 2011a). In a Dutch survey, the prevalence of the use and misuse of 
cannabis and other illicit drugs among individuals with ID, on the other hand, seemed relatively 
high compared to that in individuals without ID (VanDerNagel et al., 2011a).
Based on previous studies, the total prevalence of SUD was estimated by Sturmey, Reye, Lee 
and Robek (2003) around 0.5–2% of the ID population. In an American study using Medicaid 
files, Slayter (2010) found that 2.6% (n = 9484) of the clients with a diagnostic code for ID 
also had a code for SU related treatment. A capture-recapture analysis, however, showed that 
the reported 4.0% SUD in an ID facility and 5.2% ID in an addiction medicine service in the 
same region in The Netherlands had limited overlap. Single source data thus underestimate the 
population prevalence of co-occurring SUD and ID (VanDerNagel et al., 2014). The prevalence 
of SU(D) in ID also highly depends on sample characteristics (Carroll Chapman, & Wu, 2012). 
For instance, in a British community-based study among 1023 adults with mild to profound 
ID, Cooper, Smiley, Morrison, Williamson and Allen (2007) found 1% of SUD diagnosis, while 
McGillicuddy and Blane (1999) found 21% alcohol misusers in a community sample (n = 
122) with mild to moderate ID in the US. In referred samples (see e.g., Chaplin, Gilvarry, & 
Tsakanikos, 2011; Didden, Embregts, Van der Toorn, & Laarhoven, 2009) or forensic samples (see 
e.g., Hassiotis et al., 2011; Lindsay et al., 2013) even higher percentages of substance misusers are 
found. Although risk factors for SUD for individuals with ID have not been identified yet, these 
studies suggest that those with mild or borderline ID, psychiatric co-morbidity and forensic or 
severe behavioural problems are especially at risk for developing SUD. 
The epidemiological findings illustrate some of the challenges associated with establishing 
prevalence rates of SU(D) in ID, including (1) definition of ID-group (in- or excluding the high 
risk group with borderline ID; IQ 70–85); (2) differences between specific subgroups (such 
as those receiving ID service or SUD treatment, those with co-morbid psychiatric disorders 
or forensic patients); (3) definitions of terms such as substance use and misuse, as well as the 
scope of SU (in- or excluding use of tobacco and/or prescribed drugs); (4) methodological and 
measurement issues (use of proxy or self-report); (5) problems associated with stigma and denial 
of substance related problems (both by individuals with ID and their caregivers); (6) variations in 
prevalence rates over time; and (7) differences between countries, cultures and regions (differences 
in socio-economical factors, ID service and addiction treatment facilities and alcohol and drugs 
related policies and legislation; Carroll Chapman & Wu, 2012). Thus, representative and large 
scale studies on SU(D) in ID are hindered by practical and methodological challenges. Those 
identified with SUD are probably the ‘tip of the iceberg’ and may not be representative for the 
total population (VanDerNagel et al., 2011a).
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Screening and assessment of substance use disorders
Parallel to the lack of data on population prevalence of SU(D) in ID, co-occurring SU(D) and ID 
often remains unrecognised in individual clients (VanDerNagel et al., 2011a). In many if not 
most ID services, there is a lack of screening and formal assessment of SU(D) and staff members 
mostly rely on their clinical judgement to tap SU(D), even while they indicate that they lack the 
skills and knowledge to do so (McLaughlin, Taggart, Quinn, & Milligan, 2007; VanDerNagel 
et al., 2011a). Unfortunately such judgements are proven to be unreliable (Connors, & Maisto, 
2003; Wilson, Sherritt, Gates, & Knight, 2004). For example, proxy reports such as those of staff 
members typically underestimate clients’ SU (Wilson et al., 2004). Also, because of the lack of 
systematic screening, staff members’ attention is predominantly drawn to the more severe cases, 
disregarding the less progressed cases and thereby missing opportunities to intervene at an early 
stage (VanDerNagel et al., 2011a). 
Systematic screening for SU(D) in the ID population is further hindered by the fact that suitable 
instruments are lacking. Widely used screening instruments for SU(D) such as the CAGE 
(Mayfield, McLeod, & Hall, 1974), MAST (Selzer, 1971) and AUDIT/DUDIT (Babor, Higgins-
Biddle, Saunders, & Monteiro, 2001; Berman, Bergman, Palmsteirna, & Schlyter, 2003) are 
unfit for this population because of (1) the requirement of (substance-related) knowledge that 
individuals with ID often lack, (2) the use of lengthy phrases, difficult wordings or (double) 
negative phrases, and (3) the tendency of individuals with ID to acquiescence (i.e., to agree with 
whatever statement has been given) as well as to ‘‘say nay’’ regarding questions relating to social 
taboos such as SU (Finlay & Lyons, 2001; Heal & Sigelman, 1995; McGillicuddy, 2006; Sturmey 
et al., 2003; VanDerNagel, Kiewik, van Dijk, de Jong, & Didden, 2011b). Hence, because a 
number of reasons, ID services often fail to recognise co-occurring SU(D) and ID.
Treatment of substance use disorders
Although interventions for SUD in individuals with ID have been developed in the past decade, 
little has been published on their effectiveness (Kerr et al., 2013; McGillicuddy, 2006). Kerr et 
al. (2013) identified nine tobacco and alcohol-related interventions for individuals with mild to 
moderate ID. Several conclusions may be drawn from their review. First, their findings suggest 
that – with minor adaptations in the communication – interventions based on motivational 
interviewing techniques can be applied and seem to be effective in increasing the motivation of 
individuals with ID to enter into and adhere to treatment (see also Frielink & Embregts, 2013). 
Second, there is some evidence that educating clients with ID about the adverse effects and 
risks of SU improves their substance-related knowledge. These interventions typically consist 
of several weekly group sessions, in which clients are provided with information about tobacco 
smoking and alcohol drinking (e.g., motives for drinking or smoking, the law, short and long 
term effects and adverse consequences of smoking and drinking) and which aim to reduce SU 
and to prevent the development of SUD. It should be noted, however, that these interventions 
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not always lead to a reduction in SU (e.g., Kelman, Lindsay, McPherson, & Mathewson, 1997; 
Lindsay, McPherson, Kelman, & Mathewson, 1998). Third, a number of interventions developed 
for individuals with ID aim for behavioural change, such as cutting down or quitting SU, and 
improving skills related to this behavioural change such as social skills, coping skills and refusal 
skills. These interventions seemed effective in eliciting behavioural change and reducing SU.
Several problems can be identified when examining both the design and methodology of the 
studies as well as the interventions themselves. First, the studies were of poor to moderate 
methodological quality, often used small participant numbers (range 1–138, median 7) and in 
most cases failed to include a control or comparison group. Kerr et al. (2013) therefore conclude 
that the body of evidence on the feasibility, appropriateness, meaningfulness and effectiveness of 
SU(D) interventions for individuals with ID is small. Second, the interventions were often short 
(3–12 sessions, median 7), relatively simple of nature and lacked a theoretical foundation. Also, all 
these interventions seemed to focus on SU, rather than SUD, and disregarded possible co-morbid 
disorders or psychosocial problems. The evidence for the effectiveness of these interventions thus 
remains at the level of pilot tests.
INSIGHTS FROM OTHER FIELDS
In ID services, SU(D) is often seen as a behavioural problem that can be amended in relatively 
brief and targeted behavioural and/or educational interventions. In this section, we will discuss 
insights on the conceptualisation of SUD from other fields, such as general psychiatry and 
addiction medicine. The implications these insights have on the care and treatment of individuals 
with ID and SUD will be discussed later in this chapter.
Substance use disorder is a multifaceted problem
In addiction medicine, SUD is conceptualised as a multifaceted problem that cannot be explained 
by a single factor and is often associated with co-morbid physical and psychiatric disorders and 
other psychosocial problems. This is reflected in the biopsychosocial model, which emphasises 
the complex interplay between biological (e.g., genetics, physiological effects of substances), 
psychological (e.g., personality traits, co-morbid psychiatric disorders) and social factors (e.g., 
social economical status, peer pressure) (Donovan, 2005). For example, while SU is to a high 
degree dependent on social conventions (e.g., toasting with a glass of wine, taking a cigarette-
break), biological and psychological factors such as genetics and personality traits contribute 
to inter-individual differences in vulnerability for developing SUD (Conrod, Pihl, Stewart, & 
Dongier, 2000; Merikangas & McClair, 2012; Wong & Schumann, 2008). All factors – biological, 
psychological and social – interact with each other and can increase or decrease the risk for 
developing SUD in a given individual.
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The multifaceted nature of SUD is also reflected in the high co-morbidity between SUD and 
physical and psychiatric problems (Kessler, 2004; Mertens, Lu, Parthasarathy, Moore, & Weisner, 
2003; O’Brien et al., 2004). For example, epidemiological studies estimated that between 20 
and 50% of clients receiving mental health treatment have had a lifetime diagnosis of SUD and 
over half of the clients in addiction medicine have had a co-morbid psychiatric disorder in their 
lifetime (Center for Substance Abuse Treatment, 2007). The co-morbidity of SUD and physical 
and psychiatric disorders leads to further complications: co-morbidity increases symptom 
severity of both disorders, complicates treatment and causes additional psychosocial problems 
including failure at work or school, delinquency, financial problems and homelessness (Horsfall, 
Cleary, Hunt, & Walter, 2009; Sterling, Chi, & Hinman, 2011). As opposed to a relatively 
simple behavioural problem, SUD is therefore best conceptualised as a complex and multifaceted 
disorder that is caused by multiple factors and is associated with co-morbid problems.
Substance use disorder is a brain disease
In the 90s, it became clear that SUD is characterised by disruptions in brain regions important to 
the motivational, reward and inhibitory control processes (Koob, 2013; Volkow, Wang, Tomasi, 
& Baler, 2013). These neural adaptations are reflected in dual process models, which state that 
behaviour is influenced by both implicit, automatic processes (e.g., attention, evaluation of 
environmental cues and approach/avoidance behaviour) and explicit, controlled processes (such 
as executive control and motivation) (e.g., Bechara, Noel, & Crone, 2006; Gerard, Gibbons, 
Houlihan, Stock, & Promery, 2008; Wiers et al., 2007). Both these types of processes are 
implicated in SUD.
The implicit processes are associated with the limbic system of the brain (Nestler, 2005) which 
becomes hypersensitive to the rewarding effects of substances (Robinson & Berridge, 2003, 2008). 
More specifically, the rewarding effects of substances and related stimuli (e.g., external stimuli 
such as persons, places and drug paraphernalia, but also interceptive stimuli including emotions, 
stress and craving) become overvalued at the expense of other rewards (Hyman, Malenka, & 
Nestler, 2006; Nestler, 2005). As a result, these stimuli seem attractive, ‘grab attention’ and 
elicit approach behaviour (Robinson & Berridge, 2003, 2008). Indeed, research has shown that 
SUD is associated with biases in cognitive processing, including biases in attention, evaluation 
and approach tendencies. SUD also leads to changes in the explicit processes, which are associated 
with the frontal cortex. As a result of reduced baseline activity in regions of the frontal cortex 
(hypofrontality; Dackis & O’Brien, 2005; Hyman et al., 2006) clients with SUD show poorer 
executive functioning and consequently have impaired top-down control over behaviour. Both 
the effects of SUD on the implicit processes as well as on the explicit processes have been shown 
for a wide range of substances including tobacco, alcohol, cannabis and cocaine (for a review, see 
Field & Cox, 2008; Verdejo-García, Lawrence, & Clark, 2008). This demonstrates that, even 
though each class of drugs has its own pharmacological mechanisms, they share several functional 
changes in the nervous system when used repeatedly.
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The dual process models thus theorise that SUD is not merely a behavioural problem, the result 
of faulty decision making or even the result of a lack of willpower, but in part reflects structural 
neural adaptations that often exert their influence outside conscious control.
Substance use disorder is chronic
Rather than resulting from a personal choice (or flaw for that matter), SUD is seen as a chronic 
disorder, similar to other chronic medical illnesses such as diabetes mellitus, hypertension and 
asthma (McLellan, Lewis, O’Brien, & Kleber, 2000). Evidence for this comes from three different 
research areas (Dennis & Scott, 2007): epidemiology, clinical treatment and biological studies. 
First, results of epidemiological studies show that SUD most often develops during adolescence 
(14–16 years) and lasts for several decades (Swendsen et al., 2012). Second, there is a large body 
of clinical research indicating that 40–60% of alcohol or drug misusers relapse – even after 
prolonged periods of abstinence – and require multiple treatment episodes spanning several years 
to recover from SUD (Bailey, Herman, & Stein, 2013; Dennis, Foss, & Scott, 2007; National 
Institute on Drug Abuse, 2012). Also, treatment adherence and relapse rates of SUD treatment 
are quite similar to those of other chronic medical illnesses (McLellan et al., 2000). Third, there 
is evidence for a biological basis underlying the chronicity of SUD, demonstrating that SUD is 
associated with several changes in the brain that impact decision making, emotional states and 
behaviour (see earlier in this chapter). These substance-induced alterations of the brain often 
persist way beyond cessation, resulting in a continued vulnerability for relapse (Johanson et al., 
2005; Petry, 2001). However, they do seem to diminish after prolonged periods of abstinence (for 
a review see Garavan, Brennan, Hester, & Whelan, 2013), providing arguments for the need for 
long-term rehabilitation and care.
FUTURE DIRECTIONS
Based on the current status on SU(D) in ID and the insights of SUD described in the previous 
section, we can conclude that considering SUD in ID as a behavioural problem does no justice to 
the complex and chronic nature of SUD and leads to a simplified view on how individuals with 
ID and SUD should be cared for or treated. In this section, we propose several lines of research 
(see Table 1 for a brief overview) to accommodate a conceptual change of SUD as a result of which 
the understanding and care of SUD in individuals with ID are enhanced.
Prevalence and risk factors of substance use disorders
The inter-individual variability in vulnerability to developing SUD not only calls for more 
knowledge on prevalence and risk factors of SU in the total population of individuals with ID 
(Carroll Chapman & Wu, 2012; McGillicuddy, 2006), but also across specific high-risk groups 
within this population.
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With regard to the population prevalence of SU(D) among individuals with ID, research in 
larger samples of individuals with ID is needed to plan treatment capacity and develop strategies 
for prevention and early detection (Carroll Chapman & Wu, 2012; VanDerNagel et al., 2014). 
This research should include a variety of research methods, such as biomedical markers of SU, 
administrative data and multicentre studies (e.g., Connors & Maisto, 2003; Slayter, 2010; 
VanDerNagel et al., 2014). Also, this research should take into account the challenges described 
earlier. For example, definitions of both ID (in- or excluding individuals with borderline ID) 
and SU (in- or excluding tobacco use) influence the prevalence of SU(D) and should therefore be 
justified in the study design.
Prevalence studies are also helpful in identifying groups at risk, which in turn contributes to the 
targeted prevention of SU(D) (McGillicuddy, 2006). Based on the current literature, individuals 
with mild to borderline ID, individuals with co-morbid psychiatric disorders and individuals in 
forensic facilities seem to be at increased risk for developing SUD. Future studies should further 
explore risk factors for SUD, including motives for SU, client characteristics (e.g., personality 
traits, coping skills, executive functioning including working memory, behavioural inhibition, 
delay discounting) and social factors (e.g., living arrangements, employment, social environment, 
peer pressure). Primary and secondary prevention strategies can then target these risk factors and 
their effectiveness can be explored in studies with larger samples and internally valid designs.
Considering the chronic nature of SUD, there is a need for studies into the age at which individuals 
with ID commonly start to use substances, the development of SUD after initial SU and rates 
of relapse after cessation. This research identifies risk factors associated with the development 
of SUD and long-term consequences of SUD (Carroll Chapman & Wu, 2012) and could point 
out similarities and differences between individuals with ID and their non-disabled peers, for 
example in the risk of developing SUD after initial SU and the consequences of SU(D) – which 
are thought to differ between the two groups (e.g., Burgard et al., 2000; McGillicuddy, 2006; 
Slayter, 2008). Last, as Didden et al. (2009) suggest, associations between SUD and co-morbid 
physical or psychiatric disorders and other psychosocial problems may also provide a new line of 
inquiry which leads to a better understanding of the development of SUD in individuals with ID 
and the implications co-morbidity has on the care for individuals with ID.
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Table 1. Brief overview of the current status of substance use disorder (SUD) in individuals with 
intellectual disability (ID), directions for future research in this area and recommendations for policy 
and practice.
Topic Current Status Directions for future research Recommendations for policy 
and practice
Prevalence 
and risk 
factors
Individuals with ID are at 
risk for developing SUD 
and experience more severe 
consequences of SU(D). 
The prevalence of SUD 
highly depends on sample 
characteristics. There are 
certain high-risk groups (e.g., 
individuals with mild to 
borderline ID, those with co-
occurring psychiatric disorders 
or forensic patients).
Research in this area is plagued 
with several challenges, 
including practical and 
methodological issues.
Establish the prevalence of SUD 
among individuals with ID in 
general and across specific high-
risk groups within this group. 
Include a variety of research 
methods.
Explore risk- and protective 
factors for SUD, including client 
characteristics, and develop 
prevention strategies aimed at 
these risk factors.
Study the course of SUD in 
individuals with ID.
Be aware that SU(D) is common 
and that all types of substances 
are used by individuals with ID. 
Pay attention to high-risk 
groups (such as individuals with 
mild to borderline ID, those 
with co-occurring psychiatric 
disorders or forensic patients).
Screening 
and 
assessment
SU(D) often remains 
unrecognised, partly due to a 
lack of screening and formal 
assessment.
SU is often assessed using 
collateral reports such as those 
of staff members. 
Develop screening and 
assessment instruments of SU(D) 
and co-occurring problems 
targeted to needs of those with 
ID.
Remove SU of stigma by 
making it a common subject 
of conversation. Educate staff 
members in SUD and increase 
their skills in recognising, 
screening and assessing SU(D). 
Implement SU(D) screening in 
routine diagnostic procedure. 
Extend SUD assessment with 
assessment of co-occurring 
problems
Treatment There is a small number of 
published SUD treatment 
interventions for individuals 
with ID. 
The interventions are often 
short and relatively simple 
in nature, focussing solely on 
SUD.
The body of evidence on 
the effectiveness of the 
interventions is very small.
Develop interventions:
of less to more intensity and 
duration; targeted at the 
biological, psychological and 
social aspects of SUD; taking 
into account co-occurring 
problems; tailored to the needs 
of individuals with ID. 
Investigate the applicability 
and effectiveness of existing 
evidence-based pharmacological 
and psychosocial interventions 
in individuals with ID. 
Identify barriers to treatment 
access and propose ways to aid 
referral. 
Identify ways to promote 
collaboration and cross-
fertilisation between sectors of 
the health care system. 
Include biological and 
psychological and social 
interventions in the treatment 
arsenal. Implement stepped 
care; match the intensity of the 
intervention to the severity of 
SUD. Structure SUD treatment 
according to the chronic care 
approach; also focus on long-
term management.
Tailor all interventions to the 
needs of individuals with ID.
Collaborate with other sectors of 
the health care system to provide 
integrated treatment. 
Educate others about your 
area of expertise to promote 
collaboration.
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Screening and assessment of substance use disorders
Screening and assessment of SU(D) are essential, especially in high risk groups such as those with 
mild to borderline ID. To aid early detection, there are four lines of inquiry and areas of concern 
to policy and practice. First, it is advised that SU becomes a common subject of conversation with 
clients and is removed of possible stigma. Second, staff members need to be educated about the 
underlying mechanisms of SUD and contemporary views on SUD and trained to increase their 
skills in recognising the signs of SU(D), addressing SU with their clients and motivating them 
to enter into and adhere to treatment in the case of SUD (see also Moore & Lorber, 2004). Third, 
it is advised that service providers systematically screen for SU(D). This should not be limited to 
clients at risk for developing SUD or clients suspected of SU, but instead be implemented in the 
routine diagnostic procedure applied to all clients with mild to borderline ID. Fourth, research 
should be directed at developing and implementing screening instruments of both SU(D) and 
physical, psychiatric and psychosocial co-morbidity that are tailored to the needs of individuals 
with ID. These instruments should then be implemented in the routine diagnostic process. Below 
are two examples of such research currently being undertaken.
First, the Substance Use and Misuse in Intellectual Disability Questionnaire (SumID-Q; 
VanDerNagel et al., 2011b), a Dutch language instrument, has been developed to assess SU, 
risk factors of SUD and SU consequences in individuals with mild to borderline ID. It takes into 
account challenges individuals in this group have with lengthy or complex phrases and difficult 
wording, substance-related jargon and knowledge and tendencies to acquiescence or ‘say nay’ 
(VanDerNagel, Kemna, & Didden, 2013). In the SumID-Q, SU is discussed in an empathetic, 
non-confrontational way. The first part of the SumID-Q interview assesses the client’s familiarity 
with substances (e.g., alcohol, cannabis), presenting substance-related pictures and asking what 
is shown. This will clarify the terminology of the client, which is then used in the remainder of 
the interview to prevent misunderstandings and to make the client feel at ease. In the second 
part of the interview clients are asked about their knowledge of and attitude towards using these 
substances, as well as SU by close others (i.e., friends, family, staff members). Discussing these 
topics without (negative) judgement facilitates the client to speak freely and truthfully when 
asked about his own SU. Patterns of SU are further explored by asking about frequencies and 
quantities of SU and circumstances in which substances are regularly used. Preliminary data show 
promising validity and feasibility (VanDerNagel & De Jong, 2012). We are currently validating 
the SumID-Q, examining its feasibility, reliability and validity in subgroups of individuals with 
ID (e.g., adolescents, forensic clients) and implementing the SumID-Q in ID facilities, mental 
health care settings and centres for addiction medicine and general psychiatry.
Second, studies into substance-induced brain alterations (e.g., cognitive biases and deficiencies 
in executive functioning) are needed to better understand the role of cognitive performance in 
the development and maintenance of SUD and similarities and differences between individuals 
with ID and their non-disabled peers. For example, deficiencies in executive functioning among 
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individuals with ID could provide a partial explanation for their heightened risk for developing 
SUD, as these deficiencies have been identified as vulnerability markers (Van Duijvenbode, 
Didden, Korzilius, Trentelman, & Engels, 2013). Implicit measures of cognitive biases and 
executive functioning could also be used as screening or assessment instruments for SUD, they 
may predict treatment outcome or be incorporated in SUD treatment (Stacy & Wiers, 2010). 
As these measures do not rely on verbal capacity of clients, are generally easy to conduct and are 
less susceptible to social desirability, they might be especially useful in the care for individuals 
with ID and SUD. Preliminary results indicate not only that computerised tasks to measure 
cognitive biases – such as the visual dot probe task (MacLeod, Mathews, & Tata, 1986) and the 
approach avoidance task (Rinck & Becker, 2007) – are applicable in individuals with ID but also 
that IQ does not appear to be associated with the strength of these biases (Van Duijvenbode et 
al. 2012b). In line with other research (e.g., Garavan et al., 2013), the results also suggest that 
substance-induced deficits in information processing and executive functioning diminish over 
time and are no longer present in long-term abstinent alcoholics, both with and without ID 
(Van Duijvenbode, Didden, Bloemsaat, & Engels, 2012a; Van Duijvenbode et al., 2012b; Van 
Duijvenbode et al., 2013). However, these results are preliminary and there is a need to replicate 
these studies. We are currently conducting studies aimed at replicating and expanding these 
findings in current substance users with ID, examining the role of IQ and executive functions 
more closely, identifying the most appropriate measures and parameters and implementing the 
measures into the process of screening, assessment and treatment of SUD in individuals with ID 
in clinical practice.
Treatment of substance use disorders
The nature of SUD as a multifaceted problem calls for the development of treatment approaches 
that take multiple (risk) factors into account (Shapiro, Coffa, & McCance-Katz, 2013). The 
biopsychosocial approach of SU(D) provides a framework for developing such treatment 
models. From this model it follows that research should be directed at developing a variety of 
interventions, both biological, psychological and social (Reif et al., 2014). A first line of inquiry 
should therefore be to adopt existing evidence-based psychosocial treatment interventions 
(such as cognitive behavioural therapy, community reinforcement approach and motivational 
interviewing) to the needs of those with ID (for suggestions see Degenhardt, 2000; Kerr et al., 
2013; McGillicuddy, 2006) and to study their effectiveness. Although steps have been made in 
doing so, these initiatives often remain at the level of pilot studies and are often not published. 
Research should therefore also be directed at studying their effectiveness in larger samples and with 
strong methodological designs. These interventions should also take into account co-morbidity 
with physical and psychiatric disorders and other psychosocial problems. The development of 
dual diagnosis (ID plus SUD) or even triple diagnosis (ID plus SUD plus psychiatric disorder) 
treatment interventions is therefore warranted.
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A second line of inquiry is to identify treatment approaches aimed at substance-induced brain 
alterations of which a procedure called cognitive bias modification (CBM) is an example. Research 
in individuals without ID has shown that CBM is effective in reducing SU and the risk of relapse 
(Wiers, Gladwin, Hofman, Salemink, & Ridderinkhof, 2013). Combining CBM with cognitive 
behavioural strategies in which new skills (e.g., social skills, coping skills and refusal skills) are 
learned could therefore be an important step towards effective and multifaceted SUD treatment. 
Another example is the use of pharmacological strategies for treating SUD. A recent review 
suggests that a series of proven-effective medications are available for non-ID individuals to 
stabilise SU(D), reduce craving and facilitate abstinence (Van den Brink, 2012). Considering 
the impairments in brain function associated with individuals with ID (Mental Health Special 
Interest Research Group, 2001), the applicability, side-effects and effectiveness of CBM and 
pharmacological strategies in this population remain to be investigated.
As SUD is a chronic disorder, treatment interventions should be structured according to the 
chronic care approach (McLellan, McKay, Forman, Cacciola, & Kemp, 2005; White, Boyle, 
& Loveland, 2003). This approach implies the need for a broad spectrum of less to more 
intensive treatment forms (Dennis & Scott, 2007; McLellan et al., 2005). Related to this is the 
implementation of stepped care, where the intensity of the treatment is matched to the severity 
of SUD (McLellan et al., 2005). Long-term management and monitoring of clients is another 
crucial aspect of successful treatment. This does not only do justice to the nature of SUD but also 
allows therapists to quickly respond to any changes in the client’s life that may affect treatment 
success. Research should therefore be directed at developing extended interventions for SUD and 
successful strategies for maintaining therapeutic contact and client monitoring for a number 
of years. Research into effective therapeutic and pharmacological relapse prevention strategies, 
chronic care and harm reduction is also necessary to improve the client’s quality of life and 
minimise societal costs (Collins et al., 2012; Marlatt & Witkiewitz, 2005).
Last, the complex nature of SUD in ID calls for a close collaboration between different sectors of 
the health care system, including general psychiatry, addiction medicine and ID services (French et 
al., 2000; Godley, Godley, Dennis, Funk, & Passetti, 2007; Sannibale et al., 2003). This promotes 
adequate referral to addiction medicine, a smoother transition between the different forms of 
treatment and health care sectors and has been proven to be effective in improving abstinence 
rates (e.g., Godley et al., 2007; Sannibale et al., 2003) and reducing long-term societal costs 
(French et al., 2000). Unfortunately, there are still many barriers to treatment access, especially 
for individuals with ID. Research suggest that fewer than 25% of the people in need for SUD 
treatment receive such treatment and this percentage may be even less in individuals with ID 
(Slayter, 2011). And, if they do, they often are not able to profit from it and are at high risk 
for drop out (Degenhardt, 2000). Collaboration should therefore be complemented with cross-
fertilisation between the different sectors. As McLaughlin et al. (2007) note, professionals in ID 
services can educate other professionals about the care for individuals with ID, while professionals 
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in addiction medicine can educate others about the nature and treatment of SUD. This could then 
initiate a joint strategy in providing effective care for clients with ID and SUD.
CONCLUSION
Although often overlooked in the past, SU(D) in individuals with ID has gained attention over 
the past decade. In this selective and critical review, we have provided an overview of the current 
status of SUD in ID, identified gaps in the current literature base and highlighted several issues 
that need to be addressed in future research. Knowledge on prevalence is scarce and tools for 
screening, assessing and treating SUD in this population are needed. In ID care, SUD is also 
often conceptualised as a relatively simple and isolated behavioural problem that can be cured 
with simple and short interventions. This perspective is not in line with current knowledge of 
SU(D) in other fields, in which SUD is conceptualised as a complex, chronic brain disease that 
warrants treatment. Due to the complex nature of SUD, ID services need to work closely together 
with addiction medicine and general psychiatry to provide clients with SUD with appropriate 
assessment, care and treatment. While there are challenges inherent to this, research is needed on 
a variety of topics, including prevalence and risk factors, screening and assessment and treatment. 
This research, together with the recommendations we have made in this chapter, could enhance 
the understanding of SUD in ID and improve the care of individuals with ID and SUD.
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Staff perspectives of substance use and misuse among 
adults with intellectual disabilities enrolled in Dutch 
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ABSTRACT
Background: The use of psychoactive substances seems to be a growing problem among clients of 
Intellectual Disability Services (IDS). However, rates of substance use in Dutch IDS are unknown, 
and it is unclear how services deal with substance related problems.
Aims: This study explores staff members’ perspective on occurrence of substance use, users’ 
profiles, and service policies regarding substance use. 
Method: A semi-structured questionnaire asked respondents to comment on lifetime, current 
and problematic substance use among their clients, provide case reports, and describe policies 
regarding substance related problems. 
Findings: Data from 39 IDS were included. Estimations of occurrence of substance use varied 
greatly across services. Alcohol was reported to be used most often, but in lower percentages than 
in the general population. Cannabis and other drugs were reported to be used relatively often 
when compared to the general population. 
Case reports on 86 substance users were analyzed. Subgroups of users were identified including 
a group of younger clients with both cannabis and alcohol use, and a group of older clients 
with mild ID using alcohol only. Psychiatric comorbidity and lack of daytime activities were 
highly prevalent among cases. Services reported on their interventions and policies concerning 
substance use, rating psychosocial and restrictive measures as most effective, and collaboration 
with addiction facilities and rewarding abstinence as least effective. Most services reported to 
have inadequate expertise on substance use.
Conclusions: According to respondents, clients with both borderline and mild ID use 
substances. Case reports suggest different patterns of use across age groups and level of ID, and 
indicate that substance users face a number of other psychosocial problems. Respondents report 
to be inadequately equipped to meet clients’ needs and to develop effective policies. The low 
effectiveness of mainstream addiction treatment or consultation suggests that there is a need for 
more cross-system collaboration. 
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INTRODUCTION
Persons with mild or borderline Intellectual Disability (ID) are known to use and misuse 
psychoactive substances, such as alcohol, tobacco, cannabis, and other drugs (Burgard, Donhue, 
Azrin, & Teichner, 2000; McGillicuddy, 2006; Taggart, McLaughlin, Quinn, & Milligan, 2006). 
Though prevalences seem to be relatively low, substance use in this population may be associated 
with a higher risk of substance misuse and addiction (Burgard et al., 2000; McGillicuddy, 2006; 
Taggart et al., 2006), more serious physical complications (Westermeijer, Kemp, & Nugent, 
1996), and emotional, behavioral, and psychosocial consequences (Didden, Embregts, Toorn, 
& Laarhoven, 2009; Krishef, 1981; Taggart et al., 2006; VanDerNagel, 2007). Staff members 
of Intellectual Disability Services (IDS) reported a lack of knowledge and skills regarding 
assessment, treatment, and management of substance use and identified problems of inter-agency 
working and accessibility of addiction care (Degenhardt, 2000; Lottman, 1993; McLaughlin, 
Taggart, Quinn, & Milligan, 2007; Sturmey, Reyer, Lee, & Robek, 2003; VanDerNagel, 2007). 
In the Netherlands, IDS support approximately 147000 clients with ID (Ras, Woittiez, van 
Kempen, & Sadiraj, 2010). The majority of IDS are connected to the Dutch Association of Health 
Care Providers for People with Disabilities (Vereniging Gehandicaptenzorg Nederland, VGN). 
Although it is suggested that problems related to substance use among clients from IDS are 
growing in the Netherlands due to de-institutionalization (Geus, Kiewik, VanDerNagel, & 
Sieben, 2009; VanDerNagel, 2007), little is known about how services perceive this issue and 
deal with substance use among their clients. This study explores the perspective of Dutch IDS on 
substance use occurrence among their clients with mild and borderline ID as well as on substance 
use cases, practices, and policies. 
METHOD
Participants 
Services connected to the VGN network (n = 153) were invited to participate in this study if they 
provide support to adults with mild or borderline ID (IQ between 50 and 85). 
Procedure
Information about the study, a link to the web based questionnaire, and a printed questionnaire 
were sent to the main address of all VGN organizations, followed by an email reminder four 
weeks later. Services were free to choose which staff member was best suited to complete the 
questionnaire. After data collection, non-responding organizations were interviewed about their 
motives for not responding. 
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Instrument 
Researchers from both addiction care and IDS developed our questionnaire. Focus groups 
identified relevant topics, reached agreement on definitions and face validity of questions. The 
questionnaire was then successfully pretested among several respondents (4 staff-members from 
IDS). The final questionnaire consisted of four parts. First, general data about the IDS and 
the respondents were collected (total number of clients, number of clients with IQ between 
50 and 85, types of services, job description of respondent). Second, respondents were asked to 
provide data on past-, present-, and problematic use (combining DSMIV definitions of substance 
abuse and dependency; American Psychiatric Association, 2000) of several substances (alcohol, 
cannabis, and ‘other drugs’) in their IDS. In the third part, respondents were asked to report on 
the last five clients with substance use that were brought to their attention. The case report forms 
included structured questions about clients gender and age, level of ID, type of substance use and 
living arrangements, and open ended questions on psychiatric comorbidity, use of medication and 
interventions for substance related questions. The last part of the questionnaire assessed practices 
and policies concerning substance.
Analysis
Quantitative data were collected and analyzed using SPSS17 software. Data on substance use 
provided by IDS were summarized in box plots. To correct for service size, weighted mean 
percentages were calculated, dividing the sum of substance users by the sum of clients in all 
services. Differences between case reports of clients with mild (n = 44) and borderline (n = 42) ID 
were tested using Mann-Whitney tests for continuous data and Chi Square or Fisher Exact tests 
for nominal data. Qualitative data were classified using DSM-IV classification (for psychiatric 
comorbidity) and farmacological groups (for prescribed medication). Responses on interventions 
and policies were evaluated and categorized (for instance: restrictive measures including limiting 
personal freedom or amount of money to be freely spent) by two researchers (J.VDN. & M.K.) 
independently. Differently appraised items were discussed before finally being classified. 
RESULTS
Participating ID service providers
Overall, 153 questionnaires were sent to members of the VGN network. Eleven IDS did not have 
clients with an IQ between 50 and 85; therefore, they were excluded from the study. From the 
remaining 142 services, 50 responded within the data collection period (January – March 2009). 
Four IDS did not have any substance users among their clients and chose not to provide data 
on their population or policies. Therefore these responses could not be included in the analysis. 
Another four were unable to provide data, and three questionnaires were excluded because of 
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missing data. Non-responders were interviewed about their reasons of not responding. The main 
reasons for not responding were lack of time and resources to participate and low accessibility to 
relevant data rather than the absence of substance related problems.
General data on service providers and respondents
The remaining 39 questionnaires (response rate of 27.5%) provided data for both smaller and 
larger IDS (median 200 clients, range 12-4000 clients) from all regions of the Netherlands. These 
services support approximately 25000 clients, of whom over 9600 have a mild or borderline ID. 
Respondents were managers (n = 26, 66.7%), psychologists (n = 10, 25.6%), and medical doctors 
(n = 3, 7.6%). They used different, often multiple sources of information, including their own 
judgment (n = 30, 77%), clients files or database (n = 23, 59%), and contacts with co-workers 
(n = 8, 21%). Only three respondents (7.6%) based their responses on a systematic inventory of 
substance use. 
 
Estimations of substance use among clients
A total of 38 service providers provided data on the past, current, and problematic (that is, 
substance dependence or abuse) use of alcohol, cannabis and ‘other drugs’ among their clients. 
Mann-Whitney tests revealed no differences in reported percentages between the respondents 
who were (very) sure (n = 24, 70%) and those who were not sure about the accuracy of their data. 
Some respondents were not able to provide information on all topics, leading to missing values 
especially for current and lifetime use. Reported percentages of substance use varied greatly across 
services (Figure 1). 
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1a. Alcohol use (%)   1b. Cannabis use (%)    1c. Other Drugs use (%)      1d. Problematic use (%)
    
          Lifetime   Current              Lifetime   Current              Lifetime  Current                   Alcohol Cannabis Other 
          (n = 36)     (n = 34)    (n = 36)    (n = 34)                (n = 33)   (n = 31)             (n = 37)   (n = 37)   (n = 34)   
 
Figure 1. Substance use in Intellectual Disability Services 
Spread in reported substance use in IDS (5th percentile, 1st quartile, 3rd quartile, 95th percentile), median (grey 
line), and weighted mean (black line). 
 
According to our respondents, alcohol is the most commonly used substance among their 
clients (Figures 1 & 2). The reported percentages of problematic drinking relative to the 
percentage of current use seem similar to those found in the general population, that is, 
with approximately one problematic drinker for every 11 non-problematic drinkers (Laar, 
Cruts, Verdurmen, van Ooyen-Houben, & Meijer, 2008). Concerning cannabis and other 
drugs, the ratio of problematic to current use seems much higher. Strikingly, the rate of 
reported problematic cannabis use even outnumbers problematic alcohol use. 
 
 
Figure 2. Substance use in IDS (current) 
Proportion of reported use in IDS according to data on current use percentages. 
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According to our respondents, alcohol is the most commonly used substance among their clients 
(Figures 1 & 2). The reported percentages of problematic drinking relative to the percentage of 
current use seem similar to those found in the general population, that is, with approximately 
one problematic drinker for every 11 non-problematic drinkers (Laar, Cruts, Verdurmen, van 
Ooyen-Houben, & Meijer, 2008). Concerning cannabis and other drugs, the ratio of problematic 
to current use seems much higher. Strikingly, the rate of reported problematic cannabis use even 
outnumbers problematic alcohol use.
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Case Reports
Respondents were asked to report on the last five clients with (any) substance use problems who 
had come to their attention. Overall, 102 Case reports were submitted but 16 incomplete reports 
were excluded. Table 1 summarizes main characteristics of the 86 cases included in this study. 
Demographic variables
Most cases concerned males (n = 70, 81%), ages 16 to 66 years. Most clients (n = 63, 73%) 
lived in a community based facility in independent or group housing. Twelve clients lived in 
a residential facility. Other living arrangements included living with relatives. One client was 
imprisoned. Most clients engaged in one or more daytime activities, but still, 21 (24.4%) had no 
structured activities at all (Table 1). 
Psychiatric comorbidity and use of prescribed drugs 
Psychiatric comorbidity, mainly developmental disabilities (ADHD and autism spectrum 
disorder), personality disorders, and challenging behavior, was present in almost half of the cases. 
In 38 cases (44.7%), clients used prescribed medication, predominantly psychoactive drugs. 
Anticonvulsant use and use of other somatic medication was strikingly low. Substance related 
medication comprised opiate replacement therapy with methadone (n = 2), an aversive drug (n = 
1), and acamprosate (n = 1). 
Cases analyzed by level of ID 
Slightly more than half of the cases (n = 44, 52%) concerned clients with mild ID. These clients 
were significantly older compared to clients with borderline ID (Mann-Whitney .041). ADHD 
diagnoses were significantly higher in clients with borderline ID. Interestingly (though not 
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statistically significant), the majority of the clients living in residential settings had borderline 
ID.
Table 1. Client Characteristics according to Case Reports 
Total  
n = 86 
IQ 70-85 
n = 42 (48%)
IQ 50-70 
n = 44 (52%) p
Gender (n = 86)
Male 70  (81%) 
 
35 (83.3 %)
 
35 (79.5%) .652
Age, years (n = 85)
Range
Mean (SD)
Median 
16 – 66 
29.7 (11.9)
26.0 
n = 41      
17 – 57 
26.8 (9.9) 
23.0 
n = 44      
16 – 66 
32.4 (13.0)
29.5 
.041
Living arrangement (n = 86)
Residential
Group housing
Independent living
Other
12  (14%)
27  (31%)
36  (41%)
11  (13%)
 9  (21.4%)
12 (28.6 %)
16 (38.1 %)
 5 (11.9 %)
 3  (6.8%)
15 (34.1%)
20 (45.5%)
 6 (13.6 %)
 
.051
.581
.489
.810
Daytime activities (n = 86) a ⁪  
Day centre
Work
School
Other
None
41  (47%)
29  (34%)
4   (4.7%)
10  (11%)
21  (24.4%)
19 (45.2%)
16  (38.1%)
 4  (9.5%)
 7  (16.7%)
11 (26.2%)
22 (50%)
13 (29.5 %)
 0 (0%)
 3  (6.8%)
10 (22.7%)
.659
.402
.036
.154
.754
Psychiatric diagnosis (n = 85) a ⁪  
Yes
ADHD
Autism spectrum disorder
Personality disorder
Affective disorder
Psychotic disorder
Other
41  (48.2%)
10  (11.7%)
12  (14.1%)
12  (14.1%) 
 8   (9.4%)
 5   (5.9%)
 2   (2.4%) 
n = 41
24 (58.5%)
 8 (19.5%)
 8 (19.5%)
 7 (17.0%)
 3  (7.3%)
 2 (4.8%)
 0  (0%) 
n = 44
17 (38.5 %)
 2 (4.5%)
 4 (9.1%)
 5 (11.4%)
 5 (11.4%)
 3 (6.8%)
 2 (4.5%)
.067
.047
.183
.478
.501
1.000 FE
.494 FE
Medication use (n =85) a ⁪  
Yes
Anticonvulsants
Anxiolytics/Hypnotics
Antidepressants
Stimulants
Antipsychotics
Substance related
Other somatic
38   (44.7%)
 3    (3.5%) 
 7    (8.2%)
 9   (10.6%)
 4    (4.7%)
13  (15.3%)
 4    (4.7%)
 7   (8.2%)
n = 41
17 (41.5%)
 1  (2.4%)
 3 (7.3%)
 2 (4.9%)
 4 (9.8%)
 7 (17.1%)
 1 (2.4%)
3 (7.1%)
n = 44 
21 (47.7%)
 2 (4.5%)
 4 (9.1%)
 7 (15.9%)
 0 (0%)
 6 (13.6%)
 3 (6.8%)
 4 (9.1%)
.562
1.000 FE
1.000 FE
.157 FE
.053 FE
.695
.616 FE
1.000 FE
Substance use pattern (n =86) 
Alcohol only
Cannabis only
Alcohol and Cannabisb ⁫
Stimulantsc⁬ ⁬
Opiates only
No actual use 
28 (32.6%)
 7  (8%)
31 (34.8%)
13 (15.1%)
 1 (1.2%)
 6 (7.0%)
 8 (19.0%)
 4 (9.5%)
16 (38.1%
10 (23.8%)
 0 (0%)
4 (9.5%)
20 (45.5%)
 3 (6.8%)
15 (34.1%)
 3 (6.8%)
 1 (2.3%)
 2 (4.5%)
.009
.710 FE
.699
.028
1.000 FE
.428 FE
FE Fisher Exact test 
a ⁪   Multiple response option, total > 100%   
b Includes one client misusing medication
c⁬ Stimulant use with or without other substances
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Substance use 
Alcohol was used in 68 (79.1%) cases, in 28 cases as the sole drug, and in other cases combined 
with either cannabis (n = 31) or stimulants (n = 9). Overall, 48 clients used cannabis; in all 
but 7 cases used cannabis in combination with other substances. Clients using methadone or 
benzodiazepines prescribed by a medical doctor (n = 9) were not considered opiate/ benzodiazepine 
users unless they misused the medication (n = 1). In six cases, clients used no substances at the 
time of the survey; however, they all used alcohol in the past, some of them in combination with 
cannabis (n = 4) or stimulants (n = 2). Figure 3 summarizes actual substance use in all 86 cases. 
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Proportion of reported use    Patterns of use 
Figure 3  Substances used in case reports (n = 86) 
  
Cases analyzed by pattern of use  
Clients using alcohol only (n = 28) were older (mean age 39.9, median 41 years, Mann 
Whitney 0.000), more often mildly intellectually disabled (χ2 = 0.041), and more often 
living in their own apartments (χ2 = 0.046). On the other hand, clients who used both 
alcohol and cannabis were younger (mean age 24, median 23 years, Mann Whitney 0.003), 
with both IQ groups evenly represented. These clients lived in residential settings 
significantly more often (χ2 = 0.002). Most stimulant users had borderline ID (χ2 = 0.028). 
They were generally younger (mean age 23.2, median 22 years, Mann Whitney .018) and 
most used other drugs as well. No differences were found in psychiatric comorbidity or 
medication use among users of different substances. 
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Figure 3 Substances used in case reports (n = 86)
Cases analyzed by pattern of use 
Clients using alcohol only (n = 28) were older (mean age 39.9, median 41 years, Mann Whitney 
0.000), more often mildly intellectually disabled (χ2 = 0.041), and more often living in their own 
apartments (χ2 = 0.046). On the other hand, clients who used both alcohol and cannabis were 
younger (mean age 24, median 23 years, Mann Whitney 0.003), with both IQ groups evenly 
represented. These clients lived in residential settings significantly more often (χ2 = 0.002). Most 
stimulant users had borderline ID (χ2 = 0.028). They were generally younger (mean age 23.2, 
median 22 years, Mann Whitney .018) and most used other drugs as well. No differences were 
found in psychiatric comorbidity or medication use among users of different substances.
Policies and Practices
Substance use policies and practices 
The majority of the services had some type of policies on substance use. These consisted 
predominantly of discouraging or prohibiting substance use. However, several respondents 
reported difficulties with enforcing these policies. While restrictive policies seem to prevail at 
the organizational level, various interventions for clients who use substances are used in the daily 
practices. Effectiveness of different interventions varied (Table 2). 
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Table 2. Interventions for Substance Related Problems
 ‘effective or ‘very effective’
Type of intervention a n %
   Psychosocial interventions 20 55%
   Restrictive measures 30 53%
   Psycho education 24 46%
   Intensifying daily care 32 41%
   Referral to / collaboration with addiction care 25 16%
   Rewarding abstinence / reduction of use 9 0%
a Multiple response option 
Most services (79%) had inadequate expertise on substance use problems. Overall, 70 remarks 
were made on educational issues, expressing the need for staff training on topic such as effective 
treatment and preventive interventions (n = 20), substances and their effects (n = 16), suitable 
policies and how to adhere to them (n = 12), and collaboration options (n = 9). Several respondents 
(n = 13) commented on a general lack of expertise, suitable materials, and information on the 
topic. The majority (69%) of IDS collaborated with an addiction treatment facility. Cross-system 
collaboration involved mostly client- based interventions (56%) or staff training (41%).
DISCUSSION & CONCLUSIONS
According to the opinion of service providers in the Netherlands, many clients from IDS with 
mild or borderline ID use alcohol and other drugs. According to our respondents, alcohol is 
used most often, though probably less often than in the general population. On the other hand, 
cannabis and other drugs seem to be used relatively often, with high rates of problematic cannabis 
use. Reported percentages may reflect different patterns of use in the ID population or may be due 
to reporting bias, i.e., to differences in the way respondents are informed about and pay attention 
to different types of substance use. For instance, the relatively low percentage of reported alcohol 
use may partially be explained by reporting bias, because of the general acceptance of the use of 
this substance. Hence, (non-problematic)alcohol use is less likely to come to the attention of staff 
member. On the other hand, Dutch cannabis policies (possession of small amounts of cannabis 
for personal use has been decriminalized), may be a factor explaining high cannabis use among 
clients with ID (VanDerNagel, 2007). These ‘liberal’ policies, though said not to lead to higher 
percentages of use in the general population (Laar et al., 2008), may lead – for some clients- to 
the assumption that cannabis use is harmless, and (combined with factors such as availability and 
peer pressure) to higher prevalence of use (VanDerNagel, 2007). 
Reporting bias could be present in client profiles also. Users of cannabis and other drugs were 
overrepresented in the client profiles compared with estimated rates in IDS (Figure 2 and 3). 
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The percentages of psychiatric comorbidity and the use of psychotropic medication also suggest 
that case reports reflect more severe cases. Interestingly, the use of medication other than 
psychotropics seems extremely low, especially considering that both substance use and ID are 
associated with higher levels of somatic complications. This may suggest that respondents were 
not fully informed about the cases on which they reported. 
Contrary to the assumption that substance use is associated with deinstitutionalization (Sturmey 
et al., 2003), substance use, according to case reports, is present in all subgroups of clients, 
including clients in residential care. Though strategies to improve psychosocial factors (e.g., 
daytime activities) are rated very effective, a significant proportion of clients (case reports) had no 
structured activities at all. Respondents reported that their IDS are not adequately equipped to 
handle substance related issues and seek collaboration with addiction care in vain. Interestingly, 
commonly advocated strategies, such as rewarding abstinence (Degenhardt, 2000), are rated far 
less effective than restrictive measures. 
The results of this study should be interpreted in the context of some limitations. Response 
rates were low, and several questionnaires had to be excluded because of missing data. Among 
non-responders and IDS excluded questionnaires both services who do and services who do not 
recognize substance use problems among their clients. It remains unclear whether results from 
participating IDS can be generalized to all Dutch IDS. We did not include questions about the use 
of nicotine or caffeine. Further, data were collected at the institutional level, and respondents were 
mostly not involved in primary care. Since most services lack systematic registration of substance 
use among their clients, respondents have to rely on other sources. Therefore, data presented in 
this survey reflect the perceptions of services’ management, psychologists, and doctors rather than 
on client-based epidemiological research: therefore, they have to be interpreted with caution. 
This said, since staff members play a very important role in both recognizing potential problem 
areas and finding solutions, staff perspectives on substance use can be critical in both raising and 
addressing the topic. Additionally, more client and caseworkers based research is needed both in 
the field of IDS and in addiction care to establish valid prevalence rates and to evaluate whether 
emerging patterns are representative of the entire population. 
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CHAPTER 4
Capture recapture estimation of the prevalence of mild 
intellectual disability and substance use disorder
This chapter has been published as: 
VanDerNagel, J. E. L., Kiewik, M., Postel, M. G., van Dijk, M., Didden, R., Buitelaar, J. K., 
& de Jong, C. A. J. (2014). Capture recapture estimation of the prevalence of mild intellectual 
disability and substance use disorder. Research in Developmental Disabilities, 35, 808-813. 
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ABSTRACT
Persons with Mild to Borderline Intellectual Disability (MID) have been identified as a group 
at risk for Substance Use Disorder (SUD). However, prevalence estimates of co-occurring SUD 
and MID rely largely on single source studies performed in selected samples. To obtain more 
reliable population estimates of SUD and MID, this study combines data from an Intellectual 
Disability Facility (IDF), and an Addiction Treatment Centre (ATC) in a semi-rural area in The 
Netherlands. Capture-recapture analysis was used to estimate the hidden population (i.e., the 
population not identified in the original samples). Further analyses were performed for age and 
gender stratified data. Staff members reported on 88 patients with SUD and MID in the IDF 
(4.0% of the IDF sample) and 114 in the ATC (5.2% of the ATC sample), with 12 patients in 
both groups. Only strata for males over 30 years provided reliable population estimates. Based 
on 97 patients in these strata, the hidden population was estimated at 215. Hence the estimated 
total population of males over 30 years old with MID and SUD was 312 (95% CI 143-481), 
approximately 0.16% (0.05 – 0.25%) of the total population of this age and gender group. 
This illustrates that while patients with co-occurring SUD and MID often receive professional 
help from only one service provider, single source data underestimate its prevalence, and thus 
underestimate treatment and service needs. Therefore, population prevalence estimations of co-
occurring SUD and MID should be based on combined multiple source data. 
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INTRODUCTION
Little is known about the prevalence of substance use disorders (SUD) among persons with a 
mild or borderline intellectual disability (MID) (Carroll Chapman & Wu, 2012; McGillicuddy, 
2006; VanDerNagel, Kiewik, Buitelaar, & DeJong, 2011). This is problematic because in this 
group the use of psychoactive substances - such as alcohol, cannabis and other illicit drugs - is 
associated with high levels of substance misuse and addiction. Reliable estimations of population 
prevalence are needed to plan treatment capacity and develop strategies for prevention (Carroll 
Chapman & Wu, 2012; McGillicuddy, 2006; VanDerNagel et al., 2011). Though population-
based studies into SUD and co-occurring MID are lacking, several smaller-n studies conducted 
in various clinical, residential, and community settings, have provided data on prevalence rates 
of substance use, misuse, or abuse by persons with intellectual disabilities. For instance, among 
patients from addiction treatment facilities, Westermeijer, Kemp, and Nugent (1996) found that 
6% of them had mild ID. In a sample of persons (n = 122) with mild to moderate ID from local 
community agencies, McGillicuddy and Blane (1999) found that 21% were misusing alcohol. 
Didden, Embregts, Van der Toorn, and Laarhoven (2009) found that among a sample of 39 
patients with MID admitted to a specialized inpatient treatment facility, 46% were substance 
misusers. Chaplin, Gilvarry, and Tsakanikos (2011) reported that among referrals to a psychiatric 
facility for ID, 29% were substance misusers (n = 115). Since these studies concern highly 
selected samples the prevalence rates cannot be generalised. Moreover, these studies do not specify 
substance use rates for relevant subgroups, such as gender and age based strata, even though SUD 
prevalence rates differ across these groups (Laar et al., 2011). Finally, prevalence data from single 
sources (e.g., treatment facilities) are limited since persons with MID and SUD can be referred to 
several types of facilities. 
Under Dutch law, persons with MID and SUD are eligible for help from both an Intellectual 
Disability Facility (IDF) and an Addiction Treatment Centre (ATC). Persons with an IQ between 
70 and 85 are also eligible for IDF support and treatment if they have significant impairments 
in adaptive behaviour and if they present with a range of psychosocial problems such as 
unemployment, financial problems, and social isolation. Many persons with MID do not need (or 
want) inpatient or outpatient institutional care and are thus missed in surveys in IDF samples 
(Ras, Woittiez, van Kempen, & Sadiraj, 2010). Since persons with MID and SUD also seem to 
be less likely to receive addiction treatment or to remain in treatment (Carroll Chapman & Wu, 
2012; VanDerNagel et al., 2011), data from ATCs will not cover the total population with SUD 
and MID either. Thus, although persons with both MID and SUD are eligible for two types of 
support or treatment, it has been noted that many of them receive only one type of help or no help 
at all (VanDerNagel, Kiewik, & Didden, 2012). Hence, prevalence rates of co-occurring SUD and 
MID cannot be reliably estimated from single sources, such as ATCs or IDFs. Nevertheless, single 
source information has been used to estimate population prevalence, and has served as a basis for 
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policy makers. For instance, in 2007 the Dutch Health Minister estimated – based on reports 
from IDFs – that in The Netherlands (total population about 16.8 million) (Centraal Bureau voor 
de Statistiek [Statistics Netherlands], 2007) there were ‘several hundreds’ of youth present with 
MID and SUD (Parliament proceedings, 2007). From clinical experience and data of a survey 
among IDFs (VanDerNagel et al., 2011) we concluded that this is an underestimation of the true 
population rate of SUD and MID (VanDerNagel et al., 2011; VanDerNagel et al., 2012). 
In the present study, we used the data from an ATC and an IDF, located in a semi-rural area in 
the eastern region of The Netherlands with approximately 600,000 inhabitants (Centraal Bureau 
voor de Statistiek [Statistics Netherlands], 2010). In a capture recapture analysis we estimated 
the total number of individuals with both MID and SUD in this region. To obtain information 
on relevant subgroups, we also performed age- and gender-based stratified analysis.
MATERIALS AND METHODS
Overview
The capture recapture method estimates the number of individuals in a population using data 
from multiple and incomplete samples (Böhning, 2008; Brittain & Böhning, 2009; Chao, 2001). 
In its original biological application, a sample (n
1
) from a target population (N) is captured, 
marked and released while the second sample (n
2
) is recaptured later. An estimate of the total 
population size can then be obtained by dividing the number of marked individuals (n
1
) by the 
proportion of marked individuals in the second sample (m
2 
/ n
2
). 
Capture recapture analyses has also been applied in human populations and proven especially 
useful when the target population is elusive or when reliable screening instruments are not 
available (Allgar et al., 2008; Böhning, 2008; Holland et al., 2006). In these applications, two 
(or more) independent datasets can be used as samples. Individuals who are found in both datasets 
are the ‘recaptured’ group. Major advantages of this strategy are that neither dataset needs to be 
complete and that the analysis provides an estimate of the ‘hidden’ population (i.e., the population 
not present in the original samples). 
The assumptions of capture recapture analyses are that (1) the population size is constant during 
the sampling time and (2) all subjects can be matched (for instance by their social security numbers 
or a combination of name, gender and date of birth) (Chao, 2001; Gill, Ismail, & Beeching, 2001). 
Additionally, this approach assumes that (3) each subject in the target population has an equal 
chance of being sampled (homogeneity assumption) and that (4) the samples are independent 
(Gill et al., 2001). In our study, the first assumption is met because the data were collected in 
a relatively short time period. The second assumption is also met because of the availability of 
unique patient identifiers and the possibility to match individuals in both samples. To reduce the 
chance of violating the (third) assumption of homogeneity, gender- and age-based stratification 
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is used to reduce heterogeneity (i.e., the existence of subgroups with unequal [re]catchability). 
Sample dependence (a violation of assumption 4) in our study is not assumed since ATC and IDF 
care are not mutually exclusive. Referral criteria for both types of care are independent of the 
involvement of other care. Also, the Chao estimator (see Equation 1) that we used is relatively 
robust to violations of the assumption of independency (Brittain & Böhning, 2009).
Equation 1: Chao’s estimator
robust to violations of the assumption of independency (Brittain & Bo¨hning, 2009).
N ¼ ðm2 þ n01 þ n10Þ þ ðn01 þ n10Þ
2
4m2
VARðNÞ ¼ ðn01 þ n10Þ
2
4m2
ðn01 þ n10Þ
2m2
þ1
 2 (1)
with N = estimated population size, and 95% CI =N� 1.96 HVAR(N).
2.2. Data sources
In the present study, data from patients with co-occurring MID and SUD from (1) an ATC and (2) an IDF were used. The
ATC (2196 patients at the time of sampling) is the main addiction treatment provider while the IDF is one of the major
service providers (2200 clients) in a semi-rural area in the Netherlands. Each individual has a coordinating staff member
who oversees the care of each individual. All staff members (59 in the ATC, 37 in the IDF) were asked to identify patients
with co-occurring MID and SUD presently in their caseloads and to provide their patient identiﬁers. Though formally not
required, patients (or their representatives), signed upon admittance to agree to anonymous use of their ﬁles for scientiﬁc
and/or management purposes. Ethical clearance for this study was obtained by the scientiﬁc boards of the participating
centres.
2.3. Records and patient identiﬁers
Both the ATC and IDF use electronic patient records with unique patient identiﬁers. Using these identiﬁers, doubles in
each list were deleted ﬁrst and then patient ﬁles were used by two of the authors (JVDN and MK) to validate MID and SUD
diagnosis. MID was deﬁned as an IQ in the mild to borderline range (IQ 50–85) assessed either formally by a standardized
and validated test or informally by a history of special education or institutionalization in a facility for thosewithMID. SUD
was deﬁned as either DSM-IV-TR Substance Abuse (305) or Substance Dependence (303.9 and 304), with the exception of
nicotine dependence (305.1). Interrater reliability for the presence of SUD andMIDwas good (kappa = 0.74). Case ﬁleswere
further screened to record patient characteristics, and to assess substance use patterns as well as the involvement of other
agencies (other ATC or IDF). Demographic data (name, gender and date of birth) were used to identify patients who were
present in both samples, and were then deleted from the database.
2.4. Statistical analysis
Independent samples t-tests, Chi-square tests, and Fischer exact tests were used to test differences in patient
characteristics between IDF and ATC samples (SPSS 19.0). Prevalence rates for SUD and co-occurring MID in the IDF and ATC
samples were calculated based on single source data. Population prevalences for SUD and co-occurring MID in this
geographical area were calculated using the capture recapture data and population statistics from the Statistics Netherlands
database (Centraal Bureau voor de Statistiek [Statistics Netherlands], 2010). Population prevalences and prevalences broken
down by gender and age were calculated using Chao’s estimator (see Eq. (1)). To this purpose, we used the younger (<30
years) patients as one age stratum and divided the remaining patients into two roughly equal subgroups (30–44 years and
>45 years).
3. Results
In the ATC, 34 staff members (58%) reported on 144 patients with MID and in the IDF, 25 staff members (68%) identiﬁed
106 patients with SUD. After screening for doubles and excluding patients for whom ID or SUDwere not conﬁrmed, the ATC
list (n1) comprised 114 patientswith ID. The IDF list (n2) included 88 patients. No signiﬁcant differenceswere found between
these samples in terms of age, gender, ethnicity or level of ID (mild versus borderline ID) (Table 1). Signiﬁcantly more
patients used stimulants and benzodiazepines in the ATC than in the IDF.
3.1. Estimation of prevalence based on single sources
Overall, 114 ATC patients identiﬁed withMID comprised 5.2% of the ATC population. In the IDF, the sample of 88 patients
accounted for 4% of the total number of patients. Only twelve patients were in both samples. However, additional case ﬁle
screening revealed that 10 patients identiﬁed in the ATC sample were also patients of the IDF (and thus were missed in the
IDF sample) and 12 IDF patients were also patients of the ATC. Including these patients resulted in an increase of the
percentage of patients with MID in the ATC to at least 5.7% and the percentage of SUD in the IDF to at least 4.5%. Another IDF
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J.E.L. VanDerNagel et al. / Research in Developmental Disabilities xxx (2014) xxx–xxx 3
G Model
RIDD-2184; No. of Pages 6
Please cite this article in press as: VanDerNagel, J. E. L., et al. Capture recapture estimation of the prevalence of mild
intellectual disability and substance use disorder. Research in Developmental Disabilities (2014), http://dx.doi.org/
10.1016/j.ridd.2014.01.018
With   estimated population size, and 95  CI = N ± 1.96 √VAR(N)
Data sources
In the present study, data from patients with co-occurring MID and SUD from (1) an ATC and 
(2) an IDF were used. The ATC (2,196 patients at the time of sampling) is the main addiction 
treatment provider while the IDF is one of the major service providers (2,200 clients) in a semi-
rural area in the Netherlands. Each individual has a coordinating staff member who oversees the 
care of each individual. All staff members (59 in the ATC, 37 in the IDF) were asked to identify 
patients with co-occurring MID and SUD presently in their caseloads an  to provide their 
patient identifiers. Though formally not required, patients (or their representatives), signed upon 
admittance to agree to anonymous use of their files for scientific and/or management purposes. 
Ethical clearance for this study was obtained by the scientific boards of the participating centres. 
 
Records and Patient identifiers
Both the ATC and IDF use electronic patient records with unique patient identifiers. Usi g these 
identifiers, doubles in each list were deleted first and then patient files were used by two of the 
authors (JVDN and MK) to validate MID and SUD diagnosis. MID was defined as an IQ in the 
mild to borderline range (IQ 50-85) assessed either formally by  standardized and validat  test 
or informally by a history of special education or institutionalization in a facility for those with 
MID. SUD was defined as either DSM-IV-TR Substance Abuse (305) or Substance Dependence 
(303.9 and 304), with the exception of nicotine dependence (305.1). Interrater reliability for 
the presence of SUD and MID was good (kappa = .74). Case files w re further screened to rec rd 
patient characteristics, and to assess substance use patterns as well as the involvement of other 
agencies (other ATC or IDF). Demographic data (name, gender and date of birth) were used to 
i entify pati s who w re present in both sample , and wer  then deleted from the database. 
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Statistical Analysis
Independent samples t-tests, Chi-square tests, and Fischer Exact tests were used to test differences 
in patient characteristics between IDF and ATC samples (SPSS 19.0). Prevalence rates for SUD 
and co-occurring MID in the IDF and ATC samples were calculated based on single source data. 
Population prevalences for SUD and co-occurring MID in this geographical area were calculated 
using the capture recapture data and population statistics from the Statistics Netherlands database 
(Centraal Bureau voor de Statistiek [Statistics Netherlands], 2010). Population prevalences 
and prevalences broken down by gender and age were calculated using Chao’s estimator (see 
equation1). To this purpose, we used the younger (< 30 years) patients as one age stratum and 
divided the remaining patients into two roughly equal subgroups (30-44 years and > 45 years). 
RESULTS
In the ATC, 34 staff members (58%) reported on 144 patients with MID and in the IDF, 25 staff 
members (68%) identified 106 patients with SUD. After screening for doubles and excluding 
patients for whom ID or SUD were not confirmed, the ATC list (n
1
) comprised 114 patients with 
ID. The IDF list (n
2
) included 88 patients. No significant differences were found between these 
samples in terms of age, gender, ethnicity or level of ID (mild versus borderline ID) (table 1). 
Significantly more patients used stimulants and benzodiazepines in the ATC than in the IDF.    
Table 1. Characteristics of patients in IDF sample and ATC sample
ATC sample IDF sample t/χ2 df p
n = 114 n = 88
Age (SD) 40.8 (12.6) 37.8 (13.5) 1.6 200 .11
Gender (male) 84 (74%) 67 (76%) .16 1 .69
Ethnicity (Dutch) 102 (89%) 82 (93%) .84 1 .36
Mild ID a 46 (40.4%) 47 (53.4%) 3.4 1 .07
Substance useb
   Alcohol
   Cannabis
   Stimulants c 
   Opiates 
   Benzodiazepines
93 (81.6%)
40 (35.1%)
37 (32.5%)
13 (11.4%)
16 (14.0%) 
75 (85.2%)
36 (40.9%)
13 (14.8%)
3 (3.4%)
4 (4.5%)
.47
.71
8.3
4.4
5.0
1
1
1
1
1
.49
.40
.004
.06 (FE)
.03 (FE)
FE: Fischer exact test
a As opposed to borderline ID
b Multiple response option
c Including XTC
Estimation of prevalence based on single sources
Overall, 114 ATC patients identified with MID comprised 5.2% of the ATC population. In the 
IDF, the sample of 88 patients accounted for 4% of the total number of patients. Only twelve 
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patients were in both samples. However, additional case file screening revealed that 10 patients 
identified in the ATC sample were also patients of the IDF (and thus were missed in the IDF 
sample) and 12 IDF patients were also patients of the ATC. Including these patients resulted in 
an increase of the percentage of patients with MID in the ATC to at least 5.7% and the percentage 
of SUD in the IDF to at least 4.5%. Another IDF was involved in 23 ATC patients.
Estimation of prevalence based on capture recapture methodology
Though patients with co-occurring SUD and MID are eligible for dual (ATC and IDF) care, the 
overlap between the two sources is limited (table 2). This indicates an underestimation of the 
population of patients with co-occurring MID and SUD. 
Table 2. Number of patients in IDF sample, ATC sample and both. 
Intellectual Disability Sample
Present Absent Total
Addiction 
Treatment
Sample
Present m
2 
= 12 n
01 
= 102 n
1
= 114
Absent n
10 
= 76 n
00 
= ? 76 + ?
Total n
2
= 88 102 + ? N = 190 + ?
N: total population, n
00
: hidden population
   
Application of Chao’s estimator for capture recapture analysis resulted in a total population 
estimate of N = 850 (95% CI 426 – 1274). Thus, under the assumption of homogeneity, the 
hidden population of patients with both MID and SUD is estimated to be 660 (range 236-1084). 
Capture recapture analysis of stratified data
Stratified analysis, however, showed differences in recapture frequencies and estimated sampling 
rates for several strata (Table 3). 
Table 3. Age and gender strata. 
ATC
n
1
IDF
n
2
Both
m
2
Estimated
N (95% CI)
Sampling
rate (%)a p 
Males
 < 30 yrs 20 25 1 506 (- 442 – 1454) 8.7% < .001
  30 – 45 yrs 33 20 4 175 (29 – 322) 28.0%
  45+ yrs 31 22 5 140 (41 – 240) 34.3%
Females
  < 30 yrs 10 7 1 72 (- 53 – 197) 22.2% n.a.
  30 – 45 yrs 12 7 1 90 (- 68 – 249) 20.0%
  45+ yrs 8 7 0 n.a. n.a.
a (n
1
 + n
2
 - m
2
 )/N 
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Women were recaptured only twice, thus providing a high degree of uncertainty in the population 
estimates for these strata. For two of the female strata, capture recapture analysis provided an 
estimate with a negative lower bound for the 95% confidence interval. In the third subgroup, no 
calculations were made because of the lack of overlap between n1 and n2. Taken as one group, the 
confidence interval around the population estimate for women also contained zero (not in Table), 
thus no estimate for the number of females with SUD and MID can be given. Young males (< 30 
years) were relatively infrequently recaptured, and population estimates for this subgroup could 
not be reliably calculated. The data for males between 30 and 45 years (n = 49) and males older 
than 45 years (n = 48) provided valid population estimates and comparable sampling rates (Table 
3). In sum, the population of male patients over 30 years with SUD and MID was estimated 
to be 312 (95% CI 143-481). Based on this estimate, males over 30 years with MID and co-
occurring SUD account for approximately 0.16% (0.05 – 0.25%) of the total population of this 
age and gender group (approximately 193,000, Centraal Bureau voor de Statistiek [Statistics 
Netherlands], 2010) in this area. 
DISCUSSION
In the present study, we used two samples, one from an Intellectual Disability Service (IDF, 
n = 88) and one from an Addiction Treatment Centre (ATC, n = 114), to estimate the number 
of patients with MID and SUD in a semi-rural area in The Netherlands. To our knowledge, it is 
the first to apply capture recapture analysis to estimate the prevalence of co-occurring MID and 
SUD. The percentages found in the IDF and ATC samples, namely 4.5% and 5.7% respectively, 
were lower compared to those found in studies by for example McGillicuddy and Blane (1999) 
and Westermeijer et al. (1996). These differences in single source prevalence estimates probably 
do not reflect a true difference in prevalence rates; rather, they result from incomplete sampling 
in our study. Unlike in single source studies, incomplete sampling is not a major issue in capture 
recapture analysis. Capture recapture techniques were specifically developed to use multiple 
incomplete samples to provide population estimations. 
Our initial capture recapture analysis revealed a large ‘hidden’ population of patients with MID 
and SUD. However, age and gender based stratified analysis showed unequal capture probabilities; 
hence, stratified data must be presented. The population estimate for male patients over 30 years 
with both MID and SUD was more than three times the number found in our original sources. 
This illustrates once more how single source data may underestimate population prevalence rates. 
Moreover, if we extrapolate the outcomes of capture recapture analysis, the number of males over 
30 years with SUD and MID in the Netherlands would be over 8,000 patients. 
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Unfortunately, due to the lack of recaptures in these strata, we were not able to calculate prevalence 
rates for younger age groups and females. The lack of recapture may indicate that subgroups 
of patients with MID and SUD differ with regard to the support or treatment they receive. 
Especially the relative underrepresentation of younger males in the ATC sample – traditionally 
the group with most SUD problems – is striking. This may reflect either that SUD and MID in 
this gender and age group are less prevalent, less detected, or – more plausible because of the high 
ratio of patients of this age group in the IDF compared to the ATC – not (yet) seen as reason for 
referral to specialized addiction care. 
Even though persons with SUD and MID are eligible for double support or treatment (i.e. from 
both an ATC and IDF), the majority (133 patients, 70%), only received one type of care. Contrary 
to suggestions given by other authors (e.g. Slayter, 2010) we cannot attribute this to financial 
hindrances, since in The Netherlands both types of care are either reimbursed by the state or 
covered by the mandatory health care insurance. By consequence, even if financial hindrances 
to dual care are small, data from either ATCs or IDFs will underestimate the prevalence rate of 
individuals with SUD and MID. Also, it can be doubted whether all of these patients receive 
optimal care. 
CONCLUSIONS
This study shows how single source data underestimate the prevalence of co-occurring SUD and 
MID. Capture recapture analysis can be used to estimate the prevalence of MID and co-occurring 
SUD from combined ATC and IDF data, even when both facilities do not provide data on all 
patients. Therefore, the treatment and service capacity planning for patients with MID and co-
occurring SUD should be based on combined multiple source data instead of single source data. 
Combining – and not merely adding – data from multiple sources in capture recapture analysis 
provides a more reliable estimate of population prevalence of SUD and MID. 
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CHAPTER 5
Substance use in individuals with mild to borderline 
intellectual disability: a comparison between self-report, 
collateral-report and biomarker analysis
This chapter has been accepted for publication:  
VanDerNagel, J. E. L, Kiewik, M., van Dijk, M., Didden, R., Korzilius, H. P. L. M, van der 
Palen, J., Buitelaar, J. K., Uges, D. R. A., Koster, R. A., de Jong, C. A. J. (in press) Substance 
use in individuals with mild to borderline intellectual disability: a comparison between self-
report, collateral-report and biomarker analysis. Research in Developmental Disabilities. 
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ABSTRACT
Background and Aims: Individuals with mild or borderline intellectual disability (MBID) are 
at risk of substance use (SU). At present, it is unclear which strategy is the best for assessing SU 
in individuals with MBID. This study compares three strategies, namely self-report, collateral-
report, and biomarker analysis.
Methods and Procedures: In a sample of 112 participants with MBID from six Dutch facilities 
providing care to individuals with intellectual disabilities, willingness to participate, SU 
rates, and agreement between the three strategies were explored. The Substance use and misuse in 
Intellectual Disability -Questionnaire (SumID-Q; self-report) assesses lifetime use, use in the previous 
month, and recent use of tobacco, alcohol, cannabis, and stimulants. The Substance use and misuse 
in Intellectual Disability - Collateral-report questionnaire (SumID-CR; collateral-report) assesses staff 
members’ report of participants’ SU over the same reference periods as the SumID-Q. Biomarkers 
for SU, such as cotinine (metabolite of nicotine), ethanol, tetrahydrocannabinol (THC), and its 
metabolite THC-COOH, benzoylecgonine (metabolite of cocaine), and amphetamines were 
assessed in urine, hair, and sweat patches.
Results: Willingness to provide biomarker samples was significantly lower compared to 
willingness to complete the SumID-Q (p< .001). Most participants reported smoking, drinking 
alcohol, and using cannabis at least once in their lives, and about a fifth had ever used 
stimulants. Collateral-reported lifetime use was significantly lower. However, self-reported past 
month and recent SU rates did not differ significantly from the rates from collateral-reports 
or biomarkers, with the exception of lower alcohol use rates found in biomarker analysis. The 
agreement between self-report and biomarker analysis was substantial (kappas .60 - .89), except 
for alcohol use (kappa .06). Disagreement between SumID-Q and biomarkers concerned mainly 
over-reporting of the SumID-Q. The agreement between SumID-CR and biomarker analysis was 
moderate to substantial (kappas .48 - .88), again with the exception of alcohol (kappa .02). 
Conclusions and Implications: In this study, the three strategies that were used to assess 
SU in individuals with MBID differed significantly in participation rates, but not in SU rates. 
Several explanations for the better-than-expected performance of self- and collateral-reports are 
presented. We conclude that for individuals with MBID, self-report combined with collateral-
report can be used to assess current SU, and this combination may contribute to collaborative, 
early intervention efforts to reduce SU and its related harms in this vulnerable group. 
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INTRODUCTION
Individuals with mild to borderline intellectual disability (MBID) (IQ 50-85, American 
Psychiatric Association [APA], 2013) are at risk of substance use (SU) and substance use disorder 
(SUD; Carroll Chapman & Wu, 2012; van Duijvenbode et al., 2015). For epidemiological purposes 
as well as case identification in clinical settings, several strategies may be used to assess SU: self-
report, collateral-report (report by professionals, family members, or peers on participant’s use), 
and biomarker analysis of urine, hair, or sweat patches. At present, it is unclear which strategy is 
most suitable for the assessment of SU in individuals with MBID. 
In individuals without MBID, self-report, collateral-report, and biomarker analysis have been 
compared in a range of studies (see e.g., Akinci, Tarter, & Kiriski, 2001; Connors & Maisto, 
2003; de Beaurepaire et al., 2007; Fendrich, Johnson, Wislar, Hubbell, & Spiehler, 2004). 
In epidemiological studies, collateral-report has yielded similar or lower estimations of SU 
compared to self-report (e.g., Connors & Maisto, 2003; Stasiewicz et al., 2008). However, self-
report has yielded lower SU rates compared to biomarker analysis (see e.g., Fendrich et al., 2004). 
Specifically, high rates of under-reported illicit drug use and alcohol use (i.e., no self-reported 
SU while biomarker analysis was positive) have been found, combined with lower rates of over-
reported SU (i.e., self-reported SU while biomarker analysis was negative) (Akinci, Tarter, & 
Kiriski, 2001; de Beaurepaire et al., 2007). For instance, in patients in a psychiatric hospital, de 
Beaurepaire et al. (2007) found that 52% under-reported and 14% over-reported illicit drug use 
and 56% under-reported and 23% over-reported alcohol use compared to the biomarker analysis. 
For tobacco use, the rates of under-reporting were much lower (1-10%; Rebagliato, 2002). 
In individuals with MBID, both collateral-report and self-report have been used to estimate the 
rates of SU (see Carroll Chapman & Wu, 2012; van Duijvenbode et al., 2015). However, both 
strategies have shortcomings. For instance, some evidence suggests that collateral-report is more 
sensitive to more severe cases of SU in MBID (VanDerNagel, Kiewik, Buitelaar, & De Jong, 
2011a). Additionally, self-reported SU may be even more biased in individuals with MBID, 
especially when questionnaires not adapted to the needs of this group are used (McGillicuddy, 
2006; van Duijvenbode et al., 2015). 
Given the potential for bias related to self-report and collateral-report, biomarker analysis seems 
appealing as a more objective measurement of SU in individuals with MBID. Nevertheless, its 
usability and validity depend on several factors. First, false positive testing can occur due to 
environmental contamination (e.g., second hand smoking, or accidental transfer of the substance 
to the sampling site), the use of prescribed medication, or the use of products such as baby wash 
(Brahm, Yeager, Fox, Farmer, & Palmer, 2010; Cotten, Duncan, Burch, Seashore, & Hammett-
Stabler, 2012). Second, false negative testing can occur due to tampering with the sample 
(‘cheating the drug test’) or dilution of the substance in incidental use (Fendrich et al., 2004; 
Hoiseth et al., 2008). Third, both the window of detection of SU and the threshold of detectable 
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use vary across different types of biomarker analysis. For instance, hair analysis is suitable to detect 
SU over long periods, depending on hair length (Cooper, Kronstrand, & Kintz, 2012; Koster, 
Alffenaar, Greijdanus, VanDerNagel, & Uges, 2014a). Drug patches absorb traces of substances 
and their metabolites through the skin during the time they are worn, which can be up to one 
week (Koster, Alffenaar, Greijdanus, VanDerNagel, & Uges, 2014b). Urine analysis provides 
information about more recent use based on the pharmacokinetic properties of the substance of 
interest from days or even hours (cocaine, alcohol) to weeks (cannabis, nicotine) before sampling 
(Moeller, Lee, & Kissack, 2008a; Wojcik & Hawthorne, 2007). Finally, feasibility of large scale 
biomarker testing and participation rates are limited, since hair and sweat patch analysis is costly 
and biomarker sampling is to some extent seen as invasive and intrusive (Fendrich, Johnson, 
Wislar, Hubbell, & Spiehler, 2004).
In short, all three strategies to assess SU – self-report, collateral-report, and biomarker analysis 
– have their strengths and weaknesses, and it is unclear how they perform when applied to 
individuals with MBID. In this study, we compared a) self-reported SU measured by the Substance 
use and misuse in Intellectual Disability - Questionnaire (SumID-Q, VanDerNagel, Kiewik, Van Dijk, 
De Jong, & Didden, 2011b; VanDerNagel, Kemna, & Didden, 2013), b) collateral-reported 
SU measured by the Substance use and misuse in Intellectual Disability Collateral-report questionnaire 
(SumID-CR), and c) biomarker analysis of urine, hair, and sweat patches in individuals with 
MBID. Our main objectives were to compare willingness to participate in each strategy, to assess 
SU rates across the three strategies, and to explore agreement and disagreement among them. 
Regarding willingness to participate, we hypothesized that (1) there would be greater willingness 
to participate in SumID-Q than with biomarker analysis, and (2) willingness to participate in 
hair and sweat patch sampling would be lower compared to willingness to participate in urine 
sampling. Furthermore, we hypothesized that (3) SU rates measured with biomarkers would be 
higher than those measured with self-report and collateral-report, (4) SU rates measured with 
biomarker samples with a large window of detection (i.e., hair and sweat patch analysis) would be 
higher than those measured with samples with a smaller window of detection (i.e., urine analysis), 
and (5) self-reported lifetime SU would be higher compared to collateral-reported lifetime SU, 
especially for illicit substances. Regarding the agreement and disagreement between the three 
strategies, we hypothesized that there would be (6) moderate agreement between SumID-Q and 
biomarker analysis as well as between SumID-CR and biomarker analysis, (7) under-reporting of 
SU when SumID-Q and SumID-CR are compared with biomarkers, and (8) under-reporting of SU 
when collateral-report is compared to self-report. 
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METHODS
Participants
Between November 2011 and December 2012, six organizations of the Dutch Association of 
Healthcare Providers for People with Disabilities invited 135 individuals with intellectual 
disabilities (ID) who had access to substances to participate. Two individuals refused to 
participate for unspecified reasons, three had no MBID, one individual withdrew consent during 
the SumID-Q interview and caregivers of two individuals withdrew consent to participate. Whilst 
127 individuals (94%) completed the SumID-Q, 15 individuals (11% of the original sample) 
refused to provide any biomarker samples and as such were excluded from the study, leaving a 
total sample of 112 (83%) participants (see Table 1 for participant characteristics). 
Collateral-report of SU was sought for the remaining 112 participants from the staff members, 
who were all involved in the day-to-day care of the participants. This resulted in 97 completed 
SumID-CR questionnaires (87%). A power analysis (with G*Power Version 3.1.92) assessing the 
ability to detect a statistically significant difference showed that testing 2x2 contingency tables 
with this sample size would yield a power of .89 at a medium effect size (w = 0.30, Cohen, 1992) 
and an α of .05. 
Table 1. Participant Characteristics (N = 112)
M(SD)          n (%) 
Gender 
Male 
Age (in years) 
Level of IDa 
Mild (IQ 50-70)
Borderline (IQ 71-85)
Mean IQ (n = 79) a
ID Service 
Residential facility
Community facility
Outpatient
39.2 (15.9) 
64.9 (8.7) 
75 (66.4)
73 (65.2)
39 (34.8)
22 (20.2)
40 (36.7)
50 (44.6)
a Based on information provided by the ID facility
Measurements
Self-report: The SumID-Q (VanDerNagel et al., 2011b; VanDerNagel et al., 2013) was used 
to assess lifetime, last month, and recent use of tobacco, alcohol, cannabis, and stimulants 
(cocaine and amphetamines), as they are the substances used most often by individuals with 
MBID residing in Dutch facilities (VanDerNagel et al., 2011a). To decrease self-report bias, 
the questionnaire comprised (1) adapted item structure and wording, (2) visual aids, and (3) a 
step-by-step non-confrontational approach (VanDerNagel et al., 2013). The SumID-Q assesses 
participants’ familiarity with substances (by showing a standardized set of substance-related 
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pictures and asking participants to identify them), substance knowledge and attitudes, and SU in 
participants’ social environment (e.g., peers’, family members’, and professional caregivers’ SU). 
Although the results related to these items are not directly relevant to this study, they serve as a 
means to discuss SU openly. The participants were then asked ‘Have you ever use this?’ (lifetime 
use; yes/no response format) for each substance, and if so, ‘Once or more often?’ and ‘How old 
were you (the first time)?’. Subsequently, SU patterns (frequency, quantity, circumstances) and 
past month and recent SU (yes/no) were assessed. To enable comparison of SumID-Q responses 
with urine samples, ‘recent use’ was defined differently for cannabis and tobacco (two weeks) and 
for alcohol and stimulants (two days). Participants who did not recognize any pictures of a certain 
type of substance were classified as self-reported ‘non-users’ of this substance. The administration 
of the SumID-Q took 45 to 60 minutes.
Collateral-report: The Substance use and misuse in Intellectual Disability Collateral-report (SumID-CR) 
was used to assess staff members’ rating of participants’ SU. For each substance (i.e., tobacco, 
alcohol, cannabis, and stimulants) and reference period (i.e., lifetime, previous month, and 
recent), three response options were given: ‘probably used’/‘probably did not use’/‘do not know’. 
Responses in the latter category were excluded from the analysis. The collateral-report was 
completed within 10 to 15 minutes. 
Biomarkers (urine, hair, and sweat patches): Urine samples were analyzed using Gas Chromatography 
(GC) and immunoassay. Liquid Chromatography, coupled with tandem Mass Spectrometry (LC-
MS/MS), was used to analyze relevant substances in hair and sweat patches (Koster et al., 2014a, 
2014b). Tobacco use was measured by cotinine in urine, hair and sweat patches. Alcohol use was 
measured by ethanol in urine, but for technical reasons not in hair and sweat patches (Kintz & 
Nicholson, 2014; Koster et al., 2014a, 2014b). Cannabis use was measured by THC-COOH 
in urine and by THC in hair. THC and THC-COOH could not be measured in sweat patches 
because of technical issues, which have also been reported in previous studies (e.g., De la Torre 
& Pichini, 2004). In urine, sweat patches, and hair, amphetamines and benzoylecgonine, the 
main metabolite of cocaine, were used to measure stimulant use. Cut-off concentrations from our 
laboratory (Koster et al., 2014a, 2014b) and from well-established references (Bush, 2008; Cooper, 
Kronstrand, & Kintz, 2012; Mayo Medical Laboratories, 2015) were used to classify test results 
as positive or negative. Detection of a substance with a concentration below its cut-off value was 
classified as negative. Recent SU according to biomarkers was defined as a positive urine test for 
each substance, and monthly use according to biomarkers was defined by any positive biomarker 
analysis for each substance. Unfortunately, two hair samples, two patches, and a urine sample 
were lost in the mail, six hair samples were not analyzed for technical reasons, and three sweat 
patch sets were not worn correctly. Therefore, our biomarker analysis included 104 urine samples, 
44 hair samples (five without corresponding urine samples), and 27 sets of sweat patches. 
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Procedure
A trained research assistant visited participants at their residence or another venue of their choice. 
Following a video presentation explaining the content and aim of the study, informed written 
consent was obtained from participants as well as their legal representatives or primary caregiver. 
Participants with sufficient scalp hair length (≥ 2 cm, ± 0.79 inches) completed the SumID-Q 
and provided a urine sample. During a second visit one month later, they provided a hair sample 
(diameter 0.5 cm, taken 1 cm from the scalp to minimize contamination). Participants with 
insufficient scalp hair length to provide a hair sample (< 2 cm) were asked to wear a transdermal 
patch and change it weekly (this was supported by their primary caregiver). After wearing 
sweat patches for four consecutive weeks, participants completed the SumID-Q and provided a 
urine sample. Samples were sent to the laboratory by regular postal service and stored until the 
analysis. Primary caregivers completed the SumID-CR on the same day as the SumID-Q interview. 
Participants received a small gift (worth approximately €2,50 / $2,70) after the second visit. 
The Medical Ethical Review Board Twente (NL27716.044.09) approved the study, which was 
conducted in accordance with the Declaration of Helsinki (World Medical Association, 2013). 
Data analysis
The data were analyzed with IBM® SPSS® Statistics (version 21). Differences in willingness 
to participate between the SumID-Q interview and biomarker sampling and between different 
biomarker sampling methods were quantified using Chi-square tests. To test whether SU rates 
varied across various assessment strategies, Cochran’s Q test statistic was calculated. To test the 
agreement corrected for chance agreement between the SumID-Q, the SumID-CR, and biomarker 
analysis, we calculated Cohen’s kappas and used Landis and Koch’s (1977) interpretation. To 
analyze under- and over-reports, we calculated percentages, comparing SumID-Q with biomarker 
analysis as the criterion as well as SumID-CR with the SumID-Q as the criterion. Statistical 
significance was set at an alpha level of .05. In case of post-hoc tests, Bonferroni correction was 
applied for multiple comparisons, by dividing the alpha level by the number of comparisons.
RESULTS
Differences between SumID-Q and biomarker analysis in willingness to participate
In addition to the fifteen individuals who refused to provide any biomarkers, several were not 
willing to participate in either the urine analysis or the hair/sweat patch analysis. This resulted in 
significantly lower biomarker participation (77% for urine sampling, 62% for hair or sweat patch 
sampling) compared to SumID-Q participation (94%, χ2(2, n = 135) = 39.95, p < .001). Post hoc 
tests revealed that willingness to participate in the SumID-Q was significantly higher compared 
to both the urine testing (χ2(1, n = 135) = 15.85, p < .001) and the combined hair or sweat patch 
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testing (χ2 (1, n = 135) = 40.10, p < .001). Willingness to participate was significantly lower in 
hair or sweat patch testing compared to urine testing (χ2 (1, n = 135) = 7.00 p < .001). 
SU rates according to the three measurements
Most participants reported smoking, drinking alcohol, and using cannabis at least once in their 
lives, and about a fifth had ever used stimulants. Self-reported lifetime SU rates were significantly 
higher compared to collateral-reported SU rates for smoking, alcohol use, and cannabis use but 
not for stimulant use (Table 2). 
No significant differences in past month SU rates were found among self-report, collateral-report, 
and biomarker analysis, except for the lower alcohol use rates found with biomarkers (Table 2). 
Hair and sweat patch analysis identified four users of tobacco and two users of stimulants who had 
no positive urine samples. No participants tested positive for THC in their hair. As such, previous 
month SU rates based on all biomarkers did not differ significantly from those found with urine 
analysis alone (Q(1) = 3.00, p = .083 for smoking; Q(1) = .00, p = 1 for cannabis use; and Q(1) = 
2.00, p = .157 for stimulant use). 
Recent SU rates differed significantly across the three strategies for tobacco use and alcohol use 
(Table 2). Post hoc tests showed that self-reported recent smoking did not differ significantly from 
either collateral-report or biomarkers (Q(1) = 1, p = .317, and Q(1) = 3, p = .083, respectively). 
Collateral-reported recent smoking was not significantly lower compared to recent smoking 
according to biomarkers when Bonferroni correction was applied (Q(1) = 4, p = .046). Post hoc 
tests further showed that recent alcohol use rates found with urine analysis were lower compared 
to those found with the SumID-Q (Q(1) = 25, p < .001) and SumID-CR (Q(1) = 49, p < .001). 
Additionally, SumID-CR recent alcohol use rates were significantly higher than SumID-Q rates 
(Q(1) = 26.5, p < .001). 
 
Agreement among the three measurements
The agreement among SumID-Q, SumID-CR, and biomarker analysis varied across substances and 
types of biomarkers (Table 3). Kappas were substantial for tobacco use and very low for alcohol 
use. Self-reported recent cannabis use agreed substantially with the results of urine analysis, 
whilst collateral-reported recent cannabis use agreed moderately. Agreement of self-reported and 
collateral-reported cannabis use in the previous month with hair analysis was non-significant. 
Agreement of self-reported and collateral reported stimulant use with biomarkers could not be 
assessed reliably due to the low rate of stimulant use among participants. 
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Table 2. SU rates according to SumID-Q, SumID-CR and biomarker analysis
 Self-report 
(n = 112)
Collateral report
(n = 97)
Biomarkersa Q(1)
 
p
      
Lifetime use
Tobacco
Alcohol
Cannabis
Stimulants
Monthly use
Tobacco
Alcohol
Cannabis
Stimulants
Recent use
Tobacco
Alcohol
Cannabis
Stimulants
86.6%
97.3%
59.8%
21.4%
68.8%
66.1%
14.3%
2.7%
66.1%
25.9%
13.4%
0%
78.4%
88.7%
41.2%
17.5%
67.0%
67.0%
13.4%
1.0%
64.9%
57.7%
11.3%
0%
NA
(n = 112)
70.5%
0.9% c
9.8%
2.7% 
(n = 104)
72.1% 
1.0%
10.6%
1.0%
6.4
4.5
12.3
0.4
Q(2) b
0.2
114.9
3.2
0.5
 
6.5
70.9
2.4
- 
.011
.035
< .001
.527
p
.905
< .001
.199
.799
.039
< .001
.301
-
a Recent use based on 104 urine samples, monthly use based on 104 urine-, 44 hair-, and 27 sweat patch 
samples 
b Cochran’s Q based on full data 
c Based on urine samples (n = 104) only
Under- and over-reporting of SumID-Q and SumID-CR compared with biomarkers 
Disagreement between SumID-Q and biomarkers involved both under-reporting and over-
reporting of SU, and varied by types of samples and reference periods (Table 3). Five participants 
reported that they did not smoke but tested positive for urine cotinine, giving an under-reporting 
rate of 7%. No over-reporting was found for recent smoking. The disagreement between cotinine 
in hair or sweat patches compared with the SumID-Q and SumID-CR involved two cases of under-
reporting (9%) and ten cases of over-reporting (21%). Regarding alcohol and cannabis use, 
we found no under-reporting when SumID-Q and SumID-CR were compared with biomarkers. 
However, over-reporting of alcohol use was very high (96%): 26 participants stated that they had 
used alcohol in the days before urine sampling (mean number of units = 7, SD = 5.8), but only 
one urine specimen tested positive. In self-reported cannabis use, we found an over-reporting rate 
of 26% for recent use and 31% for monthly use (Table 3). 
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Table 3. Agreement between SumID-Q and SumID-CR and biomarker analysis a
n TP FP FN TN kappa 95% CI 
Tobacco 
Urine Cotinine vs
SumID-Q 
SumID-CR
Hair Cotinine vs
SumID-Q
SumID-CR
Sweat Patch Cotinine vs
SumID-Q
SumID-CR
Any Biomarker Cotinine vs
SumID-Q
SumID-CR
Alcohol
Urine Alcohol vs
SumID-Q
SumID-CR
Cannabis 
Urine THC vs
SumID-Q
SumID-CR
Hair THC vs
SumID-Q
SumID-CR
Any biomarker THC vs
SumID-Q
SumID-CR
Stimulant use
Urine Stimulants vs
SumID-Q
SumID-CR
Hair Stimulants vs
SumID-Q
SumID-CR
Sweat Patch Stimulants vs
SumID-Q
SumID-CR
Any biomarker Stimulants vs
SumID-Q
SumID-CR
104
86
44
38
27
26
112
95
104
82
104
82
44
36
112
88
104
83
44
36
27
24
  
112
91
70
59
20
16
18
17
72
61
1
1
11
6
0
0
11
6
0
0
1
0
 
0
0
1
0
0
0
9
7
1
1
5
4
25
49
4
5
6
5
5
7
0
0
0
0
1
0
2
1
5
4
0
0
2
2
7
5
0
0
0 
3
0
0
0
3
1
0
1
1
0
0
2
1
29
23
15
15
6
6
28
25
78
32
89
68
38
31
96
72
103
83
42
35
26
24
107
89
.886
.888
.602
.643
.724
.719
.747
.779
.057
.016
.824
.545
.000
.000
.790
.483
.000
-
.656
.000
.000
-
.315
- .011
.789 - .984
.780 - .995
.371 - .834
.405 - .882
.427 – 1
.421 – 1
.592 - .866
.642 - .916
0 - .379
0 - .191
.656 - .993
.246 - .845
0 - .744
0 - .813
.615 - .966
.211 - .755
0 - 1
-
0 – 1
0 – 1
0 – 1
-
-.180 - .810
-.027 - .004
a Using biomarker analysis as reference
TP = true positive, FP = false positive, FN = false negative, TN = true negative
- Because of empty cells these values cannot be calculated
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Agreement and under- and over-reporting of the SumID-CR compared with the SumID-Q
The agreement between SumID-CR and SumID-Q for smoking and cannabis use was moderate 
to almost perfect (see Table 4), with the largest disagreement for lifetime cannabis use (staff 
members under-reported by 34%). Agreement between self-reported and collateral-reported 
alcohol use was low for lifetime use, substantial for monthly use, and moderate for recent use. 
Staff members under-reported lifetime use but over-reported recent alcohol use compared to self-
report. The agreement between SumID-Q and SumID-CR was moderate for lifetime stimulant 
use, with more over-reporting than under-reporting by staff. For monthly use, no agreement was 
found between SumID-Q and SumID-CR, with under-report by staff members (Table 4). 
Table 4. Agreement between SumID-CR and SumID-Q a
n TP FP FN TN Kappa 95% CI
Tobacco
  Lifetime
  Monthly
  Recent
Alcohol
  Lifetime 
  Monthly
  Recent
Cannabis
  Lifetime
  Monthly
  Recent
Stimulants
  Lifetime
  Monthly
  Recent
94
95
94
94
88
89
73
88
88
72
91
90
73
65
63
82
58
24
29
8
8
9
0
0
1
0
0
2
6
32
1
5
3
6
1
0
9 
1
1
9
2
2
15
6
5
4
2
0
11
29
30
1
22 
32
28
69
72
53
88
90
 
.628
.975
.976
.110
.748
.315
.577
.519
.614
.557
-.015
-
.423 - .833
.928 – 1 
.928 – 1 
-.154 - .374
.640 - .925
.168 - .462
.407 - .747
.271 - .767
.371 - .857
.314 - .800
-.036 - .006
-
a Using the SumID-Q as reference
TP = true positive, FP = false positive, FN = false negative, TN = true negative
- Because of empty cells, these values cannot be calculated
DISCUSSION
In this study, we compared self-reported SU (SumID-Q), collateral-report by staff members 
(SumID-CR), and urine, hair, and sweat patches collected from a sample of 112 individuals with 
MBID. To our knowledge, this is the first study to compare these strategies to assess SU in 
individuals with MBID. 
Irrespective of the assessment strategy, high rates of alcohol and tobacco use and slightly lower 
– but nonetheless substantial – illicit drug use rates were found. In fact, with the exception of 
alcohol use, lifetime and past month SU rates among participants were higher compared to SU 
rates in the general population in the Netherlands (past month tobacco use ~25% , alcohol use 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Substance use and misuse in Intellectual Disability, Chapter 5
74
~77%, cannabis use ~5%, stimulant use <1%; Laar & Ooyen-Houben, 2015). Whether this is due 
to sampling characteristics or is actually indicative of higher SU rates in Dutch individuals with 
MBID than the general population remains to be seen. Higher levels of smoking in individuals 
with mild ID, however, have been reported before (Žunić-Pavlović, Pavlović, & Glumbić, 2013; 
Kiewik, VanDerNagel, Kemna, Engels, & de Jong, 2016). Also, it has been hypothesized that the 
cannabis possession policies in Holland (i.e., possession of small amounts of cannabis for personal 
use is not prosecuted) may lead individuals with MBID to assume that cannabis use is harmless 
(VanDerNagel et al., 2011a). This in turn could explain high levels of cannabis use in our study, 
as well as willingness to disclose this use.
Participation rates differed significantly across the three strategies. In accordance with 
epidemiological studies conducted in the general population (e.g., Fendrich et al., 2004), 
participation in biomarker sampling was lower compared to participation in self-report. This 
may be ascribed to the relatively invasive nature of biomarker sampling and to the additional 
visits required to collect sweat patches. In addition, even though confidentiality of participants’ 
test results was assured, individuals with risky SU behavior and those who perceived more severe 
consequences of having their SU identified may have been less willing to participate in the 
biomarker analysis. For those who were not willing to provide any biomarker samples and hence 
were excluded from the study (n =15, 11% of the original sample), this hypothesis could not be 
further explored. However, in participants who refused either the urine sample (n = 8, 7% of the 
final sample) or the hair or sweat-patch sample (n = 28; 25% of the final sample), no significant 
differences were found in self-reported SU rates compared with participants who did provide 
these samples (χ2(1, n = 112), p´s .184 - .905). 
Regarding SU rates, our hypothesis based on research involving non-ID participants, which 
proposed that SU rates found with biomarker analysis would be higher compared to self-reported 
and collateral-reported SU rates, was not confirmed. SU rates found with biomarker analysis did 
not differ significantly from self-reported or collateral-reported tobacco, cannabis, and stimulant 
use; and self-reported and collateral-reported alcohol use rates were higher compared to those 
in biomarkers. The agreement between the SumID-Q and SumID-CR versus biomarker analysis 
was also better than expected. Contrary to our expectations and findings in the literature (Akinci 
et al., 2001; Beaurepaire et al., 2007), we did not find high levels of under-reporting with 
the SumID-Q or with the SumID-CR. In fact, under-reporting of recent smoking (7.%) of the 
SumID-Q and SumID-CR may in fact be even lower, since three participants classified as false 
negatives for self- and collateral-reported recent smoking had urine cotinine levels of 11, 14, 
and 16 ng/ml, which may also be explained by environmental contamination of the biomarker 
samples (Moeller, Lee, & Kissack, 2008; Rebagliato, 2002). In addition, self-report compared 
to biomarkers indicated over-reporting of monthly tobacco use (21%), cannabis use (31%), and 
recent and monthly alcohol use (96%). A possible explanation for both the higher than expected 
levels of self-reported SU and the high levels of agreement between self-report and biomarker 
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analysis, is that our participants were less reluctant to report SU compared to participants in 
previous studies. This may be attributed to the context of this study, which assured participants 
that their data would remain confidential and that they would not face any consequences of SU 
disclosure. Also, the structure of the SumID-Q, which aims to facilitate an open discussion of 
SU through a rather indirect approach, may have contributed to these results. For cannabis, the 
low levels of under-reporting in this study may be related to Netherland’s cannabis policies. The 
strikingly low rates of alcohol use found in biomarker analysis and the associated high levels of 
alcohol over-reporting may be attributed to a smaller window of detection of alcohol in urine 
(University Medical Center Groningen, 2016) and the lack of long-term biomarker analysis of 
alcohol use. Contrary to our hypothesis, the availability of hair and sweat analysis results for 
tobacco, cannabis, and stimulant use did not result in higher SU compared to urine analysis alone. 
For THC, the detection sensitivity of the hair analysis seems lower than for the urine analysis, as 
no subjects tested positive for THC in hair despite having corresponding positive urine samples. 
When comparing self-report and collateral-report, as expected, lifetime self-reported SU was higher 
for lifetime tobacco use, alcohol use, and cannabis use. However, contrary to our expectations, self-
reported and collateral-reported SU rates for past month and recent SU were similar, except for 
recent alcohol use. According to the staff members in our study, most participants who consumed 
alcohol in the last month had done so in the last few days. By contrast, self-reported recent use 
was much lower compared to self-reported monthly use. The cause of this discrepancy remains 
unclear and warrants further investigation. Individuals with MBID may only consume alcohol on 
special occasions, although staff members may assume that those who drink will do so on a regular 
basis. Another explanation may be that participants are willing to admit to occasional drinking 
but not to more frequent or recent drinking. However, these explanations remain speculative, and 
they will need to be explored in further research on self-reported and collateral-reported alcohol 
use patterns of individuals with MBID. Agreement between self-reported SU and collateral-
reported SU was moderate to substantial for almost all substances and almost perfect for the 
most overt SU (i.e., smoking). For recent and past month illicit drugs (cannabis and stimulant 
use) as well as for lifetime SU, staff members were more likely to under-report rather than over-
report. Despite risks of under-reporting being present, the relatively high degree of agreement 
between self-reported and collateral-reported SU is promising. When staff members are aware of 
SU among their clients who also feel free to discuss SU openly, there are procedures in place to 
stage interventions to prevent SU-related problems from worsening.
Limitations 
The findings of this study should be interpreted in the light of several limitations. First, the 
number of completed cases was limited, predominantly due to lower willingness to participate 
in hair and sweat patch testing. Second, we limited our study to the substances used most 
often by individuals with MBID residing in Dutch facilities (VanDerNagel et al., 2011a), and 
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thus did not include other substances such as non-prescription opioids. Third, given the low 
number of individuals who were found to be using stimulants, the findings from earlier studies 
(e.g., Fendrich et al., 2004), which showed that drug testing can identify under-reporting of 
this substance, could neither be confirmed nor rejected in this study. Fourth, participant’s prior 
knowledge of biological testing may have increased self-report accuracy. Therefore this accuracy 
may not reflect that in day-to-day care. Fifth, biomarker analysis rendered less than optimal 
results for several substances and reference periods. 
Accurate biomarker analysis relies upon ideal sampling conditions, and this means that urine 
samples should be collected soon after SU to avoid false negative results due to metabolism and 
excretion of the drug. In hair and sweat patch samples, traces of infrequent SU are diluted by 
periods of non-use, as the collected samples contained sweat or hair from previous weeks to months. 
Infrequent SU may not be detected by biomarker analysis (Fendrich et al., 2004; Hoiseth et al., 
2008). Therefore, whilst positive biomarker analysis may confirm drug use and provide results 
consistent with self-reported SU, negative biomarker analysis results do not necessarily mean no 
SU has occurred and may therefore falsely contradict self-reported SU. Although repeated and 
frequent biomarker sampling (e.g., several times a week) would theoretically be a solution, this 
may not be feasible in most situations. Less invasive micro sampling techniques, such as dried 
blood spots (a finger prick and a single drop of blood on a special card) or oral fluid sampling 
in combination with the sensitive LC-MS/MS analysis technique might be an option for future 
biomarker analyses. 
CONCLUSIONS
Comparing three strategies to assess SU in individuals with MBID, we found lower willingness 
to participate in biomarker sampling than in self-report. A rather large number of participants 
reported having used substances, and contrary to the findings in non-ID populations, biomarker 
analysis did not result in a higher number of identified substance users. It remains to be seen 
if this finding can be explained by characteristics of the MBID group, the methodology of the 
SumID-Q, or by factors related to the less than optimal performance of biomarker analysis.. 
However, we can conclude that given the additional costs and lower participation rates of 
biomarker analysis (especially for hair and sweat patches), using this strategy in the future seems 
to be of limited additional value compared to self-report or collateral-report. Therefore, it appears 
that for individuals with MBID, self-report combined with collateral-report can be used to assess 
current SU, and this combination may contribute to collaborative, early intervention efforts to 
reduce SU and its related harms in this vulnerable group. 
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CHAPTER 6
Substance use in individuals with mild to borderline 
intellectual disability in the Netherlands: an exploration 
of rates and risks
This chapter has been submitted as: 
VanDerNagel, J. E. L., Kiewik, M., Didden, R., Korzilius, H. P. L.M., van Dijk, M., van der 
Palen, J., Buitelaar, J. K., de Jong, C. A. J. (submitted). Substance use in individuals with mild 
to borderline intellectual disability in the Netherlands: an exploration of rates and risks. 
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ABSTRACT 
Background and Aims: Little is known about rates and risk factors of substance use (SU) in 
individuals with mild to borderline intellectual disabilities (MBID, IQ 50-85). This hinders 
targeted prevention and treatment. In this study we assessed SU rates and risk factors in 
individuals with MBID. 
Methods: Participants were 419 adults (63% male, average IQ = 66) in 16 Dutch disability 
services. Lifetime and current SU, SU picture recognition, knowledge, attitudes and modelling 
were assessed with the Substance use and misuse in Intellectual Disability – Questionnaire 
(SumID-Q). Demographic, contextual and diagnostic factors were combined with SumID-Q data 
to predict SU status.
Results: Lifetime licit SU (alcohol and tobacco) was 97%, lifetime illicit SU (predominantly 
cannabis) was 50%. Current users of tobacco (62%), alcohol (64%), and cannabis (15%) initiated 
SU at a younger age than those who desisted SU (ps < .001). Participants with mild ID and 
those with borderline ID did not differ in SU rates (ps .429 – .812), or age at SU initiation (ps 
.221 - .853). Current licit SU and lifetime illicit SU were related to male gender, younger age, 
and (for smoking and stimulant use) to lack of daytime activities. However, these factors did not 
contribute to multivariate models when recognition, knowledge, attitudes and modelling were 
added. The models correctly identified current SU in 84% (smoking) and 74% (drinking), and 
lifetime SU in 76% (cannabis) and 84% (stimulants) of the participants. 
Conclusions: Almost all of 419 participants with mild to borderline intellectual disability 
reported lifetime licit, and about half reported lifetime illicit substance use. This calls for 
systematic screening for substance use, and development of preventative and treatment 
interventions targeted to this group.
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INTRODUCTION
Individuals with mild to borderline intellectual disability (MBID) have been identified as a 
risk group for negative consequences of substance use (SU), and substance use disorder (SUD) 
(Burgard, Donohue, Azrin, Teichner, 2000; Carroll Chapman, & Wu, 2012; van Duijvenbode, 
VanDerNagel et al., 2015; Hassiotis, Gazizova, Akinlonu, Bebbington, Meltzer, & Strydom, 
2011; McGillicuddy, 2006; McGillivray, & Moore, 2001). Unfortunately, little is known about 
SU prevalence and risk factors in individuals with MBID. This hinders addiction medicine and 
MBID services to take preventative actions and implement targeted treatment. In this study, we 
used the Substance use and misuse in intellectual disability – Questionnaire (VanDerNagel, Kemna, & 
Didden, 2013; VanDerNagel et al., 2016) to assess SU rates and its risk factors in individuals 
with MBID. 
According to the DSM5 (American Psychiatric Association, 2013), an intellectual disability (ID) 
involves 1) impairments of general mental abilities, that 2) impact adaptive functioning in the 
conceptual, social and practical domain, and that 3) occur during the developmental period. While 
its severity is based on (impairments in) adaptive functioning, in the DSM5 text description the 
former DSM-IV criterion of an IQ-test score approximately two standard deviations below the 
population mean (i.e., an IQ of 70 or below) is still used. Borderline intellectual functioning 
is defined as an IQ in the 71-84 range (American Psychiatric Association, 2013). Though the 
level of ID may be described as ‘borderline’ (BID) or ‘mild’ (MID, IQ 50 – 70), in the MBID 
group a variety of problems accumulate, including poorer physical and mental health, social 
disadvantages, limited social support, overrepresentation in the forensic and mental health 
system (Lindsay, Carson, Holland, Taylor, O’Brien, & Wheeler, 2011; Wieland & Zitman, 2015), 
and limited access to services including addiction treatment (van Duijvenbode, VanDerNagel et 
al., 2016; Slayter, 2010). 
Rates of SU(D) in MBID vary greatly across studies, depending on sampling characteristics (Carroll 
Chapman, & Wu, 2012; van Duijvenbode, VanDerNagel et al., 2015). Several demographic, 
contextual and diagnostic factors have been associated with SU(D) in MBID, such as younger than 
30 years old, male, no structured daytime activities (To, Neirynck, Vanderplasschen, Vanheule, 
Vandevelde, 2014; VanDerNagel, Kiewik, Buitelaar, & de Jong, 2011a), and living independently 
(Taggart, McLaughlin, Quinn, & Milligan 2006; To et al., 2014). Furthermore, SU(D) in MBID 
is associated with psychiatric or behavioural (Chaplin, Gilvarry, & Tsakanikos, 2011; Didden, 
Embregts, van der Toorn, & Laarhoven, 2009) and forensic problems (Crocker, Côté, & Toupin, 
2007; Hassiotis et al., 2011; McGillivray, Gaskin, Newton, & Richardson, 2015). For instance, 
among 39 patients with MBID in an inpatient treatment facility, 28% abused alcohol, and 36% 
drugs (Didden et al., 2009). In a psychiatric outpatient facility (n = 115), 17% alcohol misuse, 
6% cannabis misuse and 3% cocaine misuse was found (Chaplin et al., 2011). In offenders with 
ID, several studies found SUD rates of approximately 60% (Crocker et al., 2007; Hassiotis et 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Substance use and misuse in Intellectual Disability, Chapter 6
82
al., 2011; McGillivray et al., 2015). On the other hand, in several community based samples 
only 1% had a SUD diagnosis (Cooper, Smiley, Morrison, & Williamson, Allan, 2007; Taggart 
et al, & Milligan 2006). As to SU, in a Belgian study in 123 individuals with MBID living 
independently, 48% smoked, 46% drank alcohol, and 2% used illicit substances in the past 
month (Swerts, Vandevelde, VanDerNagel, Vanderplasschen, Claes, & de Mayer, 2016). Smoking 
rates in other community based samples of adults with ID, were much lower, for instance 1.9% in 
social education centers (Whitaker, & Hughes, 2003), and 9.3% in attenders at day care centers 
(Taylor, Standen, Catajar, Fox, & Wilson, 2004). In adolescents with MBID, however, current 
smoking rates varied from 14% (Emerson, & Turnbull, 2005) to 34% (Žunić-Pavlović, Pavlović, 
& Glumbić, 2013) and in forensic ID samples smoking rates are reported to be up to 60% 
(Chester, Green, & Alexander, 2011). 
One of the challenges to assess rates of SU(D) in individuals with MBID is the lack of valid 
instruments. While self-reported SU in the general population is associated with high levels 
of under-report (see e.g., Fendrich, Johnson, Wislar, Hubbell, & Spiehler, 2004), self-report in 
individuals with MBID may be even more biased, especially when mainstream questionnaires 
are used (van Duijvenbode, VanDerNagel et al., 2015; McGillicuddy, 2006; VanDerNagel et al, 
2013). We therefore developed the SumID-Q to assess SU in MBID (VanDerNagel et al., 2013; 
VanDerNagel, Kiewik, van Dijk, de Jong, & Didden, 2011b), and found moderate to almost 
perfect agreement with biomarker analysis, and low levels of under-report (VanDerNagel et al, 
2016). This may be the result of its step-by-step non-confrontational approach, in which SU 
picture recognition, knowledge, attitudes, and modelling are assessed before participant’s SU is 
discussed. Based on previous studies, it is unclear if these factors are associated with SU status. 
For instance, though alcohol-related knowledge was poor in people with mild ID compared to 
non-ID groups (McCusker, Clare, Cullen, & Reep, 1993), alcohol and tobacco related knowledge 
in other studies were not associated with drinking and smoking in MBID (Swerts et al, 2016, 
Whitaker, & Huges, 2003). Living together with smokers, however, was associated with smoking 
in two studies with children (Emerson, Hatton, Robertson, & Baines, 2016) and adults (Whitaker, 
& Huges, 2003) with ID. 
To summarize, rates of reported SU(D) in MBID seem related to sample characteristics, but 
the relationships between demographic, contextual, diagnostic, and SU related factors remain 
unclear. Knowledge about these relations may contribute to an effective assessment, as well as 
to prevention and targeted treatment of SU(D) in this group. Furthermore, the majority of these 
studies were conducted abroad, and may not reflect the situation in the Netherlands. 
Therefore, in this study we used the SumID-Q to assess SU rates and risks in individuals with 
MBID who receive care from Dutch disability services. More specifically this cross-sectional 
study aimed to:
(1) determine lifetime and past month rates of alcohol, tobacco, cannabis, and stimulant use; 
(2) assess whether age at initiation of SU differs between a) current users, versus participants who 
desisted SU, and b) participants with mild ID (IQ 50 – 70) versus borderline ID (IQ 71-84);
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(3) identify demographical, contextual, and diagnostic risk factors for SU;
(4) assess the contribution of SU related factors (i.e., SU recognition, knowledge, attitude, and 
modelling) to a model for SU based on demographical, contextual, and diagnostic factors alone.
METHODS
Participants and settings
In 2010 and 2011, individuals from 22 organizations of the Dutch Association of Healthcare 
Providers for People with Disabilities [Vereniging Gehandicaptenzorg Nederland, VGN] were 
invited to participate. These organizations provide a range of services, including supported 
living, institutional living, day-care centres, supported employment, and outpatient services. 
Individuals were eligible for participation if they 1) received care from one of these organizations, 
2) were ≥ 18 years old, 3) had MBID (IQ 50 – 85), and 4) had no such language or communication 
problems that participation was unfeasible.
Data and Instruments
Demographic, contextual and diagnostic characteristics: 
Data on demographic (date of birth, ethnicity, marital status), contextual (living arrangement, 
daytime activities), and diagnostic (BID, MID, full-scale IQ [TIQ]) characteristics were obtained 
from participants’ professional caregivers.
Substance use: 
The Substance use and misuse in Intellectual Disability - Questionnaire (SumID-Q) (VanDerNagel et 
al., 2011b; 2013; 2016) assess lifetime and past month (recent) SU. It is a structured interview 
that incorporates several strategies to reduce bias in self report in individuals with MBID, 
including 1) adaptation of item structure and wording, 2) use of visual aids, and 3) a step by step 
non-confrontational approach. It starts with assessing participants’ familiarity with substances 
(tobacco, alcohol, cannabis, stimulants [i.e., cocaine and amphetamines] and other illicit drugs) 
by showing substance related pictures from a standardized set, asking for each picture ‘What is 
this?’. In the case of an incorrect response, the interviewer assesses if the participant can provide 
an adequate description of the substance when the mainstream name of the substance is presented 
(‘What is weed?’). If the participant can neither identify any of the pictures related to a specific 
substance, nor describe it correctly, he or she is classified as not being familiar with this substance, 
and no further questions about this substance are asked. For each of the substances correctly 
recognized, further questions on substance knowledge and attitudes, and SU modelling are asked. 
Then, the participant is asked for each substance ‘Did you ever use this?’ (lifetime use; yes/no 
response format); and, if yes, ‘Once or more often?’ and ‘How old were you the first time?’ For the 
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four substances most commonly used by individuals with MBID in the Netherlands (i.e., tobacco, 
alcohol, cannabis, and stimulants) (25), SU patterns, and current SU is assessed. Reliability of the 
subscales in this study was good for picture recognition (α = .87), SU knowledge (α = .80), SU 
attitudes (α = .82), and acceptable for SU modelling (α = .76). Administration of the SumID-Q 
takes 45 to 60 minutes. 
 
Procedure 
Of the 22 organizations from the VGN network that were asked to participate in this study, five 
declined and one was unable to fulfill the intention to participate. The remaining 16 organizations 
were asked to randomly select 10% of individuals with MBID in their facilities, and provide their 
contact details for recruitment purposes. However, several organizations could not or would not 
(because of privacy issues) provide a list based on level of ID, and therefore recruited participants 
themselves. Participants were visited at a venue of their choice by a trained research assistant 
who explained the study procedures using a DVD presentation and an illustrated leaflet with 
an easy to read text. Written informed consent was obtained from both the client and his or her 
(legal) representative. Participants received a small gift (worth approximately €2.50 / $2.70) 
after the interview. The study was approved by the Medical Ethical Review Board Twente 
(NL27716.044.09) and was conducted in accordance with the Declaration of Helsinki (World 
Medical Association, 2013). 
Data analysis
Data were analyzed with SPSS (version 21). For each substance, composite scores were calculated 
for SU recognition (number of pictures correctly identified, range 0 - 8), knowledge (number of 
correct answers, maximum score = 8), positive attitude towards SU (maximum score = 10), and 
SU modelling (maximum = 15). 
To determine lifetime and current SU rates, we calculated percentages of participants who used 
‘never’/’once’/’more than once’, and in the past month.
To assess whether age at initial SU differed between a) current users versus participants who 
desisted SU (i.e., participants who had used a substance at some time in their lives, but not in the 
last month), and b) participants with MID versus BID, we used Kaplan Meier curves, and the log 
rank test to compare survival times to age at initial use. 
To identify demographical, contextual, and diagnostic risk factors for current tobacco and 
alcohol, and for lifetime cannabis and stimulant use, we calculated associations between these 
variables and SU status. For independent variables age and IQ, quartiles were used. Variables 
with univariate p values < .20 were entered into a stepwise forward multiple logistic regression 
analysis comparing current users with non-users (for alcohol and tobacco use), and lifetime users 
with non-users (cannabis and stimulants), and they remained in the model if this resulted in a 
significant (p < .05) change in - 2Loglikelihood. 
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To assess the contribution of SU recognition, knowledge, attitudes, and modelling to this model, 
we first assessed the univariate associations between these factors (divided in quartiles, or – if 
impossible due to skewed data – in two or three groups) and SU status within the subgroup of 
participants who were familiar with the substance of interest (recognition score ≥ 1). Then, in a 
stepwise forward procedure, these variables were added to the model based on demographical, 
contextual, and diagnostic variables alone, if univariate p values were < .20, and they remained in 
the model if this resulted in a significant (p < .05) change in - 2Loglikelihood.
RESULTS
Participants
A total of 600 individuals met our inclusion criteria, client representatives withheld consent in 
three individuals with a history of SUD, and in 26 individuals for other reasons, 147 individuals 
gave no informed consent, and data from five individualswere removed because of premature 
termination of the interview. Thus, 419 participants (70%) were included in the sample (Table 
1). 
SU rates 
Lifetime substance use
Almost all participants (n = 407, 97%) had used substances licit in the Netherlands (alcohol and 
tobacco) at least once in their lives, and a large proportion (n = 208, 50%) had used at least once 
illicit substances (Table 2.). No significant differences in lifetime use (ps between .429 and .742) 
were found between participants with MID versus those with BID. 
Current substance use
In the past month, only 81 participants (19%) had not used substances at all. About a third (n = 
142) used one substance, mainly tobacco (n = 64, 15%), or alcohol (n = 77, 18%). Almost half of 
our participants (n = 196, 47%) used more than one substance, mainly tobacco and alcohol (n = 
133, 32%) or tobacco, alcohol and cannabis (n = 50, 12%). In total, 15% (n = 64) used cannabis 
or stimulants. No significant differences in current SU rates (ps between .558 and .812) were 
found between participants with MID versus BID. 
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Table 1. Participant Characteristics (N = 419).
Variable (n) Mean (SD) n %
Gender  
  Male 264 63.0
Age (404) 34.5 (14.4)     
Marital status (404)
   Married
   Divorced
   Widowed
   Other
23 
24 
6
351
5.7
5.9
1.5
83.9
Living arrangement (408)
   Spousea
   With children
   Other family
   Single
   Group
34
6 
12 
166 
190 
8.1
1.4
2.9
39.6
45.3
Level of ID  
   Mild
   Borderline
   IQ (255) 66.1 (9.3)
 273
146
 
65.2
34.8
 
Etnicity (417)
   Caucasian  
   Other
383 
   34
91.4
8.1
ID Service  
   Institutional grounds
   Community facility 
   Otherb
66 
219 
134
15.8
52.3
32.0
a Participants living with a spouse, with or without children
b Includes supported living and case coordination services
Table 2. Self-reported lifetime and past month SU rates & ages of onset.
Lifetime use Current use
Never Once More than 
oncea
Yes Age of initial SU 
(years) 
n % n % n % N % Mean SD Range
Tobacco 71 16.9 35 8.4 313 74.7 258 61.6 14.1 3.4 5 – 27
Alcohol 26 6.2 22 5.3 371 88.5 267 63.7 16.2 4.5 5 – 40
Cannabis 222 53.0 48 11.5 149 35.6 61 14.6 18.1 6.8 8 – 50
Stimulants 353 84.2 15 3.6 51 12.2 5 1.2 19.8 5.9 11 – 40
Ecstasy 345 88.5 15 3.6 33 7.9 18.6 4.7 11 – 37
Non-prescribed opioids 401 95.7 5 1.2 13 3.1 22.6 8.1 11 – 40
Non-prescribed BZD 400 95.5 4 1.0 15 3.6 25.2 11.4 13  – 44
LSD 407 97.1 6 1.4 6 1.4 17.9 3.9 11 – 25
Psychedelic mushrooms 386 92.1 17 4.1 16 3.8 18.6 4.9 11 – 40
GHB 404 96.4 9 2.1 6 1.4 18.9 3.9 12 – 25
SD = Standard deviation, BZD = benzodiazepines, LSD = Lysergic acid diethylamide, GHB = 
γ-Hydroxybutyric acid. 
a Includes participants with current SU
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6
Age at initial SU
SU initiation occurred mainly during adolescence, though several participants started to use 
tobacco and alcohol at a much younger age (Figure 1). Cannabis and stimulant use were typically 
initiated later in adolescence (Figure 1). 
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Figure 1. Age at initial use of tobacco, alcohol, cannabis and stimulants. 
Current smokers initiated smoking at a younger age than participants who desisted 
smoking (median = 13 years, IQR = 12 – 16 years, versus median = 16 years, IQR = 13 – 
18 years; χ2(1) = 11.97, p < .001) (Figure 2). Similarly, current drinkers initiated drinking at 
a younger age (median = 16 years, IQR = 14 – 18 years) compared to those who desisted 
(median = 17 years, IQR = 15 – 17 years; χ2(1) = 12.02, p < .001), and current users of 
cannabis started using at a younger age (median = 15 years, IQR = 13 – 16 years) than 
those who desisted (median = 17 years, IQR = 16 – 20 years; χ2(1) = 16.51, p < .001). No 
significant differences in age of initial use were found between current stimulant users 
(median = 24 years, IQR = 17 – 26) and participants who desisted (median = 18 years, 
IQR = 16 – 21 years; χ2(1) = 1.10, p = .293). Median survival time to initial use did not 
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Figure 2. Age at initial use of tobacco, alcohol, cannabis and stimulant use, 1 - survival plots 
depending on current SU status (current users versus users who desisted). 
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Univariate and multivariate demographic, contextual and diagnostic risk factors
Univariate and multivariate associations with current tobacco and alcohol use
Univariate and multivariate analyses of the demographic, contextual, and diagnostic 
characteristics versus current tobacco and alcohol use are presented in Table 3a. Current tobacco 
use was significantly higher in males and in those with a lack of structured daytime activities. 
Current alcohol use was significantly lower in the oldest two quartiles of participants (age > 31.9 
years) compared to the youngest quartile (age < 21.6 years). 
The multivariate model for current tobacco use contained male gender and lack of daytime 
activities. Though this model classified 63% of the participants correctly, it explained only a 
small proportion of smoking status variance (Table 3a). Similarly, the final model for alcohol use, 
based on gender and age, explained little variance, but classified 65% of the participants correctly. 
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Table 3a. Univariate and multivariate associations between demographic and contextual characteristics, 
level of ID; and current tobacco and alcohol use. 
Univariate Multivariate model
Tobacco β OR 95% CI OR β OR 95% CI OR
Constant .078  
Demographic 
   Male .53** 1.71 1.14 2.56 .57** 1.78 1.16 2.72
   Age in years (Q1)
   Q2
   Q3 
   Q4
.17
<.01
-.25
1
1.19
1.0
.78
.67
.57
.45
2.12
1.77
1.37
Contextual 
   Independent living -.21 .81 .53 1.24
   No daytime activities .71* 2.04 1.03 4.04 .76* 2.14 1.07 4.28
Intellectual functioning
 Mild ID -.09 .91 .60 1.38
 TIQ (Q1), (n = 255)
   Q2
   Q3 
   Q4 
.05
.33
.25
1
1.05
1.38
1.28
.53
.67
.62
2.09
2.85
2.66
Alcohol
Constant
Demographic 
   Male .40 1.49 .99 2.24 .39 1.47 .96 2.26
   Age in years (Q1)
   Q2
   Q3 
   Q4
-.35
-.64*
-.76*
1
.70
.53
.47
.38
.29
.26
1.30
.96
.85
-.39
-.69*
-.80**
1
.68
.50
.45
.37
.28
.24
1.25
.92
.82
Contextual 
   Independent living .21 1.24 .80 1.90
   No daytime activities .21 1.23 .65 2.31
Intellectual functioning
 Mild ID -.17 .88 .58 1.34
 TIQ (Q1), (n = 255)
   Q2
   Q3 
   Q4 
.34
.39
.72
1
1.41
1.47
2.06
.70
.71
.96
2.83
3.03
4.41
Q1 = first quartile; OR= Odds Ratio, ID = intellectual disability, TIQ = full scale IQ, * p < .05, 
** p < .01, *** p < .001
Multivariate model for current tobacco use: χ2(2, n = 387) = 11.12, p =.004. Cox & Snell R2 = .029, 
Nagelkerke R2 = .040 
Multivariate model for current alcohol use: χ2(4, n = 403) = 10.68, p =.001. Cox & Snell R2 = 0.026, 
Nagelkerke R2 = 0.036
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Table 3b. Univariate and multivariate associations between demographic and contextual characteristics, 
level of ID; and lifetime cannabis and stimulant use. 
Univariate Multivariate model
Cannabis β OR 95% CI OR β OR 95% CI OR
Constant .10  
Demographic 
   Male .44* 1.55 1.03 2.32  .34 1.41 .92 2.16
  Age in years (Q1)
     Q2
     Q3 
     Q4
.14
-.35
-1.18*** 
1
1.15
.71
.31 
.65
.40
.17 
2.04
1.24
.56 
.11
-.38
-1.21***
1
1.12
.68
.30
.63
.39
.16
1.98
1.20
.55
Contextual 
   Independent living -.23 .79 .52 1.21
   No daytime activities .39 1.47 .80 2.70      
Intellectual Functioning
  Mild ID -.07 .93 .62 1.40
   TIQ, (Q1), (n = 255)
    Q2
    Q3 
    Q4 
.44
.43
.68
1
1.55
1.53
1.97
.78
.75
.95
3.10
3.14
4.08
Stimulants
Constant -2.73  
Demographic 
   Male 1.36*** 3.90 1.93 7.91  1.34*** 3.82 1.83 7.98
  Age in years (Q1)
     Q2
     Q3 
     Q4
*
. .53
.28
-.85
1
1.69
1.33
.43
.82
.63
.17
3.47
2.79
1.10
.42
-.02
-1.04*
1
1.52
.98
.35
.72
.45
.13
3.22
2.16
.95
Contextual 
   Independent living -.45 .64 .35 1.17
   No daytime activities .83* 2.29 1.15 4.55  1.15** 3.15 1.48 6.69
Intellectual Functioning
 Mild ID .08 1.08 .62 1.89
 TIQ, (Q1), (n = 255)
    Q2
    Q3 
    Q4 
.31
.35
.41 
1
1.36
1.42
1.51 
.53
.54
.58 
3.47
3.70
3.94 
Q1 = first quartile, OR = Odds Ratio, ID = intellectual disability, TIQ = full scale IQ, * p < .05, 
** p < .01, *** p < .001 
Multivariate model for lifetime cannabis use: χ2(4, n = 391) = 25.76, p < .001. Cox & Snell R2 = .064, 
Nagelkerke R2 = .085
Multivariate model for lifetime stimulant use: χ2(5, n = 379) = 32.42, p < .001. Cox & Snell R2 = 0.082, 
Nagelkerke R2 = .139
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Univariate and multivariate associations with lifetime cannabis and stimulant use
Lifetime use of both cannabis and stimulant use were significantly related to male gender and 
younger age, and in addition, lifetime stimulant use was significantly associated with lack of 
daytime activities (Table 3b).The multivariate model for lifetime cannabis use based on age 
and gender classified 61% of the participants correctly. For lifetime stimulant use, male gender, 
younger age and lack of daytime activities contributed to the model, classifying 79% of the 
participants correctly. Compared to the models for current tobacco and alcohol use, these variables 
explained slightly more, but still small proportions of SU status variation. 
SU picture recognition, knowledge, attitudes and modelling, as risk factors for SU
Risk factors for current tobacco and alcohol use
For current tobacco and alcohol use, SU picture recognition, attitude, and modelling, but not 
knowledge were related to current smoking and drinking (Table 4a). These factors also remained 
significant in the multivariate tobacco model, which explained between 43% and 58% of the 
variance of smoking (Table 4a), and correctly identified smoking status in 84% of the participants.
For alcohol use, picture recognition did not contribute significantly to the model based on gender, 
age, and attitude and modelling. This model predicted between 19% and 26% of the variance in 
current alcohol use, and correctly identified drinking status in 73% of the participants. Tobacco 
and alcohol related knowledge did not contribute significantly to the multivariate models (Table 
4a).
Risk factors for lifetime cannabis and stimulant use
Participants who did not recognize any of the cannabis (n = 23) or stimulant related pictures (n = 
97) were excluded from the SU related analyses of these substances. For cannabis and stimulants, 
picture recognition, knowledge, attitude, and modelling contributed significantly to both the 
univariate associations and the multivariate model (Table 4b). The models explained between 
36% and 47% of lifetime cannabis use status, and between 36% and 54% of stimulant use, and 
correctly identified lifetime cannabis use in 76%, and stimulant use in 84% of the participants. 
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Table 4a. Univariate and multivariate associations between demographic, contextual characteristics, 
SU related measures; and current smoking and drinking in participants familiar with the substance 
of interest (n = 419).
Univariate Multivariate model
Tobacco β OR 95% CI β OR 95% CI
Constant -3.18
Variables from step 1
  Male gender .53** 1.71 1.14 2.56 .56 1.75 .94 3.24
  No daytime activities .71* 2.04 1.03 4.04 -.81 .45 .18 1.13
SU related 
measurements
  Recognitiona 1.39*** 4.02 2.10 7.69 1.64*** 5.14 2.00 13.20
  Knowledge (Q1) 1
    Q2 .37 1.45 .63 3.35
    Q3 .17 1.19 .53 2.64
    Q4 -.19 .83 .36 1.91
  Attitude (score 0 -1) 1
    Score 2 – 3 2.48*** 11.92 6.75 21.05 2.54*** 12.65 6.59 24.30
    Score ≥ 4 4.46*** 86.14 36.07 205.75 4.17*** 64.60 25.82 161.64
  Modelling (Q1) 1 1
    Q2 .69** 2.00 1.22 3.29 .73* 2.08 1.02 4.25
    Q3 1.42*** 4.13 2.24 7.61 1.28** 3.58 1.46 8.76
    Q4 1.62*** 5.07 2.58 9.95 1.15* 3.18 1.23 8.25
Alcohol
Constant -1.22
Variables from step 1
  Male gender .40 1.49 .99 2.24 .16 1.17 .72 1.90
  Age (Q1) 1 1
    Q2 -.35 .70 .38 1.30 .52 1.68 .84 3.35
    Q3 -.64* .53 .29 .96 .12 1.12 .58 2.18
    Q4 -.76* .47 .26 .85 -.09 .91 .49 1.72
SU related 
measurements
  Recognitiona .79** 2.21 1.30 3.78
  Knowledgeb .38 1.47 .98 2.20
  Attitude (Q1) 1 1
    Q2 1.11*** 3.02 1.72 5.32 1.16*** 3.20 1.72 5.94
    Q3 1.64*** 5.15 2.81 9.45 1.55*** 4.70 2.42 9.12
    Q4 2.08*** 7.97 4.26 14.91 1.88*** 6.57 3.39 12.71
  Modelling (Q1) 1 1
    Q2 .78** 2.17 1.29 3.656 .81** 2.24 1.26 4.01
    Q3 1.37*** 3.94 2.08 7.490 1.15*** 3.15 1.54 6.46
    Q4 1.57*** 4.80 2.63 8.760 1.25*** 3.48 1.75 6.92
Q1 = first quartile, OR = Odds Ratio, * p < .05, ** p < .01, *** p < .001
ID = intellectual disability, TIQ = full scale IQ, SU = substance use
a Participants with below maximum recognition score versus participants with maximum score
b Participants with knowledge score 0 – 5 versus >5
Expanded model for current tobacco use: χ2(7, n = 385) = 215.14, p < .001. Cox & Snell R2 = .428, 
Nagelkerke R2 = .584
Expanded model for current alcohol use: χ2(10, n = 399) = 83.16, p < .001. Cox & Snell R2 = .188, 
Nagelkerke R2 = .259
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Table 4b. Univariate and multivariate associations between demographic, contextual characteristics, 
SU related measures; and lifetime cannabis and stimulant use in participants with ID who are 
familiar with substance of interest (cannabis n = 396, stimulants n = 322).
Univariate Multivariate model
Cannabis β OR 95% CI β OR 95% CI
Constant -3.80 
Variables from step 1
  Male gender .39 1.48 .98 2.25 -.26 .77 .43 1.36
  Age (Q1) 1 1
    Q2 .17 1.19 .67 2.11 -.27 .76 .32 1.81
    Q3 -.35 .70 .40 1.23 .50 1.66 .72 3.80
    Q4 -.97** .38 .21 .70 -.31 .73 .33 1.65
SU related measurements
  Recognitiona 1.84*** 6.28 4.03 9.80 1.20*** 3.33 1.86 5.98
  Knowledge (Q1) 1 1
    Q2 1.42*** 4.14 2.24 7.67 1.10** 3.01 1.42 6.40
    Q3 2.00*** 7.41 3.76 14.59 1.34*** 3.81 1.68 8.64
    Q4 2.95*** 19.19 8.85 41.61 2.11*** 8.26 3.22 21.21
  Attitude (score 0-1) 1 1
    Score 2 1.44*** 4.22 2.59 6.86 1.33*** 3.79 2.09 6.88
    Score ≥ 3 2.90*** 18.26 8.74 38.15 2.19*** 8.94 3.63 22.03
  Modelling (Q1) 1 1
    Q2 .37 1.45 .75 2.79 -.13 .88 .40 1.94
    Q3 1.27*** 3.55 2.07 6.10 .61 1.85 .93 3.65
    Q4 2.18*** 8.86 4.37 18.00 1.04* 2.84 1.17 6.89
Stimulants
Constant -9.94 
Variables from step 1
  Male gender 1.15** 3.14 1.53 6.45 .33 1.39 .52 3.69
  Age (Q1) 1 1
    Q2 .49 1.64 .78 3.43 1.20 3.33 .77 14.39
    Q3 .28 1.33 .62 2.85 1.21 3.35 .84 13.34
    Q4 -.76 .47 .18 1.22 .69 1.99 .50 8.03
  No daytime activities .87* 2.38 1.15 4.91 .80 2.22 .75 6.56
SU related measurements
  Recognition (Q1) 1 1
    Q2 1.71* 5.51 1.11 27.39 1.98 7.21 .75 69.67
    Q3 2.74*** 15.58 3.47 68.77 2.87** 17.68 2.10 148.92
    Q4 3.82*** 45.60 10.50 198.12 3.76*** 42.86 4.95 371.41
  Knowledge (Q1) 1 1
    Q2 2.80** 16.61 2.18 126.57 2.65* 14.12 1.37 145.98
    Q3 3.02** 20.51 2.67 157.70 2.45* 11.58 1.15 117.04
    Q4 3.78*** 43.59 5.68 334.29 2.81* 16.52 1.56 174.84
  Attitude (score 0) 1 1
    Score 1 1.27*** 3.56 1.78 7.15 .97* 2.63 1.01 6.89
    Score ≥2 2.51*** 12.32 5.85 25.91 2.72*** 15.14 4.34 52.77
  Modelling (No/Yes) 1.59*** 4.90 2.71 8.88
Q1 = first quartile, OR=odds ratio, * p < .05, ** p < .01, *** p < .001, 
ID = intellectual disability, TIQ = full scale IQ, SU = substance use
a Participants with below maximum recognition score versus participants with maximum score
Expanded model lifetime cannabis use: χ 2(13, n = 347) = 151.99, p < .001. Cox & Snell R2 = 0.355, 
Nagelkerke R2 = .474
Expanded model lifetime stimulant use: χ2(14, n = 246) = 111.36, p < .001. Cox & Snell R2 = 0.364, 
Nagelkerke R2 = .543
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DISCUSSION
A lack of knowledge about SU rates and risk factors in individuals with MBID in the Netherlands 
hinders targeted prevention and interventions. Available studies are often limited to highly 
selected samples, report highly divergent rates, and provide limited knowledge on demographical, 
contextual, diagnostic and other risk factors. Furthermore, it is unclear whether international 
studies are relevant for the situation in the Netherlands. Therefore, we assessed SU rates and risks 
in individuals with MBID in several Dutch ID services. 
 
Findings
In our sample, the rates of current smoking (62%), current cannabis and other illicit drug 
use (15%), but not drinking (64%) were very high, given the SU rates in the Dutch general 
population (past month tobacco use ≈ 25%, alcohol use ≈ 77%, cannabis use ≈ 5%, stimulant use 
< 1%) (van Laar, & van Ooyen-Houben, 2015). Compared to studies in the MBID population 
(Carroll Chapman, & Wu, 2012; Emerson, & Turnbull, 2005; McGillicuddy, 2006; Swerts et al., 
2016; Taylor et al., 2004; Whitaker, & Huges, 2003; Žunić-Pavlović et al., 2013), including the 
Flemish SumID-Q study (Swerts et al., 2016), all SU rates seem rather high, but illicit drug use 
in our study stands out. This may be explained by higher levels of use and willingness to disclose 
such use, related the Dutch cannabis policies (i.e., users are seldomly prosecuted) that mislead 
some individuals with MBID to think cannabis use is legal in the Netherlands (VanDerNagel et 
al., 2013; 2016). While sampling differences may contribute to the different rates between the 
Dutch and Flemish SumID studies, the exclusion of individuals with BID in the latter does not 
explain our higher rates since we did not find differences between BID and MID in SU rates, and 
for that matter neither in age of initial use.
As described in other populations (see e.g., Carrol Chapman, & Wu, 2012; McGillicuddy, 
2006), SU initiation occurred typically in adolescence, but several participants initiated SU at 
primary school age. Participants who were current users, had started at younger ages than those 
who desisted, corroborating findings in individuals without MBID (Bolland, Bolland, Tomek, 
Devereaux, Mrug, & Wimbderly, 2016; Nelson, van Ryzin, & Dishon, 2015; Prince van Leeuwen 
et al., 2014). Though gender, age and lack of daytime activities were associated with SU, 
independent living and level of ID (MID versus BID) were not, contrary to suggestions from other 
studies (e.g., To et al., 2014; Taggart et al., 2006) Moreover, demographic and contextual factors 
were of little relevance to the final models in which SU related factors, such as substance picture 
recognition, knowledge, attitude and modelling were added. Substance related knowledge was 
significantly higher in users compared to non-users of illicit substances, but not in users of licit 
substances, as was found in the Flemish SumID-Q study (Swerts et al., 2016). For all substances, 
substance related positive attitudes and SU modelling were associated with an increase in SU 
likelihood, as previous studies in MBID found for smoking and drinking (Emerson et al., 2016; 
Swerts et al., 2016; Whitaker & Huges, 2003). 
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Limitations
Since this study had a cross-sectional design, there is a risk of recall bias and causality between 
risk factors and SU status cannot be established. For instance, SU knowledge, and positive SU 
attitudes could lead to SU, but this in turn can increase SU knowledge and positive attitudes. 
In addition, though this study concerns a relatively unselected and relatively large sample of 
individuals with MBID receiving care from a variety of settings, we cannot claim that this sample 
is representative of MBID population. Furthermore, since clustered randomized sampling proved 
to be unfeasible given the divergent ways participating organizations were sized and structured, 
and because of the lack of non-response analysis, selection bias cannot be ruled out. 
Thus, prospective studies in cohorts of individuals with MBID who have not initiated in SU are 
needed. Given the young age at SU initiation in some of our participants, as well as those in other 
Dutch studies (e.g. Kiewik, VanDerNagel, Kemna, Engels, & de Jong, 2016), these studies best 
start with samples of primary school aged participants. Since we did not distinguish between 
problematic SU, and non-problematic SU, further studies will also need to assess if and how risk 
factors are related to SUD.
 
Clinical implications & Conclusions
Given the high – and from a health and social perspective alarming – SU rates in our study, 
preventative actions that are currently in place apparently are insufficient for individuals with 
MBID. This calls for increased efforts from addiction facilities and ID services to develop and 
implement effective interventions. These interventions should target SU related attitudes, and SU 
modelling, including peer influences but also modelling by staff members. Since demographic, 
contextual and diagnostic account only for a small part of the variance in SU status, such 
interventions need to be available to all individuals with MBID. In addition, in order to identify 
(risk factors of) SU timely, a case-by-case approach using measurements such as the SumID-Q is 
needed.  
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SUMMARY OF THE FINDINGS
This project started in 2008 and focuses on the epidemiology of substance use (SU) and substance 
use disorder (SUD) in individuals with mild to borderline intellectual disability (MBID). In this 
chapter the findings of the project are summarized. As a side-kick, the state of affairs concerning 
the Substance use and misuse in Intellectual Disability-Questionnaire (SumID-Q, VanDerNagel, Kiewik, 
van Dijk, de Jong, & Didden, 2011b) will be presented. At the end of this chapter, we will turn 
to every day practice: a small survey in 10 aldermen of Dutch municipalities and three case stories 
point once more to the need for attention to the problems patients with MBID and SUD and 
the society are faced with. Scientific and clinical implications will be discussed, as well as the 
strengths and limitations of the studies included in this thesis. 
 
Chapter 1 introduces the issue of SU(D) in individuals with MBID, its clinical relevance and the 
outset of the SumID project. It also provides definitions of the core concepts in this dissertation. 
Three cases (see also VanDerNagel, Kemna, & Didden, 2013) illustrate how severe SU(D) is 
unrecognized in patients with MBID, how it can be mistaken for other problems (including 
psychiatric illness), and known SUD can be complicated by polysubstance use. In 2007, the 
acknowledgement that such cases represent an underserved yet important risk group of persons 
with dual diagnosis, led to the start of a collaboration between Tactus addiction medicine, Aveleijn 
ID services and NISPA. This collaboration was fuelled by a statement in the Dutch parliament on 
the scope and magnitude of SU in individuals with MBID (Parliament proceedings, 2007) that 
to our opinion was based on an underestimation of its rate and severity. 
Chapter 2 (van Duijvenbode, VanDerNagel et al., 2015) is a critical review of the literature on 
SU(D) in individuals with MBID. We noted that although this topic had gained attention over 
the past decade, there were still many gaps in the knowledge on prevalence and risk factors, and 
that instruments for screening and assessment as well as effective treatment interventions are 
scarce. Also, scientific developments in other fields are insufficiently incorporated in the care for 
individuals with MBID and SUD. For instance, the conception of SU(D) as a chronic, multifaceted 
brain disease has not yet translated to treatment programs that do just to its complexity. Thus, 
insights from addiction medicine and psychiatry have important implications for practices, 
policies and future research on the prevalence, screening, assessment and treatment of SU(D) in 
MBID. 
In Chapter 3 we present results from a survey among staff members from 39 Dutch intellectual 
disability services (IDS) (VanDerNagel, Kiewik, Buitelaar, & de Jong, 2011a). Using a semi-
structured questionnaire we assessed their perspectives on SU(D) among their clients, asked them 
to provide case reports and to describe policies within their services regarding SU. Alcohol was 
reported to be used at lower and illicit drugs at high rates compared to the population average. 
However, differences in reported SU rates varied greatly between services. In 86 case reports, 
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clients with mild ID compared to those with borderline ID more often used alcohol as the sole 
substance, and less often stimulants. The combination of alcohol and cannabis use was mostly seen 
in younger clients, while older clients more often used alcohol only. Psychiatric comorbidity and 
lack of daytime activities were highly prevalent among users. Respondents noted that substance 
users face a number of psychosocial problems and that they were poorly equipped to meet the 
users’ needs and to affect policies regarding SU in their facilities.
In Chapter 4 we combine data from an IDS and an addiction treatment center (ATC) in a capture 
recapture (CRC) analysis to better estimate the size of the population of individuals with SUD 
and MBID (VanDerNagel et al., 2014). In CRC analysis, the ratio of the number of subjects 
in two samples to the total number of subjects in one sample provided an estimation of the 
total population of interest. Since this includes an estimate of the ‘hidden’ population (i.e., 
the population not present in the original samples), CRC is especially useful when the target 
population is elusive or when reliable screening instruments are not available. Reports on 88 
subjects with SUD and MBID in the IDS (4% of the IDS population), and 114 in the ATC (5% 
of the ATC population), had only 12 subjects in both groups. Based on 97 subjects in the strata 
for males over 30 years of age, the hidden population was estimated at 215, and hence the total 
population within this stratum at 312 (95% CI 143-481). This study illustrates that patients 
with co-occurring SUD and MBID often receive support from only one service provider and that 
single source data underestimate its prevalence.
The Substance use and misuse in Intellectual Disability - Questionnaire
For the purposes of the studies described in chapter 5 and 6 we developed an instrument 
to assess substance use in individuals with MBID: the Substance use and misuse in Intellectual 
Disability – Questionnaire (SumID-Q, VanDerNagel, Kiewik, van Dijk, de Jong, & Didden, 
2011b; VanDerNagel, Kemna, & Didden, 2013). This questionnaire incorporates several 
strategies to reduce bias in self-report (for a description of the SumID-Q, see appendix A). 
The SumID-Q has now been successfully implemented in several Dutch ID services and 
has been translated into Danish and into Flemish (Swerts, Vandevelde, VanDerNagel, 
Vanderplasschen, Claes, & de Mayer, in press). 
In Chapter 5 (VanDerNagel et al., in press) we compare three strategies to assess substance use in 
112 individuals with MBID: self-report (SumID-Q), collateral-report by staff members (SumID-
CR), and biomarker analysis (in urine, hair, and sweat patch samples). We found high rates of 
alcohol, tobacco, and to a lesser but still substantial degree, for illicit drug use. As expected, 
we found lower willingness to participate in biomarker sampling, especially in hair- and sweat 
patch sampling. Contrary to findings in studies in non-MBID samples, we found low levels of 
under-report when using the SumID-Q. We conclude that given the additional costs and lower 
participation rates, the use of biomarker analysis to assess SU in MID seems of limited value 
compared to self-report and collateral-report. 
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In Chapter 6, we used the SumID-Q to assess SU rates and risk factors in 419 individuals with 
MBID (VanDerNagel et al., submitted). Lifetime licit SU (alcohol and tobacco) was 97%, 
lifetime illicit SU (predominantly cannabis) was 50%. Current users of tobacco (62%), alcohol 
(64%), and cannabis (15%) initiated SU at a younger age than those who desisted SU, but 
participants with mild ID did not differ from those with borderline ID in SU rates or age at SU 
initiation. Current licit SU and lifetime illicit SU were related to male gender, younger age and 
(for smoking and stimulant use) to lack of daytime activities. However, these factors did not 
contribute to multivariate models when recognition, knowledge, attitudes and modelling (i.e. 
substance use by participants peers, family, and professional caregivers) were added. The models 
correctly identified current SU in 84% (smoking) and 74% (drinking), and lifetime SU in 76% 
(cannabis) and 84% (stimulants) of the participants. We conclude that SU is highly prevalent in 
individuals with MBID, irrespective of the level of their ID or the type of care they receive. Since 
demographic, diagnostic and contextual characteristics are of limited use to define risk groups for 
SU within individuals with MBID, screening for SU on a case-by-case basis is advised. 
DISCUSSION
In this dissertation we set out to assess rates of SU(D) and its risk factors in individuals with 
MBID in the Netherlands, and to assess how SU(D) can be measured in this group. Using a 
variety of research techniques we have shown that individuals with MBID do not refrain from 
using psychoactive substances, but are in fact a group at increased risk for SU(D). Across our 
studies, irrespective of epidemiological strategy, we found higher levels of smoking, drinking 
and use of illicit substances than expected based on the literature that was available before the 
start of this project. 
Rates and risks of SU and SU(D) in individuals with MBID 
Alcohol and tobacco use were most prevalent in the populations of individuals with MBID 
observed in our studies. While alcohol use rates in MBID is lower than average in the Dutch 
population (past month alcohol use ≈ 77%), we found smoking and cannabis rates triple the 
national average (past month tobacco use ≈ 25%, past month cannabis use ≈ 5%) (van Laar, & van 
Ooijen-Houben, 2015; VanDerNagel et al., 2011; VanDer Nagel et al., submitted). 
We present several explanations for the higher SU rates in our studies compared to those found in 
the international literature before 2008. First, our focus was on individuals with BID and MID, 
the former – while a risk group for SU – often being excluded in other studies that often included 
individuals with more severe ID too. Second, we used a broader definition of SU, including for 
instance smoking and non-problematic use of alcohol. Third, in our SumID-Q studies, we used 
a questionnaire developed to the needs of individuals with MBID, which may have resulted in 
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a higher level of self-reported use. Fourth, in the Netherlands, given both the rather ‘liberal’ 
drugs policies and the focus on autonomy, substances may be easily accessible and SU may be 
socially acceptable for individuals with MBID. This may also at least partially explain the higher 
percentage of illicit drug use found with the SumID-Q in the Netherlands, compared to a study 
with the Flemish SumID-Q (Swerts et al., in press). 
Since the start of the SumID project, the number of publications on SU(D) in MBID has increased 
significantly (van Duijvenbode, van der Nagel et al., 2015). Several authors in these more recent 
studies identified individuals with BID to be at risk for SUD compared to those with average 
IQ’s. For instance, Hassiotis et al. (2008) found in a survey among 8,450 individuals in private 
households in the UK that participants with BID (n = 1,040), compared to individuals with 
average intelligence, had increased substance misuse (9.5% in BID participants, 6.4% in the 
average intelligence group). Gigi et al. (2014) compared data from the Israeli military on 12,785 
adolescents with BID, with those from 10,528 adolescents with average IQ, and found that 
individuals with BID were 1.2 times more likely to use drugs (95% CI=1.07–0.35) than those 
with average IQ, when controlled for social economic status. Thus, our findings that individuals 
with (M)BID are a risk group for SU(D), do not stand alone. 
In the Netherlands, several other studies on co-occurring SU(D) and MBID have been published. 
Though these studies do not primarily focus on epidemiology of SU in MBID, they do provide 
interesting epidemiological information. For instance, within a sample of 210 students (between 
12 and 15 years old) with MBID in Dutch special education schools, Kiewik et al. (2016) found 
that 50% had smoked, 75% drank alcohol at least once, and that they initiated in such behavior 
in their early teens (Kiewik, VanDerNagel, Kemna, Engels, & de Jong, 2016). Van Dijk et al. 
(2016) found that within an addiction sample, the prevalence of IQ’s in the MBID range (50-
85) was much higher (i.e., 35%) compared to the general population (van Dijk, VanDerNagel, 
Dijkstra, Didden, de Haan, & de Jong, 2016). 
Though SU may be higher in specific subgroups of the (heterogeneous) group of individuals 
with MBID, such as individuals with psychiatric co-morbidity or forensic complications, and 
though male gender, younger age, and lack of structured daytime activities have been identified 
as associated with higher levels of (SU), it is important to stress that other groups are not free 
from SU and its related problems. In fact, SU related factors (such as SU knowledge, attitudes, 
and modelling) are more strongly related to SU than demographic and diagnostic factors. Thus, 
though specific risk groups within the MBID population may warrant targeted preventative 
approaches, other individuals with MBID should not be precluded from preventative and early 
identification strategies. 
Assessment of SU in individuals with MBID
While for epidemiological purposes methods such as surveys and CRC techniques may be applied, 
in clinical practice there is a need for instruments to assess SU on a case-by-case base. Our study 
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comparing self-reported SU (using the SumID-Q), staff reported SU (using the SumID-CR) and 
biomarker analysis showed that self-report and staff report are sufficiently valid and reliable to 
assess SU in individuals with MBID. In addition to its psychometric properties, an important 
advantage of using an interview-based strategy such as the SumID-Q is that it can provide a basis 
to discuss SU in a non-confrontational style and thus provide a basis for further diagnostics and 
interventions. 
Strengths and Limitations
This project is the first large scale epidemiological project concerning SU(D) in individuals with 
MBID. It combines a variety of research strategies, and – contrary to other studies into SU(D) 
in MBID – does not focus on a highly selected population. Within the SumID project, we have 
found that individuals with MBID do use a variety of substances in rather high rates, and that 
SU can – and need to – be assessed on a case by case base. To that purpose, we developed the 
SumID-Q, an instrument that to our knowledge is the first worldwide specifically developed to 
assess SU in MBID. Limitations in our studies include selection bias, since we mainly focused on 
individuals with MBID in intellectual disability services (IDS). As our capture-recapture study 
illustrates, single source studies provide a different perspective than multiple source studies, and 
individuals with MBID within IDS may not be representative of the total MBID population. In 
addition, the response percentage for our survey on SU among staff from 153 IDS was about 35%. 
Non-response may have been associated to several factors, including absence of SU among clients. 
Participation in the SumID-Q studies may have been lower in those with SU(D), but the converse 
(i.e. subjects not willing to participate because they have no interest whatsoever in SU) can also 
be the case. Unfortunately, in the SumID-Q studies we were not granted access non-responders, 
and thus we could not assess whether responders differed from non-responders. In addition, in our 
studies with the SumID-Q, clustered randomized sampling proved unfeasible, and therefore we 
used a convenience sample. Second, relying on self-report and collateral report may have resulted 
in information bias. In the survey among IDS staff, most respondents (n = 30, 77%) relied on 
their own judgment when providing estimations of SU rates, only tree (8%) provided data from 
a systematic survey within their IDS. Reporting bias is likely in the case profiles in this study: 
users of illicit drugs were overrepresented in the client profiles compared with estimated rates 
in IDS. Even when SU is measured systematically, for instance in our studies using the SumID-Q 
and SumID-CR, individuals may withhold information on SU, and collaterals may provide biased 
information since they may not be privy to actual SU taking behavior by their clients. However, 
comparing the SumID-Q and SumID-CR with biomarker analysis, the level of underreport was 
small. Still, as to life time self-reported use, the magnitude of information bias is difficult to 
assess given the lack of a ‘gold standard’, and as to monthly and recent self-reported use our ‘gold 
standard’ of biomarker testing proved to be less ‘golden’ than expected. 
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Third, for practical reasons we limited the number of substances of interest in our studies. In our 
staff survey, we did not enquire about smoking and our capture-recapture was limited to SUD, 
excluding tobacco abuse (which was not a DSM classification at the time of this study). The 
SumID-Q, used in two of our studies, measures lifetime SU for a wide variety of substances, but 
current use only for tobacco, alcohol, cannabis and stimulants (the four substances mostly used by 
individuals with ID in the Netherlands). 
Fourth, all of our studies were cross-sectional. Hence, we can only assess current SU behavior, 
and retrospectively – to some extend – SU through the lifespan. This may have led to additional 
selection and information bias. Also, the concurrent measurement of risk factors and SU taking 
behavior, limits the inferences that can be drawn from any associations found between these 
factors. Because of differences in culture, health care and social systems, and drugs policies and 
legislations, it is probable that generalizability to other countries is limited. For all of these 
reasons, we cannot assess whether the results from our study on SU among individuals with 
MBID are representative for, and thus can be generalized to the whole population of individuals 
with MBID in the Netherlands, let alone to the population of MBID in other countries. 
IMPLICATIONS
This dissertation into the epidemiology of SU(D) in individuals with MBID in the Netherlands 
has important clinical, scientific and policy implications. Knowledge about rates and risks of 
SU(D) in MBID directs attention to a previously under- or unrecognized health issue. It provides 
data to further the development of targeted interventions. In addition, our studies provide 
essential information on how SU(D) in individuals with MBID can be assessed. Some of our 
findings have already been translated into daily practice. For instance, SU(D) in individuals 
with MBID is recognized as an important clinical problem. Several interventions directed to 
this group, such as the group intervention ‘Less booze and drugs’ [Minder drank of drugs] 
(VanDerNagel, Westendorp, Van Dijk, & Kiewik, 2016) and a CBT intervention (VanDerNagel 
& Kiewik, 2016) have been developed and are currently being studied or implemented in Dutch 
addiction facilities. Last but not least, the SumID-Q has been successfully implemented in IDS 
in the Netherlands, Belgium, and Denmark. Further translations and dissemination in other 
countries are underway. 
Notwithstanding the recent improvement in clinical care for individuals with MBID and SU(D), 
several important issues remain that warrant more attention. Before we discuss these clinical and 
scientific implications, we will return to both policy makers in the Netherlands, as well as our 
patients with MBID and SU(D). 
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At the end of this project
At the end of this project, we were interested to review the political opinions regarding the co-
occurrence of SU(D) in MBID. During the project, due to new legislation, state funded social 
care has partially been converted to municipality funded social care. Therefore, in the spring 
of 2016, we interviewed 10 aldermen in the Netherlands who are responsible for social care 
in their municipalities, about their perspectives on substance us in individuals with MBID. 
All of them commented they were not informed about the rates of SU in MBID: “Honestly, I 
would not know” (#1). Still, they perceived individuals with MBID as a risk group for SU: “I 
do think it is higher than in, let’s say our peer group”(#3). According to the aldermen, this could 
be related what Taggart (2007) would call ‘self-medicating against life’s negative experiences” and 
“social distance from the community’:“…one can get very disappointed, to be aware that you are limited 
because of your IQ... and one could want to escape this situation by taking substances” (#3). Another 
factor would be peer pressure and gullibility: “this group can be an easy prey” (#8). Conversely, 
some individuals with MBID are regarded to be less susceptible for SU : “...that they are not 
interested [in taking substances], because of their limitations. Because they live in their own world 
and are not involved the way we are”(#3). According to the aldermen, key factors in prevention 
of SU(D) in MBID is the guidance and support these individuals obtain: “It depends on how 
society, parents and caregivers deal with this issue” (#4). Several comment on supported work 
programs and cultural and sports activities to decrease SU taking risks: “…to make sure they 
[individuals with MBID] are not tempted [to use substances] because of boredom” (#4), and “… 
it increases ‘normal’ social influence”(#7). Collaboration of services and awareness of this issue is 
seen as a challenging but important factor in helping those in which SU has progressed to 
SUD: “I think it [SU(D) in individuals with MBID] is still under recognized” (#9), and “The 
question we should ask is: What do we do about this? … In response to this survey we talked about it 
in our municipality. I guess this is quite a wake-up call…”(#4). 
Though integrated services targeted to individuals with MBID and SU(D) are not yet 
available in all municipalities, at the end of this project we see the impact of targeted 
approaches in patients such as client D, E, and F, who were treated by the SumID teams of 
Tactus and Aveleijn.
Client D2, a 28-year-old mother of two children, was referred for treatment of cannabis 
dependence. Based on our regular intake procedure, she was deemed eligible to participate in 
a pilot study into our new group intervention Less Booze and Drugs (Minder Drank of Drugs; den 
Ouden, Kiewik & VanDerNagel, 2012). Part and parcel of this pilot were the administration 
of several questionnaires, including the Substance use and misuse in Intellectual Disability-  
2 This case was kindly presented to me by Marion Kiewik, Msc, Aveleijn. 
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Questionnaire (SumID-Q). During the presentation of several substance related pictures, she 
became giggly. When the picture of GHB (γ-hydroxybutyric acid) was presented, her eyes 
widened and she smiled. Although this was noted by the interviewer, it was – as instructed in 
the manual – not directly addressed. After further assessment of tobacco and alcohol related 
knowledge, attitudes, modelling and use, the client was asked with which other substance 
to proceed. When she proposed to continue with stimulants (cocaine and amphetamines), 
the interviewer asked whether the GHB list was to be completed too. After some hesitation, 
the client conceded to do so. As it turned out, her GHB use was of much more concern 
and severity than her cannabis use, the reason for referral. The client reported to have been 
reluctant to admit to GHB use before, for fear of interference of child protective services.
Client E3. The first time I saw this client he was sulking like a little kid. His bag was packed, 
and he was prepared for me to persuade him to stay. That, he did not want; he wanted to get 
“outpatient treatment”. I had heard about him before, at the staff meeting. At the age of 34 he 
had been drunk for twenty years, and had an intellectual disability of a degree that couldn’t 
be determined exactly because of his permanent intoxication. Add to that alcoholic hepatitis, 
renal failure, cachexia, and a seizure during withdrawal in the summer holiday. Palliative 
care had already been considered. His permanent drunkenness was fueled by a life of misery, 
lack of meaningful activities and simply not knowing how one could not drink. His social 
network was nil, if you would not count his beer buddies and his caregivers. This morning, 
he finally conceded to an inpatient detoxification, but now, after only two hours, he wanted 
to leave. Against his expectations, I did not object: “we’ll do what you want; but if that fails, 
we’ll do what I want. “ With a big smile he shook hands. Twice more he tried our inpatient 
program voluntarily, for indeed, outpatient care did not suffice. The last time, he asked to be 
stopped should he want to leave prematurely again. A month into the program, I met him in 
at the occupational therapy. Dressed in coveralls, a broom in his hand and chatting with ‘the 
boys’. Fifteen kilos heavier and in a much better shape. Later, he moved to a care facility at a 
farm. There he still lives, without a drop of beer. 
Client F is a 28-year-old man with an autism spectrum disorder and mild ID. His professional 
caregiver called the Tactus ID team to discuss whether a referral would be appropriate. As 
it turned out, F consumed 8 glasses of coca cola a day, and claimed to be addicted to it. 
According to screening with the SumID-Q, and in line with staff perceptions, there was no 
other SU. The client however requested to be referred to Tactus for addiction treatment, just 
like several of the other residents in his group (who had alcohol- and cannabis use disorder).  
3 This case was published in Dutch as: VanDerNagel, J.E.L. (2015). Hoop doet leven, Medisch contact,
51/52, Retrieved from www.medischcontact.nl/rubrieken/Rubrieken/Lezersverhalen/Lezersverhaal/
152220/Lezerverhaal-Permanente-dronkenschap.htm. 
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His caregiver doubted whether such a referral was needed, even though the interventions 
they had tried themselves had not yet resulted in behavioral change. After consulting with 
the staff of IDS, one of Tactus’ social workers made a house call and had ‘quite a serious 
conversation’ with the client, which resulted in a plan to gradually reduce the consumption 
of coca cola to less unhealthy quantities. Mr. F since then has been an even more enthusiastic 
advocate of the services of our team.
Clients such as D, E, and F illustrate how addiction care can be more effective for individuals with 
MBID when assessment and interventions are tailored to their needs and capacities. In client D, 
the use of GHB remained undetected by ID care, child protective services, and addiction care. 
Though she denied the use of this substance at the regular intake procedure, during the SumID-Q 
interview, she showed knowledgeable about and interested in this substance and eventually 
conceded to its use. Client E and F illustrate how individuals with MBID can be supported to 
change their behavior, even in very progressed cases such as client E. In (very) mild cases of use of 
psychoactive substances, such as in client F, both clients and staff from IDS may be supported by 
preventive or consultative interventions. 
Clinical implications
1. Focus on prevention 
While SU is not necessarily a problem in and of itself, interventions to delay or forestall SU 
contribute to the prevention of SU related problems, including the development into SUD 
(Kiewik et al., 2016). In the Netherlands, since 2014 alcohol and tobacco may not be sold to 
individuals under 18 years of age (Government of the Netherlands [Rijksoverheid], 2016). Though 
legislation will not prevent all adolescents (either with or without MBID) to use substances, as is 
shown by the high levels of illicit drug use, a clear societal statement may contribute to less SU 
in future generations. 
In addition to legislation, educational and preventative interventions need to be in place within 
but not limited to elementary schools (Kiewik et al., 2016; VanDerNagel et al., submitted). 
Though individuals in specific risk groups (e.g., those within psychiatric or forensic samples) may 
benefit from targeted (preventative) interventions, (secondary) prevention should not be limited 
to these groups given that SU(D) is far but limited to these groups. Preventative and treatment 
efforts should not be limited to the use of alcohol and illicit drugs. The use of tobacco is associated 
with severe health issues and has not received the attention that is warranted. IDS therefore 
should implement interventions to reduce tobacco consumptions, preferably not only for their 
clients but for staff members (who can be important role models to clients with MBID) as well. 
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2. Facilitate case identification
Timely identification of SU(D) in individuals with MBID may further contribute to early 
interventions and adequate treatment referral. First, this requires recognition of SU in this 
group.To this purpose, staff members in IDS should be educated on and increase their skills in 
recognising SU(D) in MBID. Furthermore, screening for and assessment of SU(D) should be 
implemented in routine diagnostic procedures. Doing so, special attention should be paid but 
not limited to high-risk groups (such as those with co-occurring psychiatric disorders or forensic 
patients). The use of an instrument such as the SumID-Q, combined with a structured collateral 
report (for instance using the SumID-CR) can contribute to both the screening process as well as 
staff member awareness of SU and its risks. In individuals who are identified as users of a specific 
substance, the use of other substances should be investigated as well since poly substance use 
often occurs. Sometimes – as illustrated in client D – the reason of referral to SUD treatment is 
less clinically relevant than the hidden co-occurring SU. 
Vice versa, in addiction medicine more attention should be directed to the identification of MBID 
in SUD patients (van Dijk et al., 2016). Here too, staff education and training in screening 
and assessment, as well as the implementation of standardized screening instruments is needed. 
Arguably, case identification should lead to targeted interventions.
 
3. Develop and implement targeted and integrated strategies for SUD treatment
As there is a lack of SUD interventions adapted to the needs of individuals with MBID, addiction 
treatment facilities and IDS need to develop collaborative strategies to provide integrated 
treatment. Interventions of less to more intensity and duration, and targeted at the biological, 
psychological and social aspects of SUD, are needed. Even in (very) progressed cases – such as client 
E – interventions that take the co-occurring MBID into account may result in more favourable 
outcomes than treatment as usual. Finally, SU(D) should not be an exclusion criterion for IDS, 
while having an MBID should not limit access to addiction services. This requires collaboration 
and cross-fertilisation between addiction and ID services and the collaborative implementation 
of newly developed protocols for SU(D) in MBID. Further steps should be taken to expand these 
interventions to account for co-morbidity with psychiatric disorders and forensic issues. 
Recommendations for future research
1. Expand the body of knowledge about epidemiology of SU in (MB)ID
Relationships between SU(D) and potential risk- and protective factors such as psychiatric co-
morbidity, forensic psychiatric complications, and social support and preventative interventions, 
as well as the incidence and course of SUD in MBID need to be explored further in studies with 
prospective designs to allow inferences about causes and effects, as well as to reduce recall and 
selection bias. Further research should also be directed to (the effects of) SU (including smoking) 
in individuals with more severe ID. Since both self-reported and collateral-reported use may be 
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less reliable in some cases or circumstances (as is illustrated by client D), further research should 
be directed to factors that influence self-report validity. In addition, further studies in translated 
versions of the SumID-Q are needed. 
2. Expand the body of knowledge about epidemiology of (MB)ID in individuals with SUD
Preliminary data from our TactIQ study showed that a large proportion of patients in addiction 
treatment facilities had an IQ in MBID range without having been identified as having an 
MBID (van Dijk et al., 2016). These studies have to be replicated in other addiction services, 
and strategies to screen for MBID in SUD samples need to be developed. Furthermore, as low IQ 
scores could also be related to cognitive damage due to SUD, or a combination of such damage 
and MBID, research should be directed to the relations between and differential diagnosis of SUD 
related cognitive damage and MBID. 
 
3. Combine multiple perspectives to get a better perspective on the scope of SU(D) in MBID
Data on SU(D) in MBID from IDS, addiction treatment samples, forensic and psychiatric services, 
need to be combined – for instance in a capture-recapture study with three or more sources – to 
better understand the magnitude of SU(D) in individuals with MBID and the interrelations with 
other psychiatric disorders and forensic issues. In addition, the biological, psychological and 
social factors related to SU(D) in MBID need to be studied. 
4. Evaluate prevention and treatment interventions
Interventions targeted to SU(D) in individuals with MBID – with and without psychiatric co-
morbidity or forensic issues – need to be further developed and studied. Although steps have been 
taken to this purpose, these initiatives often remain at the level of pilot studies. Studies in larger 
samples and with strong methodological designs, as well as in topics such as the applicability 
and effectiveness of existing pharmacological and psychosocial interventions when applied in 
the MBID group. Further research should be directed to identifying barriers to treatment, and 
methods to improve referral and promote collaboration between different health care systems. 
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A
LEKKER LEZEN SAMENVATTING4
Het SumID onderzoek
Sommige mensen roken
Sommigen gebruiken alcohol of drugs
Doen mensen met een verstandelijke beperking dat ook? 
Dat hebben we onderzocht
Het onderzoek is nu klaar
Dit is het verslag
Wat hebben we ontdekt?
Veel mensen met een verstandelijke beperking roken
Sommigen drinken alcohol 
Een aantal gebruikt drugs
Anderen doen dat niet
Eigenlijk heel logisch
Begeleiders maken zich er soms zorgen over
Ze weten dan niet wat ze moeten doen
Het is niet altijd duidelijk of iemand gebruikt
Je kan het controleren met een test
Maar je kan er ook naar vragen
Gewoon praten over gebruik, dat lukt prima
4 Leesniveau A2 - B1 (Accessibility Leesniveau Tool, www.accessibility.nl).  
80 - 95% van de bevolking is in staat teksten van dit niveau te lezen en te begrijpen. 
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En nu?
We hebben twee belangrijke tips:
1. Praat open en eerlijk over roken, alcohol en drugs
2. Praat er over voordat het voor problemen zorgt
Onze vragenlijst kan helpen er over te praten
Die lijst heet de SumID-Q
Wil je meer weten? 
Wil je meer weten over roken, alcohol of drugs?
Of wil je meer weten over dit onderzoek? 
Kijk dan op www.lvbenverslaving.nl
Bedankt!
We hebben veel hulp gehad bij het onderzoek
Daar zijn wij heel blij mee 
Heb je ook mee geholpen?  
Dan bedanken we jou enorm!
Joanneke van der Nagel
Onderzoeker SumID-project 
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SCREENING & ASSESSING SU IN MBID: THE SUMID-Q5
Challenges in screening and assessment
Screening and assessment of substance use in persons with intellectual disabilities (ID) is 
complicated because of their limited cognitive capacities and knowledge of substances, and 
tendency to biased responses (McGillicuddy, 2006; Sturmey, Reyer, Lee, & Robek, 2003; 
VanDerNagel, Kiewik, van Dijk, de Jong, & Didden, 2011). 
Widely used screening instruments (such as the CAGE, MAST, AUDIT/DUDIT) have two main 
shortcomings when using them in clients with ID. 
First, they require basic substance knowledge and a conceptual understanding that persons with 
intellectual disabilities may lack (Finlay, & Lyons, 2001; Heal, & Sigelman,1995; McGillicuddy, 
2006; Wallace, Keenum, & Roskos, 2007). For instance, in clinical practice it is observed that 
many clients do not understand that the term ‘alcohol’ is not solely reserved for strong liquor. 
Thus, those who drink beer or alcohol pops may be inclined to say ‘no’ to questions on alcohol use. 
Other clients are unaware that they are consuming psychoactive substances. In the Netherlands 
the use of cannabis – though illegal – is not prosecuted, and this drug is widely available in so 
called ‘coffee shops’. Some clients with ID confuse this policy with legalization, and several even 
concluded that cannabis use is harmless. 
Second, many persons with intellectual disability have a high tendency to give socially desirable 
answers and acquiescence (i.e. “to agree with whatever statement”) as well as to “Say Nay” 
regarding to questions relating to social taboos such as substance use (Finlay, & Lyons, 2001; 
Heal, & Sigelman,1995; Sturmey et al., 2003; McGillicuddy, 2006). These tendencies are 
especially strong when clients are questioned directly, which is the case in screening instruments, 
or when the client is interviewed in the presence of persons who are unaware of the substance use 
(SU). Interestingly, we have also observed cases in which direct questioning may lead to positively 
biased answers. That is, some clients have assented to use substances, while in fact they did not. 
These factors may lead to biased responses when persons with ID are questioned directly about 
substance use. 
Solutions to these challenges
To evoke more truthful answers on substance use, several adaptations need to be made to the 
screening process (VanDerNagel, Kemna, & Didden, 2013). Discussing substance use in an 
empathetic, open and non-confrontational interview elicits more information on substance use, 
and provides a basis for further counselling. 
The first step in an interview, then, will be to talk about substances in general. The interviewer 
should take into consideration that commonly used words can be unknown to the client. 
5 Parts of this appendix have been published before as: VanDerNagel, J. E. L., Kemna, L. E. M, Didden, R. (2013). 
Substance use among persons with Mild Intellectual Disability: approaches to screening and interviewing. NADD 
Bulletin, 16, 87-92
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Confusion on terminology can be limited by presenting pictures of substances (see e.g. Figure 1) 
and asking the client what the pictures stand for. This will clarify which words the client uses for 
various substances. The interviewer can adopt this terminology in the remainder of the interview 
to prevent misunderstandings and to make the client feel more at ease. Also, this approach will 
elicit comments that often render a lot of information (‘Oh, a bottle of beer, yeah I used to do a 
lot of those’). Last but not least, this approach helps the client to become more talkative and share 
information also on more sensitive topics such as substance use. 
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After establishing which substances are known to the client and which terms he uses for them, 
further questions can be asked to assess clients knowledge about, and attitudes towards SU 
(for sample questions, see Table 1 and 2). Here, we recommend to start with a commonly used 
substance (i.e., alcohol or tobacco). Pictograms can be used to help choose between answer 
categories (Figure 2). Asking whether family, friends or staff members use substances often evokes 
giggling remarks on how clients have caught staff members smoking secretively. Again, these 
questions on substance use by others helps the client to understand that substance use – even in 
role models – is a reality and that it can be discussed without negative moral judgement. 
 All these introductory (though relevant) questions, invite the client to speak freely and truthfully 
when – in the third step – asked about his own substance use (‘Did you ever use …’). When 
the client admits to using a type of substance, it is important to maintain a non-judgemental, 
interested attitude. The last step will be to explore substance use patterns (frequencies, quantities, 
circumstances), and the use of other substances. 
All of these steps have been lined out in the SumID-Q, a Dutch-language instrument developed to 
assess substance use, its risk factors and consequences among persons with a mild and borderline 
Intellectual Disability. The SumID-Q has been implemented in several (Dutch) Intellectual 
Disability facilities, and has been translated in Flemish and Danish. 
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The SumID-Q 
The Substance use and misuse in Intellectual Disability-Questionnaire (SumID-Q, VanDerNagel et 
al., 2011, 2013) is a Dutch language instrument developed within the SumID-epidemiology 
project to assess SU, its risk factors and consequences among persons with MBID. It 
incorporates strategies to decrease self-report bias, such as (1) adapted item structure and 
wording, (2) visual aids, and (3) a step by step non-confrontational approach.
Structure of the SumID-Q
•	 Before step 1: Establish a good working relationship, and be willing to discuss SU in an 
open, empathetic way
•	 STEP 1: Talk about substances in a non-confrontational way
- Assess client’s familiarity with substances and his terminology 
  (use pictures, Figure 1)
- Assess client’s substance knowledge & client’s attitude toward substance use 
  (Table 1 and 2, Figure 2)
•	 STEP 2: Talk about substance use in general
- Discuss SU among peers, staff, family members
•	 STEP 3: Talk about client’s own substance use step by step
- Ask about life time use (`Did you ever use … yourself?’, ‘How old were you?’, 
  ‘Was it once or more often?’)
•	 STEP 4: Further inquire about the use of this type of substance to assess
- Patterns of use (frequency, quantity)
- Circumstances (alone/with others, at home or somewhere else) 
- Effects (positive and negative)
Repeat this process for other types of substances
SumID-CR - The Substance use and misuse in Intellectual Disability - Collateral-report 
Questionnaire (SumID-CR) was developed to assess the perception of collateral informants 
(e.g. staff members, primary caregivers, family members) on client substance use, covering 
the same topics as the SumID-Q.
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Table 1. Substance related Knowledge questions in the SumID-Q   
Tobacco Children† are allowed to buy tobacco†
 Smoking is allowed everywhere
 Smoking is unhealthy for your lungs
 Smoking is unhealthy for an unborn child
 To quit smoking if you want to, is very easy 
 Smoking causes relaxation
 Tobacco packages contain warnings on smoking
 What is unhealthier: smoking cigarettes, smoking shag tobacco or ‘it doesn’t matter’?
Alcohol Driving a car after consuming 4 glases¥ of alcohol is allowed
 Children are allowed to buy alcohol
 Drinking a lot of alcohol reduces appetite
 Drinking a lot of alcohol often reduces walking ability
 Alcohol drinking changes how you feel and how you act
 Drinking a lot of alcohol can impair your memory
 What contains more alcohol, a glass of beer or a glass of spirits?
Cannabis Cannabis can be bought in a supermarket
 You can be sent to jail because of using cannabis#
 Smoking cannabis makes you hungry
 Smoking cannabis makes your eyes red
 Smoking cannabis improves your memory
 Smoking cannabis can make you mental
 When you eat ‘space cake’ you will notice its effects quickly
 Cannabis makes your sleepy
Cocaine/Speed Selling cocaine/speed is illegal
 It is allowed to export cocaine/speed to other countries  
 Using cocaine/speed makes you hungry
 Using cocaine/speed makes your heart race
 Using cocaine/speed makes you sleepy
 Using cocaine/speed makes you relaxed
 Cocaine/speed is addictive
 Almost all persons have tried cocaine/speed
* All questions are in Dutch, translation in some cases produces more complex and/or longer sentences. 
† The interviewer is instructed to explain that ‘Children’ refers to persons under the age of 16
^The interviewer shows the pictures of the two substances
¥ The interviewer is instructed but to explain that ‘glasses’ refer to standard units 
# This is not the case in the Netherlands
Table 2. Substance related Attitude questions in the SumID-Q~ 
Using … is sturdy
 Using … is stupid
 Would you accept … from a friend?
 … is tasty / pleasant‡
 Persons who … are weak
 Persons who … are clever
 Persons who … are ‘cool’
 … is a nice thing to do‡
 … is unhealthy
 Do your friends think you should use …? 
~ These questions are asked for each substance, using subject’s own terminology in the phrases (e.g. smoking 
fags is sturdy)
‡ In dutch the word ‘lekker’ is used, referring to tasty and/or pleasant bodily sensations 
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INTRODUCTIE
Dit proefschrift gaat over de omvang van en risicofactoren voor (problematisch) middelengebruik 
bij mensen met een Lichte Verstandelijke Beperking (LVB). Het beschrijft de bevindingen van 
epidemiologisch onderzoek in het Substance use and misuse in Intellectual Disabilities (SumID) project. 
Tot aan de start van dit project in 2008 was er in Nederland weinig systematische aandacht voor 
het onderwerp LVB en middelengebruik. Daardoor bestonden er uiteenlopende perspectieven op 
aard en omvang van dit probleem. 
Bij de start van het SumID project
In juni 2007 gaven de ministers van Volksgezondheid, Welzijn en Sport en voor Jeugd en 
Gezin aan dat er in Nederland ‘…enkele honderden verslaafde licht verstandelijk gehandicapte 
jongeren in de LVG-instellingen’ zouden zijn (Tweede Kamer der Staten-Generaal, 2007). 
In datzelfde jaar hadden professionals van Tactus verslavingszorg en Aveleijn verstandelijk 
gehandicaptenzorg cliënten zoals hieronder beschreven in zorg (casus uit: VanDerNagel, 
Kemna, Trentelman, & Didden, 2013).
Cliënt A is een 19-jarige jongeman (totaal IQ = 74) die gezien zijn leeftijd graag zelfstandig 
(met begeleiding) wil gaan wonen. Middelengebruik zou zich beperken tot roken en “af en 
toe een biertje”. Van ander middelengebruik is volgens cliënt en zijn ouders geen sprake. Als 
hij enkele maanden binnen de voorziening woont, wordt een wietlucht bij zijn appartement 
geroken. In een gesprek met zijn persoonlijk begeleider geeft hij aan inderdaad regelmatig 
cannabis te roken. Aanvankelijk deed hij dit buiten de woonvoorziening, maar de laatste 
tijd ook in zijn appartement. In vervolggesprekken wordt open, op niet-veroordelende 
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manier, verder over het cannabisgebruik gesproken. Cliënt wordt uitgenodigd te vertellen 
over wat in zijn perspectief voor- en nadelen van gebruik zijn. Hij staat daarna open voor 
het bespreken van risico’s van gebruik, en het maken van afspraken over gebruik. Enkele 
maanden later meldt een kennis dat hij naast cannabis ook met enige regelmaat cocaïne 
gebruikt, om de nachtdienst op zijn werk door te komen. Kort na dit gesprek heeft hij de 
woonvoorziening verlaten om samen te gaan wonen met zijn nieuwe vriendin. Verdere zorg 
heeft hij afgewezen. 
Cliënt B is een 35-jarige zwakbegaafde vrouw (totaal IQ = 76), bekend met 
ADHD, borderline persoonlijkheidstrekken en in het verleden polydruggebruik en 
cocaïneafhankelijkheid. Zij woont in een zelfstandige wooneenheid met 24-uurs zorg van 
een instelling voor gehandicaptenzorg. In de jaren na plaatsing nemen de problemen toe. 
Ze heeft stemmingswisselingen en is zeer prikkelbaar. De contacten verlopen hierdoor 
steeds moeizamer en worden minder frequent. Cliënt weet met verhalen over een verloren 
portemonnee of niet-werkende geldautomaat extra geld van haar begeleiders te krijgen, 
waarbij het onduidelijk is waar zij dit geld aan uit geeft. Begeleiders schrijven de 
stemmingswisselingen, interactieproblemen en het niet met geld om kunnen gaan toe aan 
haar verstandelijke beperking, de borderline kenmerken en de ADHD. Anderhalf jaar na 
plaatsing belt een bezorgde buurvrouw de politie nadat zij cliënt angstig heeft horen huilen. 
De agenten vinden haar gecollabeerd in de gang van haar appartement. Ze heeft enkele dagen 
meerdere grammen cocaïne gebruikt en niet gegeten of geslapen. Achteraf geeft ze aan sinds 
een jaar weer regelmatig te gebruiken. 
Cliënt C is een 38-jarige vrouw met het syndroom van Down en een IQ rond de 50. Zij 
wordt verwezen naar de alcoholpoli nadat zij eerder werd behandeld vanwege een aantal 
ernstige alcoholintoxicaties, waarvoor zij telkens op de spoedeisende hulp werd gezien. 
De middelenanamnese bij intake is positief voor alcohol en tabak, negatief voor andere 
middelen. Ze blijkt vooral baat gehad te hebben bij duidelijke leefregels: “niet meer dan 2 
glazen alcohol per dag”. Het overmatig gebruik van alcohol is volgens begeleidster ook onder 
druk van een aantal kennissen ontstaan. Cliënt geeft aan nog wel contact te hebben met deze 
mensen, maar alleen sigaretten van hen te krijgen. Desgevraagd geeft zij aan dat dit soms ook 
“speciale sigaretten, waar je lekker moe van wordt” zijn. Uiteindelijk blijkt ze onder invloed 
van alcohol of cannabis door deze ‘kennissen’ herhaaldelijk verleid te zijn tot het uitvoeren 
van seksuele handelingen.
Deze casus illustreren dat middelengebruik door mensen met een LVB lang onopgemerkt kan 
blijven, zelfs wanneer er – achteraf gezien – duidelijke aanwijzingen voor (problematisch) gebruik 
waren. Sommige gebruikers – zoals cliënt A – zijn niet genegen hun gebruik te bespreken. Soms 
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vanuit de angst voor reacties op hun gebruik, soms omdat ze het probleem met gebruik niet 
zien. Familie, vrienden en professionals die bij deze mensen betrokken zijn herkennen middelen 
gerelateerde problemen ook niet altijd. Soms speelt daarbij de misvatting een rol dat mensen met 
een LVB niet zouden gebruiken. Vaak worden symptomen van problematisch gebruik verkeerd 
geïnterpreteerd en verward met symptomen van een andere psychiatrische of een lichamelijke 
aandoening (cliënten A & B). In andere gevallen wordt wel opgemerkt dat er sprake is van 
gebruik, maar blijven de aard, omvang of (ernst van) gevolgen onduidelijk. Cliënt C lijkt zich 
bijvoorbeeld er niet van bewust dat ze met haar “speciale sigaretten” gedrogeerd wordt. 
Het systematisch screenen op gebruik kan bijdragen tot vroege opsporing en adequate verwijzing 
voor behandeling, maar ook tot gefundeerde beeldvorming over de omvang van het probleem. 
Bij de start van het SumID project was er echter geen sprake van dit soort screening, of zelfs maar 
het bestaan van de daarvoor benodigde instrumenten. De uiteenlopende perspectieven op aard en 
omvang van (problematisch) gebruik bij mensen met een LVB was de aanleiding tot het SumID 
project. In dit project werken Tactus verslavingszorg, Aveleijn verstandelijk gehandicapten 
zorg en het Nijmegen Institute of Scientist-Practitioners in Addiction (NISPA) samen. Het 
epidemiologisch onderzoek binnen het SumID project werd mede mogelijk gemaakt door een 
grote onderzoekssubsidie van ZonMW (VanDerNagel et al., 2008). 
MIDDELENGEBRUIK ONDER MENSEN MET EEN LVB
Zoals de meeste mensen komen ook mensen met een LVB in aanraking met alcohol, tabak 
en andere middelen. Zij vormen een risicogroep voor problematisch gebruik, vanwege een 
combinatie van risicofactoren zoals een lage sociaal economische status, gedrags- en psychiatrische 
problemen, gebrekkige coping vaardigheden en problemen op het gebied van werk, dagbesteding 
en financiën. Daarbij zorgt (problematisch) gebruik vaak voor interactieproblemen met 
mede-cliënten of begeleiders in de LVB zorg. In de literatuur blijken de schattingen van de 
prevalentie van (problematisch) middelengebruik onder mensen met LVB nogal uiteen te lopen. 
Daar zijn meerdere oorzaken voor. Allereerst levert het gebrek aan systematisch screenen een 
onderschatting van de aard en omvang van de problematiek op. Daarnaast hangt er veel af van de 
gebruikte definities van zowel de doelgroep, als van (problematisch) gebruik. Middelengebruik 
komt bijvoorbeeld relatief veel voor onder mensen met zwakbegaafdheid (IQ 70-85), een groep 
die in Nederland wel, maar in veel andere landen niet tot groep mensen met een verstandelijke 
beperking gerekend wordt. Daarnaast komt gebruik – net als bij mensen zonder LVB - meer voor 
onder individuen met forensische of psychiatrische problematiek. Onderzoek in deze doelgroepen 
geeft dus een ander beeld dan onderzoek in de bredere groep mensen met een verstandelijke 
beperking. Wat betreft de definitie van (problematisch) gebruik maakt het natuurlijk veel uit of 
ook tabaksgebruik en niet-problematisch alcoholgebruik wordt geregistreerd. 
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Alles bij elkaar genomen lijkt er op basis van de internationale literatuur geen eenduidig beeld te 
schetsen van de prevalentie van LVB en (problematisch) middelengebruik. Voor Nederland is er in 
2008 helemaal geen systematisch prevalentie onderzoek beschikbaar. Het Trimbos Instituut zegt 
daarover: ‘Er is dan ook behoefte aan meer nationaal onderzoek naar de prevalentie van middelengebruik, 
middelenmisbruik en de daaraan gerelateerde problemen onder deze doelgroep. ...(daarbij) dient rekening 
gehouden te worden met methodologische vraagstukken rondom de screening van het middelengebruik (en/
of misbruik) onder deze doelgroep (waaronder de vraag of zelfrapportages betrouwbaar zijn)’ (Mutsaers, 
Blekman, & Schipper, 2007, p. 25). Samenvattend waren er verschillende vraagstukken ten 
aanzien van de epidemiologie van middelengebruik bij LVB in Nederland, waaronder: 
1.  Een gebrek aan epidemiologische gegevens (over risicofactoren en prevalentie);
2.  Een gebrek aan kennis over hoe gebruik onder mensen met een LVB het best in kaart gebracht 
kon worden. 
 
DIT ONDERZOEK
Het onderzoeksplan
In het project Substance use and misuse in Intellectual Disability (SumID) wordt in het SumID-
epidemiology project de prevalentie en risicofactoren van (problematisch) middelengebruik onder 
LVB op verschillende manieren in kaart gebracht: 
1.  Een literatuurstudie (hoofdstuk 2);
2.  Een enquête onder LVB instellingen (hoofdstuk 3);
3.  Een vergelijking van cliëntbestanden van verslavingszorg en verstandelijk gehandicaptenzorg 
(hoofdstuk 4);
4.  Een vergelijking van zelfrapportage van gebruik door cliënten met de SumID-Q, rapportage 
van stafleden en urine-, haar-, en huidpleister onderzoek (hoofdstuk 5);
5.  Een landelijke studie naar gebruik en risicofactoren voor gebruik op basis van zelfrapportage 
met de SumID-Q (hoofdstuk 6).
De SumID-Q
Veel gangbare screeningsinstrumenten voor middelengebruik en verslavingsproblematiek 
zijn niet geschikt voor cliënten met een LVB, vanwege hun complexiteit, taalgebruik 
en directe benadering. Voor dit onderzoek werd daarom de Substance use and misuse in 
Intellectual Disability-Questionnaire (SumID-Q, VanDerNagel et al., 2011b) ontwikkeld om 
middelengebruik, risicofactoren voor gebruik en de complicaties daarvan bij mensen met 
een LVB in kaart te brengen. Om betrouwbare antwoorden te krijgen, wordt in de SumID-Q 
gebruik gemaakt van aan de doelgroep aangepast taalgebruik, visuele ondersteuning met 
plaatjes, en een niet-confronterende stap voor stap benadering. 
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Op basis van de onderzoeksversie van de SumID-Q werd dankzij een implementatie subsidie 
van ZonMW (VanDerNagel, Kiewik, & de Jong, 2011c) een praktijkversie gemaakt en 
beschikbaar gesteld aan Nederlandse LVB instellingen. Inmiddels zijn er ook een Vlaamse 
(Swerts, Vandevelde, VanDerNagel, Vanderplasschen, Claes, & de Mayer, in press), en Deense 
SumID-Q, en wordt er gewerkt aan andere vertalingen. 
Wat hebben we gevonden?
In onze literatuurstudie (hoofdstuk 2) werd duidelijk dat er de afgelopen jaren meer aandacht is 
gekomen voor middelengebruik en LVB. Desalniettemin zijn er veel hiaten in onze kennis over 
prevalentie (hoe vaak het voor komt) en risicofactoren. Daarbij ontbreekt het aan kennis over en 
beschikbaarheid van geschikte meetinstrumenten voor gebruik onder mensen met een LVB (van 
Duijvenbode, VanDerNagel et al., 2015). 
Met onze enquête onder Nederlandse LVB instellingen (hoofdstuk 3) toonden we aan dat 
middelengebruik onder mensen met een LVB ook in ons land tot problemen leidt. Volgens de 
instellingen werd alcohol minder vaak, en illegale middelen (vooral cannabis) vaker gebruikt dan 
in de totale Nederlandse bevolking. De verschillende instellingen gaven echter zeer uiteenlopende 
schattingen van de omvang van het probleem weer. Daardoor was het niet mogelijk een eenduidig 
totaalbeeld te schetsen. Op basis van 86 case-reports leken cliënten met LVB vergeleken met 
cliënten met zwakbegaafdheid vaker alleen alcohol te gebruiken. Zwakbegaafde cliënten 
gebruikten relatief vaker stimulantia (amfetaminen en cocaïne). Jongeren gebruikten vaker 
de combinatie van alcohol en cannabis, en oudere cliënten vaker alleen alcohol. Cliënten met 
problematisch middelengebruik hadden relatief vaak psychiatrische problemen, en gebrek aan 
structurele dagbesteding. Respondenten gaven aan dat de instelling vaak beperkt was toegerust 
om deze cliënten goed te helpen (VanDerNagel, Kiewik, Buitelaar, & de Jong, 2011a). 
In hoofdstuk 4 vergelijken we de gegevens over cliënten met een combinatie van LVB en 
problematisch middelen gebruik van een instelling voor verstandelijk gehandicaptenzorg, met 
een instelling voor verslavingszorg in dezelfde regio. Slechts een deel van de totale groep bleek 
bij beide instellingen bekend. Dat impliceert dat het niet goed mogelijk is om op basis van 
onderzoek bij één soort instellingen een goed beeld van de totale populatie cliënten met LVB en 
problematisch middelengebruik te krijgen. Onderzoek naar LVB en middelengebruik zou dan 
ook in zowel de LVB zorg als in de verslavingszorg plaats moeten vinden (VanDerNagel et al., 
2014). 
Om gebruik onder cliënten met een LVB goed in kaart te brengen is een vragenlijst nodig die 
geschikt is voor de doelgroep. In hoofdstuk 5 (VanDerNagel et al., in press) vergelijken we het 
gebruik dat door cliënten wordt gerapporteerd (SumID-Q), met het door stafleden gerapporteerde 
gebruik en met analyse van biomarkers in urine-, haar-, en huidpleister monsters. De bereidheid 
van cliënten om urine-, haar of huidpleister monsters af te staan was aanzienlijk minder dan 
de bereidheid om aan het SumID interview mee te doen. Anders dan we op basis van studies 
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onder mensen zonder LVB verwachtten, identificeerden we met de biomarker analyse niet meer 
gebruikers dan met de SumID-Q. We concluderen dan ook dat het gebruik van biomarkers een 
beperkte waarde heeft, en dat middelengebruik bij cliënten met LVB goed in kaart te brengen is 
met de SumID-Q. 
In hoofdstuk 6 gebruiken we de SumID-Q om in een grote groep cliënten van LVB instellingen 
(419 personen) het middelengebruik in kaart te brengen. Het overgrote deel van de deelnemers 
blijkt wel eens legale middelen (alcohol en tabak) gebruikt te hebben, en bijna de helft heeft wel 
eens illegale middelen (voornamelijk cannabis) geprobeerd. Ook het actuele middelengebruik 
is behoorlijk: 62% rookt (aanzienlijk meer dan in de algemene bevolking), 64% drinkt wel 
eens alcohol, 15% heeft afgelopen maand cannabis gebruikt, en 1% gebruikte afgelopen 
maand stimulerende middelen (speed of cocaïne). Hoewel middelengebruik in deze studie 
enigszins gerelateerd is aan factoren als mannelijk geslacht, jonge leeftijd en gebrek aan zinvolle 
dagbesteding, vallen deze invloeden weg wanneer er ook gekeken wordt naar bekendheid met, 
kennis van, attitude ten opzichte, en gebruik in de sociale omgeving van middelen (VanDerNagel 
et al., submitted). 
Bij de afronding van dit proefschrift
Bij de afronding van dit proefschrift hebben we opnieuw de mening van de politiek 
verantwoordelijken voor zorg geïnterviewd over hun perceptie van het samengaan van 
(problematisch) middelengebruik en LVB. Omdat in de tussenliggende periode de Wet 
Maatschappelijke Ondersteuning van kracht is geworden, ligt deze verantwoordelijkheid 
nu bij de gemeenten. In het voorjaar van 2016 interviewden we daarom 10 wethouders 
van evenzoveel gemeenten. Allen gaven aan weinig zicht te hebben op de aard en omvang 
van dit probleem: “…ik zal u eerlijk zeggen dat ik dat niet weet” (#1). Tegelijkertijd zagen zij 
mensen met een LVB wel als een risicogroep: “Ik denk dat het hoger is dan de groep zeg maar 
waar wij toe behoren” (#3). Dit hangt volgens de wethouders samen met wat Taggart et al. 
(2007) ‘zelfmedicatie tegen negatieve levenservaringen’ en ‘sociale afstand van de gemeenschap’ zou 
noemen (Taggart, McLaughlin, Quinn, & McFarlane, 2007): “…dat je erg teleurgesteld bent, 
dat je het ook erg beseft maar ja dat je geremd wordt, omdat je toevallig niet zo’n IQ hebt … en dan 
probeer je misschien met verslavende middelen uit die situatie te komen” (#3). Een andere factor zou 
groepsdruk en beïnvloedbaarheid zijn: “Deze doelgroep is toch makkelijk te vangen door de verkeerde 
mensen” (#8). Aan de andere kant worden sommige individuen met LVB gezien als juist 
minder kwetsbaar voor gebruik: “…dat je er juist niet mee bezig bent. Omdat je die verstandelijke 
beperking hebt. Dan leef je ook meer in je eigen wereld en kijk je ook niet zo tegen de dingen aan zoals 
wij er tegenaan kijken”(#3). In de preventie van (problematisch) gebruik in deze doelgroep 
zijn begeleiding en ondersteuning volgens de wethouders de belangrijkste factoren: “Het 
ligt er ook aan hoe de omgeving en de ouders hoe gaan ze er mee om, hoe is de begeleiding” (#4). Een 
aantal noemt hierbij gemeentelijke projecten als toeleiding naar werk, alsmede culturele en 
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sportactiviteiten om gebruik terug te dringen: “Dat ze niet in de verleiding komen van ik verveel 
me en ik ben met een groep en nou ik neem er nog een in” (#4), en “dan word je ook meer beinvloed door 
de normale maatschappij” (#7). Samenwerking tussen partijen en bewustzijn van het bestaan 
van dit probleem worden gezien als uitdagende belangrijke taak om mensen bij wie gebruik 
in problematisch gebruik is overgegaan: “…ik denk dat het [LVB en verslaving] nog niet altijd 
goed wordt gesignaleerd”(#9), en “Het is ook de vraag die je jezelf ook stelt: wat doen we er nu aan? 
Wat dat betreft is dit [deze enquête] ook wel een wake up call” (#4). Hoewel aan het eind van 
dit project nog niet in alle gemeenten een integraal zorgaanbod voor mensen met LVB en 
verslaving beschikbaar is, zien we toch de impact en meerwaarde van een doelgroep gerichte 
aanpak vanuit de teams voor LVB en verslaving van Aveleijn en Tactus, zoals geïllustreerd 
wordt door de verhalen van cliënten D, E, en F. 
 
Cliënt D6 is een 28 jarige moeder van twee kleine kinderen die voor behandeling van cannabis 
afhankelijkheid wordt verwezen naar onze poli voor mensen met een LVB en verslaving. Op 
basis van onze reguliere intake lijkt ze een geschikte kandidaat voor een pilot met onze nieuwe 
behandeling ‘Minder Drank of Drugs’. Bij de intake van deze interventie wordt de Substance use 
and misuse in Intellectual Disability- Questionnaire (SumID-Q) afgenomen. Daarbij blijkt cliënte 
tamelijk veel te weten van alle middelen in de vragenlijst, en giechelt ze bij het tonen van 
verschillende plaatjes van middelen. Bij het zien van de afbeelding van GHB zet ze grote 
ogen op en glimlacht ze. Hoewel de interviewer dit opmerkt, bespreekt hij dit – conform de 
handleiding van de SumID-Q – nog niet. Nadat de alcohol en tabak lijsten met vragen naar 
kennis, attitude, gebruik in de sociale omgeving en eigen gebruik zijn afgenomen, vraagt de 
interviewer op welk middel nu meer moet worden doorgevraagd. Wanneer cliënt voorstelt 
met stimulantia (cocaïne en speed) door te gaan, vraagt hij of de GHB lijst ook moet. Na 
enige aarzeling stemt de cliënt in. Haar GHB gebruik blijkt aanzienlijk, en ernstiger dan 
de reden voor verwijzing, haar cannabis gebruik. Cliënte geeft aan dit gebruik niet eerder 
gemeld te hebben uit angst voor bemoeienis van de kinderbescherming. 
Cliënt E7 De eerste keer dat ik hem zag zat hij als een mokkend klein kind voor me. Tas 
gepakt, en erop voorbereid dat ik hem wilde overhalen om toch te blijven. Dat wilde hij niet; 
hij wilde ‘ambulante behandeling’. Hij bracht het als het ei van Columbus. 
Ik kende hem al uit de casusbespreking. Twintig jaar verslaafd en pas 34 jaar oud. Met een 
verstandelijke beperking, waarvan het niveau door permanente intoxicatie niet meer precies 
te bepalen was. Plus inmiddels leverfunctiestoornissen, nierfunctiestoornissen, cachexie, 
o ja een onthoudingsinsult in de vakantieweek, en mogelijk ook nog het syndroom van 
6 Casus aangeleverd door Marion Kiewik, orthopedagoog generalist, Aveleijn. 
7 Gebaseerd op: VanDerNagel, J. E. L. (2015). Hoop doet leven, Medisch contact, 51/52, http://www.medischcontact.nl/
rubrieken-1/Rubrieken/Lezersverhalen/Lezersverhaal/152220/Lezersverhaal-Permanente-dronkenschap.htm.
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Korsakow. Een palliatief beleid werd al overwogen. Zijn permanente dronkenschap werd 
gevoed door een leven vol ellende, ernstige traumatisatie, gebrek aan perspectief of zinvolle 
dagbesteding en het simpelweg niet weten hoe je zonder drank zou kunnen. Zijn sociale 
inbedding was nihil, op een paar drinkebroers na dan, en tot voor kort zijn begeleidster. Maar 
zij had nu ook alle hoop laten varen. Vanochtend, toen ze hem naar de kliniek bracht had ze 
een flintertje hoop: eindelijk een detox. Maar al na twee uur zag hij het niet meer zitten: hij 
wilde weg. Geheel tegen zijn verwachting mocht hij weg van mij: ambulante begeleiding 
kon hij krijgen. Zijn begeleidster keek me boos en wanhopig aan. De deal was wel: “We doen 
nu wat jij wilt; als dat niet werkt, doen we wat ik wil”. Vol goede hoop bekrachtigde hij dat 
met een handdruk. Nog twee keer probeerde hij het vrijwillig in de kliniek, want ambulant 
lukte inderdaad niet. De laatste keer vroeg hij om tegengehouden te worden bij voortijdig 
vertrek. Een maand na opname met een BOPZ maatregel trof ik hem bij de arbeidstherapie. 
Overall aan, bezem in de hand en ouwehoeren met “de jongens”. Vijftien kilo zwaarder en 
een stuk beter in zijn vel. In die conditie verhuisde hij naar een zorgboerderij en daar zit hij 
nog. Zonder een druppel bier.
Cliënt F is een 28 jarige man met een autisme spectrum stoornis en LVB. Zijn begeleider 
neemt contact op met het LVB team van Tactus, met de vraag of verslavingszorg geïndiceerd 
is. F blijkt 8 glazen cola per dag te drinken, en geeft aan “verslaafd” te zijn. Op basis 
van screening met de SumID-Q, en overeenkomstig de indrukken van de staf, is er geen 
sprake van ander gebruik. F staat er echter op voor behandeling verwezen te worden, 
net zoals gebeurde dat bij meerdere groepsgenoten (met elk een alcohol- en/of cannabis 
afhankelijkheid). Na consultatie met het begeleidend team, heeft een preventiewerker van 
Tactus een ‘serieus’ gesprek met cliënt. Dit resulteert in een ‘afbouwschema’ waarin het 
gebruik van cola teruggebracht wordt naar minder ongezonde hoeveelheden. Sindsdien is F 
een nog enthousiastere promotor van de diensten van ons team.
Wat betekent dit voor de praktijk?
In dit onderzoek werd bevestigd dat – in tegenstelling tot wat sommige mensen nog steeds 
geloven – mensen met een LVB allerhande middelen gebruiken. Het percentage tabaksgebruik 
– toch een verslaving met zeer ernstige gevolgen – is zorgelijk hoog, en net als het percentage 
cannabis gebruik aanzienlijk hoger dan dat in de algemene bevolking. Ook alcohol wordt 
gebruikt door mensen met een LVB, zij het in mindere mate dan in de algemene bevolking. Deze 
bevindingen hebben belangrijke consequenties voor de zorgpraktijk.
1. Investeer in preventie 
Hoewel het gebruik van middelen niet per se een probleem is, kunnen maatregelen om gebruik 
tegen te gaan of uit te stellen bijdragen aan preventie van problemen door gebruik, inclusief 
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problematisch gebruik. Wetgeving – zoals de NIX18 campagnes (Rijksoverheid, 2016) – kan 
daar aan bijdragen. Omdat gebruik al op jonge leeftijd begint moeten educatieve en preventieve 
interventies ingezet worden vanaf de lagere school leeftijd. Ouders, begeleiders en behandelaars 
in zowel de verstandelijk gehandicaptenzorg als de verslavingszorg moeten zich er van bewust 
zijn dat onder hun cliënten sprake kan zijn van dubbele (LVB en verslaving), en mogelijk triple 
problematiek (LVB, verslaving en psychiatrische co morbiditeit), en moeten vaardig zijn of 
worden in het screenen op en bespreekbaar maken hiervan. Preventie en behandeling moet niet 
beperkt worden tot problematisch alcohol en druggebruik. Er is ook meer aandacht nodig voor 
preventie van tabaksgebruik, zowel onder cliënten met een LVB als onder hun begeleiders, omdat 
zij belangrijke rolmodellen kunnen zijn. 
2. Zorg voor vroege opsporing
Middelengebruik zou in de verstandelijk gehandicaptenzorg een gangbaar onderwerp van 
gesprek tussen stafleden en cliënten moet zijn en systematisch in kaart moet worden gebracht. 
Zelfrapportage met de SumID-Q blijkt daar een prima basis voor te zijn (VanDerNagel et al., in 
press). In de verslavingszorg zou standaard gescreend moeten worden op de aanwezigheid van 
een verstandelijke beperking. Tijdige opsporing hier van geeft de mogelijkheid om een aan de 
beperking aangepaste behandeling in te zetten. 
3. Zorg voor een aangepast en geïntegreerd behandelaanbod voor problematisch gebruik
Dubbele problematiek zoals de combinatie van problematisch middelengebruik en LVB vergt 
een aanpak die rekening houdt met beide aspecten. Zowel kennis van middelen, van LVB, als 
vaardigheden in het omgaan met cliënten met deze problemen zijn essentieel. Behandeling 
van problematisch middelengebruik bij LVB kan daarom het best in ketenzorgverband tussen 
verslavingszorg en LVB zorg worden georganiseerd (zie ook Slayter, 2010; VanDerNagel et al., 
2013; Van Duijvenbode, & VanDerNagel, 2016). Gelukkig zijn er inmiddels in Nederland 
verschillende behandelmethodieken voor deze combinatie van problemen beschikbaar (zie 
bijvoorbeeld VanDerNagel & Kiewik, 2016; VanDerNagel, Westendorp, van Dijk & Kiewik, 
2016).
Wat betekent dit voor vervolg onderzoek? 
Zoals altijd levert wetenschappelijk onderzoek weer stof op voor vervolgonderzoek. Voor het 
onderwerp LVB en verslaving doen we vier aanbevelingen voor vervolgonderzoek.
1. Vervolg het onderzoek naar risicofactoren voor (problematisch) gebruik 
Het onderzoek naar LVB en verslaving dat tot nu toe is gedaan is voornamelijk cross-sectioneel. 
Dat wil zeggen: het onderzoek richtte zich op de stand van zaken op één moment. Voor een beter 
begrip van risico’s op (problematisch) gebruik is het belangrijk patronen van gebruik over de 
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jaren te volgen. Bij voorkeur moet daar een grotere groep jonge mensen met LVB over langere 
tijd gevolgd worden, om te onderzoeken wie wel en wie geen middelengebruik of problemen door 
gebruik ontwikkelen. Daarnaast is onderzoek nodig naar gebruik (inclusief roken en mogelijk 
ook cafeïne gebruik) onder mensen met een matige of ernstige verstandelijke beperking. Verder is 
het belangrijk te onderzoeken welke factoren de betrouwbaarheid beïnvloeden van zelfrapportage 
van gebruik (zoals bijvoorbeeld de angst voor consequenties van gerapporteerd gebruik zoals in 
casus D beschreven), en van rapportage door derden. 
2. Onderzoek de prevalentie van en screening op LVB in de verslavingszorg
Dit onderzoek richtte zich op middelengebruik in de verstandelijk gehandicaptenzorg. 
Omgekeerd is onderzoek in de verslavingszorg naar de prevalentie en vroegtijdige opsporing 
van verstandelijke beperking zeer wenselijk. Dit is reeds in gang gezet in het TactIQ project 
(van Dijk, VanDerNagel, Dijkstra, Didden, de Haan, & de Jong, 2016), waaruit bleek dat een 
aanzienlijk deel van de patiënten in de verslavingszorg een verstandelijke beperking had.
3. Combineer meerdere perspectieven
Mensen met een LVB en verslaving krijgen soms dubbele zorg (LVB zorg én verslavingszorg), 
soms enkele zorg (LVB zorg óf verslavingszorg), en soms geen zorg. Dat betekent dat noch 
gegevens van LVB zorg, noch die van verslavingszorg een volledig beeld van de groep mensen 
met LVB en verslaving geven. Het is daarom belangrijk dat in toekomstig onderzoek naar LVB 
en verslaving niet alleen de populatie cliënten van LVB instellingen betrokken wordt. Nader 
onderzoek – bijvoorbeeld met de capture-recapture techniek - met een combinatie van data uit 
verslavingszorg, LVB zorg en bijvoorbeeld psychiatrie of forensische zorg is zeer wenselijk. 
4. Onderzoek naar effectiviteit van interventies
De afgelopen jaren zijn er diverse interventies ontwikkeld voor preventie, vroeginterventie en 
behandeling van problematisch middelengebruik bij mensen met een LVB. Hoewel dit voor de 
klinische praktijk al een behoorlijke stap vooruit is, ontbreekt het nog veelal aan wetenschappelijke 
onderbouwing. Het beschikbare onderzoek beperkt zich vooralsnog vooral tot case reports of case 
series, en pilot studies. Nader onderzoek in grotere samples met een sterker onderzoeksdesign 
zijn nodig.
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CONCLUSIES
Mensen met een Lichte Verstandelijke Beperking vormen een risicogroep voor (problematisch) 
middelengebruik. Systematische aandacht voor, en screenen op gebruik (bijvoorbeeld met de 
SumID-Q), kunnen bijdragen aan tijdige identificatie en interventies bij (dreigende) problemen. 
Hoewel er nog steeds veel werk te verzetten is, loopt Nederland inmiddels internationaal voorop 
met zowel onderzoek als methodiek ontwikkeling voor LVB en verslaving. Het thema staat 
daarnaast inmiddels ook prominent op de agenda van behandelaars en politiek. Daarmee is er een 
goede basis voor verdere ontwikkelingen in de zorg voor deze groep. 
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